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Abstract 
While for adults, a plurality of studies examines placebo responses and potential 
moderators in antidepressant trials, comparable investigations in pediatric and geriatric patients 
are scarce. This is especially problematic since the efficacy and safety of antidepressants is 
controversial in these sensitive populations: effect sizes are small and severe side effects such 
as an increased risk of suicidal thoughts and behavior have been reported. Here, it has been 
hypothesized that the lack of a consistent significant benefit of antidepressants over placebo 
could be associated with an increased response to placebo. Therefore, it is worth considering 
whether the potential of placebos can be harnessed without undermining patients’ autonomy 
through deception. 
 The emphasis of the current dissertation was twofold: first, to investigate the efficacy 
of placebos and potential moderators in pediatric and geriatric patients. Second, to 
experimentally test the necessity of deception. For this reason, two different statistical 
approaches were indicated. For the first aim, a meta-analytic approach was applied in order to 
assess differences between antidepressant and placebo interventions in pediatric major 
depressive disorder (MDD), anxiety disorders, obsessive-compulsive disorder, and 
posttraumatic stress disorder (Locher, et al., 2017; Study I), as well as in geriatric MDD, 
dysthymia and minor depression (Locher et al., 2015; Study II) along with variation in placebo 
responses and moderators. For the second goal, a basic research approach was chosen in order 
to compare the effects of openly prescribed placebos with a deceptive placebo administration 
in a standardized heat pain experiment with healthy participants (Locher, Frey Nascimento, 
Kossowsky, Meyer, & Gaab, 2017; Study III). Here, basic research represents an excellent way 
to experimentally compare these treatments in accordance with ethical principles. 
 The meta-analyses revealed that antidepressants are more effective than placebo at 
treating MDD in children and adolescents (Hedges’ g = 0.20; Study I), as well as in elderly 
people (Hedges’ g = 0.37; Study II). However, the effects were only small and did not reach 
the proposed cut-off for clinical significance. Also, placebo responses in depressed youth 
(Hedges’ g = 1.57; Study I), as well as in depressed elderly (Hedges’ g = 0.96; Study II) were 
significant and substantial. Findings of the heat pain experiment with healthy participants 
revealed that open-label placebos do not differ in their effects from deceptive placebos in 
subjective outcomes (i.e., heat pain intensity ratings: p = .136 and heat pain unpleasantness 
ratings: p = .481; Study III).  
Placebo responses are large and meaningful in children, adolescents and elderly people 
with depression. Pediatric as well as geriatric patients seem to respond well to clinician contact 
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that promotes the therapeutic alliance and other common factors such as the patients’ 
expectations and hopes of improvement. Furthermore, the ubiquitously assumed necessity of 
concealment in placebo administration is questioned and new ways in order to harness the 
potential of placebos should be considered.   
  3 
1. Theoretical Background 
1.1. The Placebo Effect 
Time has passed since Beecher (1955) claimed that placebos are powerful—a 
meanwhile numerously confirmed finding in both healthy individuals and patients with various 
clinical conditions (Forsberg, Martinussen, & Flaten, 2016). In particular, relevant placebo 
effects have been reported in medical conditions which are amenable to psychological factors 
(Wampold, Minami, Tierney, Baskin, & Bhati, 2005), such as pain (Tuttle et al., 2015), 
Parkinson’s disease (Schmidt, Braun, Wager, & Shohamy, 2014), asthma (Wechsler et al., 
2011), and nausea (Quinn & Colagiuri, 2016); as well as in mental diseases such as depression 
(Furukawa et al., 2016; Rutherford et al., 2017) and anxiety (Sugarman, Loree, Baltes, Grekin, 
& Kirsch, 2014). The original conceptualization of a placebo as an inert agent or procedure was 
unavoidably linked with a paradox: By definition, something that is inert can’t cause an effect 
(Price, Finniss, & Benedetti, 2008). Inevitably, the focus has been shifted to the concept of 
placebo effects as genuine psychobiological events (Finniss, Kaptchuk, Miller, & Benedetti, 
2010) within a psychosocial context (Moerman & Jonas, 2002). In this understanding, the 
doctor-patient relationship, consisting of both, emotional (e.g., trust, empathy, respect, 
acceptance and warmth), as well as informational (e.g., patient education, treatment 
information, and expectation management) components (Di Blasi, Harkness, Ernst, Georgiou, 
& Kleijnen, 2001; Lucassen & Olesen, 2016), is indispensable for the success of any treatment 
(Kelley, Kraft-Todd, Schapira, Kossowsky, & Riess, 2014). Accordingly, it has been shown 
that an enhanced relationship with a practitioner, combined with the therapeutic ritual of a 
placebo administration, promotes the most robust benefit when compared to placebo 
administration with only limited social support and to a waitlist control group (Kaptchuk et al., 
2008).  
Environmental and psychosocial mechanisms that contribute to placebo effects are 
numerous (Benedetti, 2008); however, two factors are most established: expectations, which 
are reinforced through verbal suggestions (Benedetti, 2002; Jepma & Wager, 2015; Kirsch & 
Weixel, 1988; Pollo et al., 2001), as well as classical conditioning, a learning of relations among 
events (Rescorla, 1988) through direct experience (Benedetti et al., 2016; Schedlowski & 
Pacheco-López, 2010; Voudouris, Peck, & Coleman, 1985) and through social observation 
(Colloca & Benedetti, 2009). Whereas expectations affect conscious physiological functions 
such as pain and motor performance, conditioning has an additional impact on unconscious 
physiological functions such as hormonal levels and immune responses (Benedetti et al., 2003). 
While the relation of these two psychological mechanisms is an ongoing subject of discussion 
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(Kirsch, 2004; Kirsch et al., 2014; Stewart-Williams & Podd, 2004), new and multimodal 
conceptual frameworks for placebo effects are likewise proposed. For example, the “somatic 
focus” model is based on the assumption that sensations, somatic attention, construal, and 
bodily states are connected (Alfano, 2015; Lundh, 1987). This model proposes that individuals 
with positive expectations selectively attend to signs of somatic improvement and interpret 
them as evidence that the placebo intervention has been successful even if their physical health 
is unchanged and the perceived signs are only part of a natural variability (Geers, Helfer, 
Weiland, & Kosbab, 2006; Walker et al., 2006). Similarly, the awareness of being treated 
promotes placebo effects and improves clinical outcomes (Colloca & Benedetti, 2016), which 
stands in contrast to hidden applications in which patients are not informed about being 
treated—what substantially minimizes the effect of placebos (Colloca, Lopiano, Lanotte, & 
Benedetti, 2004). Further, the Bayesian models of perceptual decision is becoming established 
as an innovative framework in placebo research (Geuter, Koban, & Wager, 2017). The core 
assumption is that sensory bottom-up signals trigger top-down predictions or expectations 
which result from prior knowledge or experience (Friston, 2003). If the incoming signals are in 
line with the prior knowledge, the prediction is confirmed. However, if they are not congruent, 
a prediction error signal is generated and the expectation may be adapted through a learning 
rule (Wiech, 2016). Importantly, the content of sensory signals is represented by means of 
probability (Büchel, Geuter, Sprenger, & Eippert, 2014) and we are “forever trying to stay one 
step ahead of the incoming waves of sensory stimulation“ (Clark, 2015, p. 21). Also, a 
prediction error might not automatically lead to an adaption of the expectation (Wiech, 2016) 
—an additional argument why expectations are not necessarily linked to self-fulling prophecies 
(Crombez & Wiech, 2011).  
Further, and in order to understand the complex psychological processes involved in 
placebo effects, a much broader scope of psychological variables is warranted (Geers & Miller, 
2014). Placebo effects are dynamically influenced by idiosyncratic and top-down constructs, 
such as expectations and learning experiences, yet also by other psychological variables such 
as meaning, mindsets, hope, and beliefs (Crum, Phillips, Scott, Kosslyn, & Pinkerton, 2015). 
Therefore, the placebo effect has been defined as a meaning response (Barrett et al., 2006; 
Moerman & Jonas, 2002), a process which is essentially evoked by narrative language (Brody, 
1994; Bruner, 1990). Along similar lines, there is the proposition that individual mindsets—the 
frame of mind which orients an individual to a particular set of associations and expectations—
shape how individuals respond to placebos (Crum, Akinola, Martin, & Fath, 2017; Crum & 
Langer, 2007). Further, patients themselves usually do not mention specific expectations, yet 
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rather spontaneously express hope (Di Blasi, Crawford, Bradley, & Kleijnen, 2005; Kaptchuk 
et al., 2009; D. A. Stone, Kerr, Jacobson, Conboy, & Kaptchuk, 2005). However, they are at 
the same time realistic and do not hope so much as to risk despair when the treatment doesn’t 
show immediate effects (Kaptchuk, 2011). This conceptualization of hope turns out to be a kind 
of tragic optimism and is seen as more “visceral” than the cognitive approach that expectancy 
entails (Eaves, Nichter, & Ritenbaugh, 2016; Eaves, Ritenbaugh, Nichter, Hopkins, & Sherman, 
2014).  
Taken together and without the claim of completeness, the placebo effect is closely 
related to other constructs, most prominently conditioning and expectancy, but also “somatic 
focus”, the awareness of being treated, predictions, various psychological variables and the 
patient-physician relationship. The question of relatedness, that is to what degree these 
constructs overlap or diverge, requires further investigation and would contribute to an 
enhanced theoretical understanding of these constructs and the placebo effect itself.  
1.2. Placebo Responses in Antidepressant Trials 
Almost twenty years ago, researchers had the idea to look at placebo responses in 
antidepressant trials for depression (Kirsch & Sapirstein, 1998). They assumed that major 
depressive disorder (MDD) would be good source for the investigation of placebo effects since 
an effective antidepressant treatment enables patients to elevate the suffering by replacing the 
sense of hopelessness with hopefulness (Kirsch, 2016), a mechanism which is also called 
remoralization (Frank, 1973, 1974) and which has been shown to be related to placebo effects 
(e.g., Kaptchuk et al., 2009; see above). Kirsch and Sapirstein (1998) found that improvements 
in the placebo groups correspond to 75% of the improvements in the antidepressant groups. The 
finding that only a small amount of the antidepressant response is due to the administration of 
an active medication, was replicated since then with correspondence rates up to 82% (Kirsch et 
al., 2008). Accordingly, standardized effect sizes for the antidepressant-placebo difference 
range from 0.15 for unpublished studies up to 0.37 for published studies (Turner, Matthews, 
Linardatos, Tell, & Rosenthal, 2008) and from 0.11 for mild to moderate depression up to 0.47 
for very severe depression (Fournier et al., 2010). In other words, 35% to 40% of patients 
respond to placebo (Enck, 2016; Furukawa et al., 2016) compared with a mean antidepressant 
response rate of around 50% (Rutherford & Roose, 2013; Walsh, Seidman, Sysko, & Gould, 
2002). Beyond statistical significance, the National Institute for Health and Clinical Excellence 
(NICE) proposed a definition for clinical significance in their depression guidelines from 2004 
(which they replaced by the term “clinical importance” in 2010), defined as a 3-point difference 
between antidepressant and placebo on the Hamilton Depression Rating Scale (HDRS; 
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Hamilton, 1967) or a mean drug-placebo standardized mean difference of ≥ 0.50. In response 
to criticism that argued that the NICE criterion is arbitrary (e.g., Turner & Rosenthal, 2008), 
Moncrieff and Kirsch (2015) empirically demonstrated clinical significance: They compared 
the HDRS and the clinician-rated Clinical Global-Impression-Improvement (CGI-I) scale, 
showing that a 3-point difference is undetectable by clinicians using the CGI-I scale. 
Remarkably, the clinical significance of antidepressants is failed to be reported in meta-analyses 
including published and unpublished trials (Kirsch, 2016) as the range of the antidepressant-
placebo difference lays between 1.80 to 2.51 points on the HDRS (Khin, Chen, Yang, Yang, & 
Laughren, 2011; Kirsch et al., 2008; Sugarman et al., 2014). In conclusion, there are relatively 
small but statistically significant differences between antidepressants and inert placebos—
while, however, clinical meaningful and visible significance is not given.  
Nevertheless, prescriptions of the most common antidepressants, selective serotonin 
reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), have 
doubled in the last decade according to the NHS research (2016). In 2001, for example, an 
influencing trial concluded that the “treatment with paroxetine results in clinically relevant 
improvement in depression scores” and that their findings “provide evidence of the […] safety 
of the SSRI” (Keller et al., 2001, p. 770). However, general concerns were raised about relying 
on published research to reflect the efficacy of antidepressants. First, there is the issue of 
misreported trials, meaning that the study has been erroneously reported (Doshi, Dickersin, 
Healy, Vedula, & Jefferson, 2013). Indeed, this was the case in the Keller et al. (2001) study: 
A re-evaluation of the data concluded that the efficacy of the SSRI (i.e., paroxetine) is not 
different from placebo, whether statistically nor clinically. Moreover, “there were clinically 
significant increases in harms, including suicidal ideation and behavior” (Le Noury et al., 2015, 
p. 1) and the side effect profiles differed between paroxetine and placebo (Le Noury et al., 
2015). Although placebos evoke side effects through negative expectations (Rief, Bingel, 
Schedlowski, & Enck, 2011), antidepressants produce significantly more adverse effects than 
inert placebos (Sharma, Guski, Freund, & Gøtzsche, 2016). Further, there is another basic 
problem in the field of antidepressant research: Many trials remain unpublished (Doshi et al., 
2013). The publication bias is particularly caused by multiple publication, selective publication, 
and selective reporting in trials sponsored by the pharmaceutical industry (Melander, Ahlqvist-
Rastad, Meijer, & Beermann, 2003). Hence, looking at the published literature, around 94% of 
the antidepressant studies are associated with positive outcomes. In contrast, the register of the 
Food and Drug Administration (FDA) indicates that only 51% of the analyses show an 
advantage of antidepressants over placebo (Turner et al., 2008). Notable, the criteria for 
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antidepressant drug approval require two “adequate and well-controlled” clinical trials 
indicating that the antidepressant is better than a placebo—however, there is no limit to the 
amount of studies and negative studies do not count (Kirsch, 2009). 
Furthermore, practice guidelines identify antidepressants, including SSRIs and SNRIs, 
not only for MDD, yet also for anxiety disorders (AD), obsessive-compulsive disorder (OCD), 
and posttraumatic stress disorder (PTSD) as first line pharmaceutical treatments (American 
Psychiatric Association, 2010; Bandelow et al., 2012). However, few analyses have focused on 
these other conditions and, initially, anxiety symptom relief due to antidepressants was only 
investigated for panic disorder (Mitte, 2005; Otto, Tuby, Gould, McLean, & Pollack, 2001). A 
recent meta-analysis targeting on the efficacy of SSRIs in generalized anxiety disorder and 
panic disorder, as well as in depression using published and unpublished trials (Sugarman et 
al., 2014) provided important insights: The SSRI-placebo effect size was modest and 
significant, yet not clinically significant, for both, anxiety disorders (d = 0.27) and depression 
(d = 0.32) while the two effect sizes did not differ from each other. Also, the trend of larger 
placebo pre-post effect sizes in depression (d = 1.03) than in anxiety disorders (d = 0.96), was 
not significant, indicating that placebos are equally effective and meaningful in both disorders. 
1.3. Possible Moderators 
To clarify the differentiation between antidepressant and placebo groups further, the 
source of symptom change in antidepressant trials has been grouped into factors influencing 
natural history (e.g., improvement, worsening), measurement factors (e.g., regression to the 
mean, rater bias and response bias), treatment factors (e.g., therapeutic setting and expectancy-
based placebo effects), as well as disorder characteristics (e.g., severity and duration of the 
disorder) (Rutherford & Roose, 2013). Hence, placebo effects are one component of the placebo 
response observed in clinical trials, while other components influence the symptom changes in 
patients randomized to the placebo arm (Rutherford & Roose, 2013). General treatment factors 
that contribute to the placebo response can be found in the first Section of this thesis. However, 
some specific findings regarding placebo effects in antidepressant trials should be mentioned. 
Relating to the therapeutic setting in antidepressant trials, it has been shown that the clinician 
administering the treatment explains more of the variability of outcomes than the 
psychopharmacological treatment itself (McKay, Imel, & Wampold, 2006). Also, a good way 
to indirectly measure expectancy-based placebo effects in antidepressant trials is to compare 
antidepressant response between active comparator trials (i.e., one or more antidepressant with 
no placebo group) and placebo-controlled trials (i.e., one or more antidepressant compared with 
placebo). Patients in comparator trials are aware that they have a 100% chance of receiving an 
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antidepressant, which, in turn, increases their expectancy of a treatment benefit, leading to 
enhanced placebo effects and greater antidepressant responses, which is opposed to patients in 
placebo-controlled trials who are aware that they may receive a placebo and show lower 
antidepressant response rates (Rutherford, Sneed, Devanand, Eisenstadt, & Roose, 2010; 
Rutherford, Sneed, & Roose, 2009). Similarly, the number of treatment arms is negatively 
correlated with a significant benefit of the antidepressant over placebo—a greater number of 
treatment arms enhances the probability of receiving a verum which may increase patients’ 
expectations and, accordingly, placebo responses (Khan, Kolts, Thase, Krishnan, & Brown, 
2004).  
Regarding disorder characteristics, one of the most reported findings for depression is 
that the mean differences between antidepressant and placebo groups become larger as baseline 
severity increases. However, it is controversial whether the increasing benefits, as severity 
increases, of antidepressants over placebo are due to a decrease in the responsiveness to placebo 
treatment (Kirsch et al., 2008), or an increase in responsiveness to pharmacological intervention 
(Fournier et al., 2010; Khan, Leventhal, Khan, & Brown, 2002). Furthermore, a re-analysis of 
the Kirsch et al. (2008) data set did not find that initial severity determined antidepressant-
placebo differences (Fountoulakis, Veroniki, Siamouli, & Möller, 2013), a result which has 
been also reported in a recent patient-level analysis from 34 randomized-controlled trials 
(RCTs) of antidepressants (Rabinowitz et al., 2016). Interestingly, in the latter study, the trial-
level meta-analysis—which was calculated simultaneously to the patient-level analysis—
supported previous findings of an association between baseline depression severity and drug-
placebo differences (Rabinowitz et al., 2016)1. However, one should note that of four additional 
patient-level analyses, three reported that baseline severity of depression was associated with 
antidepressant efficacy (Fournier et al., 2010; Khan, Bhat, Faucett, Kolts, & Brown, 2011; 
Khan, Brodhead, Kolts, & Brown, 2005), whereas another large investigation did not find a 
significant correlation (Gibbons, Hur, Brown, Davis, & Mann, 2012).  
1.4. Placebo Responses in Antidepressant Trials over the Lifespan  
While for adults, a plurality of studies examines placebo responses in antidepressant 
trials, comparable investigations in children and elderly people are scarce. For pediatrics, the 
lack of research in this field is partially due to the fact that placebo research in children faces 
even bigger ethical considerations than placebo research in adults, since it is acknowledged that 
children may not fully understand the associated risks or benefits of a clinical trial and may be 
                                                
1 It is well known that trial-level meta-analyses are linked to ecologically fallacious findings, where the cumulative association 
fails to reproduce associations at the individual level (Spoerri et al., 2010). 
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more suggestible than adults (Parellada et al., 2012; Simmons et al., 2014). Further, 
methodological challenges in pediatric research include difficulties enrolling children, small 
market share for active substances aimed at children, and low prevalence of many pediatric 
diseases (Martinez-Castaldi, Silverstein, & Bauchner, 2008). These ethical and methodological 
barriers in pediatric placebo research have led to a scarcity of high-quality RCTs in children as 
compared to adults (Klassen, Hartling, Craig, & Offringa, 2008). Currently, more than half of 
the pharmacological treatments used for hospitalized children are off-label or unlicensed drugs 
(Conroy et al., 2000; ‘t Jong et al., 2000) and child health care providers must often rely on 
evidence that has been generated on adult populations (Cramer et al., 2005). This is especially 
problematic since both the safety and efficacy profiles of medications may be significantly 
different for children than for adults due to divergences in developmental physiology, disease 
pathophysiology, or developmental pharmacokinetics and pharmacodynamics (Caldwell, 
Murphy, Butow, & Craig, 2004; Janiaud et al., 2017). Also, when examining a complex 
phenomenon such as the placebo effect, it is substantial to consider the fact that age and neural 
development remarkably affect overall cognition (Lau et al., 2011; Simmons et al., 2014). To 
investigate the clinical significance of antidepressants and the proportion of the drug response 
which is duplicated by placebo is therefore most warranted in patients of different ages (Alamo, 
López-Muñoz, García-García, & García-Ramos, 2014; Henry, Kisicki, & Varley, 2012). 
For youth taking antidepressants, severe side effects such as an increased risk of suicidal 
thoughts and behavior have been reported (Mann et al., 2006), leading to the “black box” 
warning on the labels of all antidepressants for pediatric use by the FDA in 2004. However, this 
remains controversial due to contradictory findings of re-analyses of the data (M. B. Stone, 
2014). The limited meta-analytic evaluations in the field of pediatric depression reveal that 
antidepressants have only small to moderate effect sizes (Garland, Kutcher, Virani, & Elbe, 
2016). A recent network meta-analysis indicated that for the primary outcome, only fluoxetine 
was significantly more effective than placebo with a moderate standardized mean difference of 
0.51 on various standardized rating scales; however, all other antidepressants—including 
second-generation SSRIs, SNRIs, yet also first-generation tricyclic antidepressants—did not 
significantly differ from placebo treatments (Cipriani et al., 2016). Similarly, another meta-
analysis on pediatric depression found that while SSRIs differed significantly from placebo, 
SNRIs and tricyclic antidepressants did not (Rojas-Mirquez et al., 2014). Even more, despite 
some correlation between response to antidepressant and to placebo in a meta-analysis (r = 
0.47), the placebo response explained more of the variance in the efficacy than the 
antidepressant response (Bridge, Birmaher, Iyengar, Barbe, & Brent, 2009). The lack of a 
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consistent significant benefit of antidepressants over placebo in pediatric depressive disorders 
(Emslie, 2009; Parellada et al., 2012) has been associated with an increased response to placebo 
rather than a decreased antidepressant response (D. Cohen et al., 2008). This contrast is not 
unique: Children tend to improve more with placebo across a wide variety of diseases (Janiaud 
et al., 2017) and depression (Rutherford & Roose, 2013) when compared to adults.  
For elderly patients with depression, the safety and efficacy of antidepressants is 
likewise controversial: Geriatric patients are more likely to have serious medical conditions and 
thus receiving polypharmacotherapy, which often causes adverse side effects and interactions 
between medications (Coupland et al., 2011). Age-related declines in the drug metabolism are 
also associated with increased rates of antidepressant side effects (Taylor, 2014). 
Methodologically, there is an underrepresentation of elderly people in RCTs, which can be 
related to study protocol restrictions with exclusion criteria on age, polypharmacotherapy, and 
comorbidities (Konrat et al., 2012; Zimmerman et al., 2016). Further, there is a lack of RCTs 
exclusively designed for geriatric patients and findings from mixed-age studies are often 
extrapolated from adults to elderly people (Broekhuizen, Pothof, de Craen, & Mooijaart, 2015). 
Again, this is troubling since pharmacokinetic and pharmacodynamics changes in the geriatric 
population, such as declines in the drug metabolism and extended elimination half-life, result 
in altered drug responses (DeVane & Pollock, 1999).  
While antidepressants have shown to be more effective than placebo in depressive 
patients aged 55–65 years regarding remission and response rates (e.g., Kok, Nolen, & Heeren, 
2012; Nelson, Delucchi, & Schneider, 2008), recent studies indicate that SSRI treatment for 
depression in people 65 years of age and older do not offer any benefits over a placebo 
(Tedeschini et al., 2011; Tham et al., 2016). Accordingly, in a RCT with depressed participants, 
authors reported a decrease of the average HDRS difference score between the antidepressant 
and placebo group with increasing age: Patients aged 45 showed a HDRS difference score of 
5.6 points, while patients aged 65 reported a negligible HDRS difference score of −0.04 
(Rutherford et al., 2017). However, the reason for the reduced effect of antidepressants in 
elderly depressed patients when compared to middle-aged patients is not yet completely 
understood. One possible explanation is that expectancies are minimized by multiplied negative 
treatment experiences throughout the lifespan (Bingel, Colloca, & Vase, 2011). This is 
supported by a recent investigation reporting that depressed patients aged 55 and older show a 
diminished expectancy effect when compared to younger participants (Rutherford et al., 2017). 
Also, elderly patients with early-onset depression and corresponding diminished motivation 
and reward-seeking behavior (Shankman, Klein, Tenke, & Bruder, 2007) report higher 
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posttreatment depression scores in the placebo arm than elderly patients with late-onset 
depression (Sneed et al., 2007). It is worth adding that in these analyses (Rutherford et al., 2017; 
Sneed et al., 2007), patients with cerebrovascular diseases and cognitive impairments such as 
dementia were not excluded; however, executive dysfunction and related learning impairments 
in elderly depressed patients have been associated with a loss of expectancy-related 
mechanisms (Benedetti et al., 2006) and a lower probability of placebo responses (Alexopoulos 
et al., 2005; Sneed et al., 2010). Further, there is the assumption that the reduced effect of 
antidepressants over placebo in late-life depression is evoked by a limited antidepressant 
response rather than a decreased placebo response when compared to middle-aged patients 
(Alexopoulos et al., 2007; Walsh & Sysko, 2005). Along similar lines, it has been shown that 
the placebo response remains powerful, also in late-life depression (Rutherford, Tandler, 
Brown, Sneed, & Roose, 2014; Sneed et al., 2008). Nevertheless, studies focusing on the 
placebo response and its mechanism in late-life depression are even rarer than those in pediatric 
depression. 
1.5. Harnessing Placebo Effects  
Given that patients of different ages demonstrate robust placebo responses in 
antidepressant trials, it is worth considering whether this can be harnessed in clinical practice 
(Simmons et al., 2014). Also, a genuine placebo effect in depression is extremely plausible, as 
the combination of placebo and supportive care has been shown to be more effective than 
supportive care alone in depressed patients (Leuchter, Hunter, Tartter, & Cook, 2014). 
However, one should bear in mind that the clinical use of placebos is not warranted since 
placebo administration involves deception and the violation of patients’ autonomy (Gold & 
Lichtenberg, 2014; Trachsel & Gaab, 2016) and the ethical maxim states that “withholding 
medical information from patients without their knowledge or consent is ethically 
unacceptable” (American Medical Association, 2016: Opinion 2.1.4). Also, patients may judge 
the use of placebos unacceptable (Bishop, Aizlewood, & Adams, 2014). Interestingly, though, 
some recent research questions whether deception is indeed an unalienable characteristic of the 
placebo effect and insinuates the possibility of openly prescribed placebos with full 
transparency (Carvalho et al., 2016; Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley, 
Kaptchuk, Cusin, Lipkin, & Fava, 2012; Sandler & Bodfish, 2008). In open-label placebo 
studies, the placebo is provided with a scientific rationale (Kaptchuk et al., 2010). A positive 
albeit realistic expectancy is verbally fostered by conveying four scientific findings: (a) 
placebos are effective (b) classical conditioning as a possible mechanism (c) compliance is 
important for outcome (d) positive expectations increase placebo effects, but are not necessary. 
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Remarkably, patients in the open-label placebo group experienced a significantly higher 
symptom reduction of irritable bowel syndrome (Kaptchuk et al., 2010) and juvenile ADHD 
(Sandler & Bodfish, 2008; Sandler, Glesne, & Bodfish, 2010) when compared to patients in a 
waitlist control group, and two further studies underpinned the effectiveness of open-label 
placebos also compared to treatment as usual conditions in patients suffering from rhinitis 
(Schaefer, Harke, & Denke, 2016) and chronic back pain (Carvalho et al., 2016). In contrast, a 
pilot open-label study with patients suffering from major depression did not find significant 
improvements compared to a waitlist control group; yet a medium effect size for open-label 
placebos was found, exceeding standardized drug-placebo differences reported in 
antidepressant RCTs (Kelley et al., 2012).  
Despite these promising results, open-label placebos with full disclosure have not been 
directly compared to deceptive placebo administration yet. Still, given the long hold belief of 
an inextricable interconnection between deceit and placebo usage (Foddy, 2009; Miller, 
Wendler, & Swartzman, 2005), an empirical investigation testing the necessity of deception in 
placebo application is most warranted. Such a study design requires a real life “deceptive 
administration” where participants in the deceptive placebo group are fully deceived at the 
beginning of the pharmacological treatment and have a 100% expectation of receiving an active 
medication, while, in fact, get a placebo. This stands in contrast to the “double-blind 
administration” where participants know that they have a 50% chance of receiving a placebo 
(Kirsch & Weixel, 1988; Koshi & Short, 2007). In the case of depressed patients, however, the 
comparison of an open-label placebo administration and a real life “deceptive administration” 
is ethically not appropriate: For instance, according to the Declaration of Helsinki in its most 
recent formulation, the use of placebo is only justifiable under the condition that no proven 
intervention exists but also where “for compelling scientifically sound methodological reasons, 
[it] is necessary to determine the efficacy or safety of an intervention”, provided that “the 
patients who receive placebo . . . will not be subject to additional risks of serious or irreversible 
harm” (World Medical Association, 2013). Antidepressants are considered as a proven 
intervention and to discontinue or delay a pharmacological treatment in order to receive a 
deceptive placebo administration could result in a potential risk. Under these circumstances, 
basic research with healthy participants represent a viable alternative. In that case, also the 
breach of trust in physicians and the medical profession can be spared (Wendler & Miller, 
2004). Here, one of the best examined conditions in placebo research with healthy volunteers 
is experimental pain (Benedetti, 2014) where it has been shown that the placebo treatment 
reveals a large effect size (Vase, Riley, & Price, 2002). Finally, at least to a certain extent, the 
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generalizability of experimental pain to clinical conditions is emphasized (Forsberg et al., 
2016). Therefore, it can be assumed that experimental pain offers an empirical starting point 
for a conceptual rethinking of the necessity of deception in placebo application. 
 2. Aims of the Thesis 
The aims of this thesis were twofold: One was to examine the efficacy of placebo and 
second-generation antidepressants in a pediatric and geriatric population, focusing on potential 
moderators of placebo outcomes. The identification of clinically significant placebo responses 
at certain stages over the lifespan where the efficacy and safety of antidepressants are of special 
concern would offer adapted treatment approaches. Here, it is worth considering whether 
powerful placebo responses can be harnessed in clinical practice—without violating ethical key 
principles of openness and transparency. Therefore, the second aim was to experimentally test 
the necessity of deception, by comparing ethically feasible open-label placebos with deceptive 
placebos.  
For this reason, two different statistical approaches were indicated. For the first aim, a 
meta-analytic approach was applied. Meta-analyses have the potential to reduce the complexity 
and scope of research findings as they statistically combine the evidence of individual studies 
with regard to the particular research question (Guyatt et al., 1995). By calculating a pooled 
estimate of the intervention effect by means of the intervention effects extracted from each of 
the included studies, a more reliable result can be obtained (Glass, 1976). 
For the second goal, a basic research approach with healthy participants was chosen. 
Experimental studies have the potential to provide greater insight into sources of variability of 
placebo effects since they allow to control for potential confounders (Price et al., 2008).  
The three investigations described in this thesis were therefore developed to add insight 
to the following research questions: 
 
(1) What potential do placebos have in pediatric and geriatric patients with depression when 
compared to antidepressants? 
 
Study I. The use of SSRIs and SNRIs in children and adolescents is still debated. 
Nevertheless, SSRIs and SNRIs are first line pharmaceutical treatments not only for MDD, yet 
also for AD, OCD and PTSD. At present, there is only one study comparing antidepressants in 
children and adolescents across these disorders. About ten years ago, Bridge et al. (2007) 
reported that the between antidepressant-placebo effect was strongest for anxiety disorders 
(Hedges’ g = 0.69), intermediate for OCD (Hedges’ g = 0.41), and only modest in MDD 
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(Hedges’ g = 0.20). This could be due to disorder-specific differences in placebo responses, 
which were not reported in the meta-analyses. Accordingly, D. Cohen et al. (2008) stated in a 
systematic review that the placebo response rate was significantly higher in pediatric studies on 
depression than in those AD and OCD. This is opposed to adult studies that found no significant 
differences in placebo effect size between depression and anxiety (Sugarman et al., 2014). 
Further and in contrast to adult studies, the influence of baseline severity on antidepressant-
placebo differences has rarely been studied in pediatric meta-analyses and did not emerge as a 
significant moderator in some studies (Bridge et al., 2009; Gibbons et al., 2012), whereas 
another meta-analysis reported the moderating effect of initial severity (Tsapakis, Soldani, 
Tondo, & Baldessarini, 2008). Thus, the goal of Study I was to conduct an updated and extended 
review to assess continuous mean differences between antidepressant and placebo interventions 
in pediatric MDD, AD, OCD, and PTSD along with between-disorder variation in placebo 
responses and moderators.  
 
Study II. Regarding late-life depression, the safety and efficacy of antidepressants is 
likewise controversial. Meta-analyses reveal that overall antidepressant effects are only modest 
for response and for remission when compared to a placebo administration (Kok et al., 2012; 
Nelson et al., 2008; Tedeschini et al., 2011; Tham et al., 2016). However, for all of these studies, 
statistical differences were only calculated for response and remission rates, yet not for 
continuous outcome data which would enable to evaluate clinical significance according to the 
NICE criterion. Also, dichotomizing continuous scores into categorical outcome data leads to 
a loss of information, reduces power and creates an artificial boundary (Altman & Royston, 
2006; Moncrieff & Kirsch, 2005). In contrast to mixed-aged findings, meta-analyses reported 
no association between initial severity and antidepressant over placebo efficacy in elderly 
people (Gibbons et al., 2012; Nelson, Delucchi, & Schneider, 2013) with the exception of 
patients suffering from depression for longer than 10 years (Nelson et al., 2013). However, 
these investigations rely on a limited number of studies and focused on MDD, only. It should 
be noted that a minority of depressed elderly patients fulfill the diagnostic criteria for MDD, 
yet elderly patients tend to underreport their symptoms, often relate it to physical burden and 
ageing itself (Giron, Fastbom, & Winblad, 2005), thus the rate of sub-threshold depression rises 
with age (Pinquart, Duberstein, & Lyness, 2006). Hence, in Study II, the goal was to conduct a 
meta-analysis in order to evaluate continuous mean differences between antidepressant and 
placebo interventions and to test whether baseline severity has an influence on outcome in a 
geriatric population with MDD, dysthymia and minor depression.  
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(2) How important is a deceptive placebo administration when compared with an ethically 
feasible open-label placebo administration in healthy participants?  
 
Study III. To date, open-label placebos with full disclosure have not been directly 
compared to deceptive placebo administration. Here, basic research with healthy participants 
represents an excellent way to experimentally compare these treatments in accordance with 
ethical principles. Therefore, the aim of study III was to compare the effects of open-label 
placebos with a deceptive placebo administration in a standardized heat pain experiment (Gaab 
et al., 2017; Krummenacher et al., 2014; Maeoka, Hiyamizu, Matsuo, & Morioka, 2015) in 
healthy participants. Additional control groups were an open-label placebo group without a 
rationale and a no treatment group.  
3. Methods  
3.1. Efficacy and Safety of SSRIs, SNRIs, and Placebo in Common Psychiatric Disorders: 
A Comprehensive Meta-Analysis in Children and Adolescents (Study I)  
Search strategy and study selection. We searched PubMed, Embase, PsycINFO, 
Cochrane, Web of Science, Clinicaltrials.gov and fda.gov and checked references of originally 
identified papers and reviews. Randomized, double blind, placebo-controlled trials of SSRIs 
and SNRIs in children and adolescents < 18 years of age published through August 2016 were 
included. Subjects were required to have a diagnosis of MDD, AD, OCD, or PTSD based on 
DSM-III, DSM-III-R, or DSM-IV-TR criteria. 
Outcome measures and data extraction. The primary outcome as defined by authors 
was chosen as the sole outcome measure for each individual study. Pre- and post-intervention 
data or mean change data had to be available. Outcomes had to be reported on a well-validated 
disorder specific scale (e.g., CDRS-R, MASC, CY-BOCS) or on a general severity scale (i.e., 
CGI-S). Only continuous outcome data were included.  
Data analysis. Comprehensive Meta-Analysis V3 (Biostat, Englewood, NJ) and R 3.2.1 
(R Foundation; Vienna, Austria) were used for calculations and analyses. Effect sizes were 
calculated as Hedges’ g (Hedges & Olkin, 1985). Random-effects models rather than fixed-
effects models were used. Fixed-effects model assumes that there is one true effect size for all 
studies and any variations are due to sampling error, whereas a random-effects model assumes 
that variations in effect sizes for the samples are a combination of sampling error and true 
variance in effect sizes (Borenstein, Hedges, Higgins, & Rothstein, 2010). Random effect sizes 
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were preferable for this meta-analysis as the studies we included were heterogeneous and the 
number of studies for the sub-analyses was relatively small. Three effect sizes were calculated 
for each included study. First, differences in mean change scores between groups were 
evaluated. Then, within-group pre-post effect sizes for both antidepressant and placebo were 
also calculated. They inform about whether a small difference between groups is explained by 
a small change in either group or a meaningful change in both groups over treatment time. 
Effect size differences between subgroups were analyzed using a mixed-effects model 
(Borenstein et al., 2010). Heterogeneity was assessed by calculating the Q statistic (Cochran, 
1950), the τ2, and the I2 (Higgins, Thompson, Deeks, & Altman, 2003). A statistically 
significant Q indicates a heterogeneous distribution, meaning that systematic differences 
between studies are present and it rejects the null-hypothesis that all the variation in effects is 
due to random error. Similarly, the higher the Q value, the more variation in the studies can be 
explained by a true variance of effects between studies (Cochran, 1954). In addition, the I2 
statistic was used to quantify inconsistency. It measures the proportion of observed variance 
across studies, that is a result of real heterogeneity rather than chance. An I2 value of 0% 
indicates no heterogeneity, a value of 25% is classified as low, 50% as moderate, and 75% as 
high (Higgins et al., 2003). The τ2 offers an estimate of the variance among true effect sizes 
(Higgins, 2008). Treatment emergent adverse events (TEAEs) and serious adverse events 
(SAEs) were examined across diagnosis categories to determine if emergent events differ 
between antidepressant and placebo administration. We also examined whether baseline 
severity of the studies is related to the between-group effect sizes. As various scales were used 
to assess baseline severity, we standardized the baseline and outcome values by dividing the 
mean values by the SD. The Z statistic was used to test the significance of the slope. In the case 
that data conforms to the null hypothesis, Z has a normal distribution. A significant Z would 
indicate that the slope is probably not zero, and hence that baseline depression severity 
moderates the effect size (Borenstein, Hedges, Higgins, & Rothstein, 2011). 
3.2. Moderation of Antidepressant and Placebo Outcomes by Baseline Severity in Late-
Life Depression: A Systematic Review and Meta-Analysis (Study II) 
Search strategy and study selection. We performed searches in Cochrane, Embase, 
PsycINFO, PubMed, and Web of Science on studies published through September 30, 2014. 
We included peer-reviewed randomized, double-blind, placebo-controlled clinical trials of 
depressed elderly individuals in a placebo group with depressed elderly individuals in an 
intervention group receiving second-generation antidepressants. The minimum age criterion 
was set at a mean or median age of 55 years, or described as elderly, geriatric or older adults. 
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We included studies investigating patients with MDD or subclinical depressive symptoms (i.e., 
minor depressive disorder or dysthymia) based on DSM-III, DSM-III-R, DSM-IV or DSM-IV-
TR. Studies in which patients had depression following cerebrovascular disease, a cognitive 
impairment, or Parkinson's disease were excluded.  
Outcome measures and data extraction. Outcomes had to be reported as mean change 
in depressive symptoms on a continuous mood scale, such as the HDRS (Hamilton, 1967) or 
Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979). 
Data analysis. Comprehensive Meta-Analysis V2 (Biostat, Englewood, NJ) was used 
for calculations and analyses. Effect sizes were calculated as Hedges’ g (Hedges & Olkin, 
1985). For the analyses we chose to use random-effects models rather than fixed-effects models 
(Borenstein et al., 2010; see Study I for details). Differences in mean change scores between 
groups were evaluated. Moreover, within-group pre-post effect sizes for both antidepressant 
and placebo were calculated. Heterogeneity was assessed by calculating the Q statistic 
(Cochran, 1950) and the I2 (Higgins et al., 2003; see Study I for details). To assess the 
moderating effect of baseline depression severity on outcome measure (i.e., mean change in 
depressive symptoms), we conducted within-group and between-group comparisons. We first 
converted the different mood scales to a standardized scale (range 0–100), using the largest 
point of each mood scale as 100%. The Z statistic was used to test the significance of the slope 
(see Study I for details). To test the moderating effect of baseline depression severity on 
outcome measures within each group, we performed meta-regression using method-of-
moments analyses (random-effects model). Further, we analyzed the mean difference scores to 
test the hypothesis that between-groups mean differences increase as a function of baseline 
depression severity. We calculated the overall baseline severity for each study (i.e., mean of 
antidepressant and placebo baseline severity, weighted by number of participants) and the 
antidepressant-placebo difference in improvement. Pearson's correlation between those two 
variables was calculated.  
3.3. Is the Rationale More Important than Deception? A Randomized Controlled Trial of 
Open-Label Placebo Analgesia (Study III)  
Between January 2016 and July 2016, healthy adults from the general Swiss population 
were recruited via advertisements for “a novel mind-body management study of individual pain 
perception”. They had to be healthy by self-report, right-handed, aged between 18 and 65 years 
and have sufficient German language skills. 
Data analysis. Participants were randomly assigned to no treatment (NT; N = 40), open-
label placebo without rationale (OPR-; N = 40), open-label placebo with rationale (OPR+; N = 
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40), and deceptive placebo (DP; N = 40). Upon arrival, all participants performed an objective 
baseline assessment of heat pain, as well as subjective heat pain ratings. After baseline 
measurements, the treatment phase was conducted. Participants in the NT group did not receive 
any treatment and were told that they are in the “no treatment group”. All participants in the 
three other groups (OPR-, OPR+, and DP) received an inert white placebo cream. In the OPR- 
group, participants were informed that they are receiving an inert placebo cream and no 
additional information regarding placebo mechanisms was provided. In the OPR+ group, 
participants were informed that they are receiving an inert placebo cream and obtained scientific 
explanations of the effects and mechanisms of placebos which were in accordance with the 
study of Kaptchuk et al. (2010). In the DP group, participants were told that they are receiving 
an analgesic cream—named “Antidolor”, containing the active substance Lidocaine—in fact 
they received an inert placebo cream. After the treatment phase, heat pain measurement 
procedures were performed again (posttreatment), regardless of group allocation. 
Primary outcomes. Pain sensation was assessed using the suprathreshold method of 
the Thermo Sensory Analyser (TSA-II). Objective heat pain tolerance was determined using 
the method of limits: Participants were asked to stop the increasing heat stimulus at the moment 
they could not stand the heat any longer. Three measurements were taken, each starting at 32 
°C, with a rise of 0.5 °C every second (Granot, Sprecher, & Yarnitsky, 2003). Following each 
heat pain tolerance stimulation, participants were asked to rate pain intensity and 
unpleasantness on Visual Analogue Scales (VAS) (Price et al., 1999). The intensity VAS with 
a range from 0 up to 100 was titled at the left by the descriptors “no pain sensation” and at the 
right by “the most intense pain sensation imaginable”. Similarly, the unpleasantness VAS 
(ranged from 0–100) was anchored by the descriptors “not at all unpleasant” and “the most 
unpleasant imaginable”. 
Statistical analyses. Primary outcomes were objective heat pain tolerance and the 
corresponding subjective intensity and unpleasantness ratings. For posttreatment heat pain 
tolerance, we calculated one one-way analysis of covariance (ANCOVA), using the treatment 
group (NT, OPR-, OPR+, and DP) as independent between-subject factor and baseline heat pain 
tolerance as covariate. Regarding intensity and unpleasantness ratings for heat pain tolerance at 
posttreatment, we conducted two separate one-way ANCOVAs with treatment group as 
between-subject factor and the corresponding outcome variable measured at baseline as 
covariate. For all three primary outcome ANCOVAs, we tested three orthogonal planned 
contrasts (one-tailed): (c1) NT group vs groups with a cream application (OPR-, OPR+, and 
DP), (c2) OPR- group vs groups with a rationale (OPR+ and DP) in order to test the significance 
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of the rationale; and (c3) OPR+ group vs DP group in order to evaluate the significance of 
deception. We calculated Cohen’s d in order to describe the standardized mean difference of an 
effect. We interpreted effect sizes as small (d = 0.2), medium (d = 0.5), and large (d = 0.8) based 
on benchmarks suggested by Cohen (J. Cohen, 1988). R 3.3.2 (R Foundation; Vienna, Austria) 
was used for calculations and analyses. 
4. Summary of the Results  
4.1. Efficacy and Safety of SSRIs, SNRIs, and Placebo in Common Psychiatric Disorders: 
A Comprehensive Meta-Analysis in Children and Adolescents (Study I)  
Our search identified thirty-six randomized, double blind trials including 6778 
participants that compared an SSRI or an SNRI against placebo in patients < 18 years with a 
diagnosis of MDD (N = 17), AD (N = 10), OCD (N = 8), or PTSD (N = 1). No disorder-specific 
subgroup analyses were calculated for PTSD, since only one study fit our inclusion criteria.  
In the between group analysis stratified by disorder, AD (g = 0.56, 95% CI [0.40, 0.72], 
p < .001) and OCD (g = 0.39, 95% CI [0.25, 0.54], p < .001) did not differ from each other (p 
= .14) but both were significantly higher (AD vs MDD: p < .001 and OCD vs MDD: p = .02) 
than the MDD group (g = 0.20, 95% CI [0.13, 0.27], p < .001). The within antidepressant group 
analysis stratified by disorder yielded no significant difference (p = .06) between studies of AD 
(g = 1.58, 95% CI [1.35, 1.81], p < .001) and MDD (g = 1.85, 95% CI [1.7, 2.0], p < .001), yet 
both yielded significantly larger effect sizes (ps < .001) than studies of OCD (g = 1.01, 95% CI 
[0.88, 1.14], p < .001). The within placebo group analysis stratified by disorder yielded a large 
placebo response for studies of MDD (g = 1.57, 95% CI [1.36, 1.78], p < .001), which was 
significantly larger (p < .001) than the effect size for studies of AD (g = 1.02, 95% CI [0.85, 
1.20], p < .001). The moderate placebo response in the OCD group (g = 0.63, 95% CI [0.47, 
0.79], p < .001) was significantly lower than both the MDD (p < .001) and AD (p = .001) 
groups.  
Side effect analysis. Compared to placebo, patients taking both SSRIs and SNRIs 
reported significantly more SAEs (SSRI: 6.80%, SNRI: 7.59%) compared to placebo (3.32%; 
p = .01), but reported no significant difference in TEAEs. 
Moderator analysis. The relationship between effect size and baseline severity was not 
significant, whether in the MDD (Z = 1.21, p = .23), nor in the AD (Z = −1.18, p = .24), or OCD 
(Z = −0.33, p =.74) subgroup analyses.  
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4.2. Moderation of Antidepressant and Placebo Outcomes by Baseline Severity in Late-
Life Depression: A Systematic Review and Meta-Analysis (Study II) 
In total, 19 studies met inclusion criteria, including a total of 5737 elderly depressed 
patients, of whom 3226 received active drug and 2511 received placebo. Based on HDRS17, 
classification of baseline depression severity ranged from mild to very severe.  
Combined over all mood scales, patients in the treatment groups showed a significantly 
higher mean change in depressive symptoms than patients in the placebo groups (g = 0.37, 95% 
CI [0.27, 0.46], p < .001). Pre-post effect sizes revealed that there is a significant treatment 
improvement in antidepressant groups (g = 1.35, 95% CI [1.14, 1.57], p < .000), as well as in 
placebo groups (g = 0.96, 95% CI [0.79, 1.13], p < .000). To clarify further the clinical 
significance of the differences between the two treatments, we referred to the NICE guidelines 
(2004). For elderly patients with mild to moderate depression (HDRS17 score of ≤ 18), Cohen's 
d was .24 (95% CI [0.02, 0.47], p = .031), for patients with an HDRS17 score in the severe 
range (19–22), Cohen's d was .39 (95% CI [0.25, 0.52], p < .001), and for patients with HDRS17 
score in the very severe range (≥ 23), we found an effect size of d = .37 (95% CI [0.09, 0.66], 
p = .011). In summary, none of the values reached the proposed cut-off of d = .5 for clinical 
significance. However, the criterion of a difference of ≥ 3 points on the HDRS was met for 
baseline HDRS17 scores of ≥ 21. 
Moderator analysis. The slope representing the overall relationship between baseline 
severity and change in symptoms was not significant in either antidepressant groups (Z = 1.47, 
p = .142) or placebo groups (Z = 1.38, p = .168), nor was baseline severity significantly 
correlated with drug-placebo differences (r =.17, p = .392). In contrast, subgroup analyses of 
studies using the clinician-rated HDRS mood scale indicated that mean change in depressive 
symptoms increased significantly in antidepressant trials (Z = 2.67, p = .008, R2 = .40) and 
placebo trials (Z = 4.46, p < .000, R2 = .50) as a function of HDRS baseline severity. However, 
this would be expected as a result of regression toward the mean, and mean differences between 
groups did not increase (r = .19, p = .469) as a function of baseline severity.  
4.3. Is the Rationale More Important than Deception? A Randomized Controlled Trial of 
Open-Label Placebo Analgesia (Study III)  
Participants had a mean age of 27.15 (SD = 9.51) years and 68% of the participants were 
female. 
Objective heat pain tolerance. Planned contrasts indicated that the groups did not 
differ regarding their objective heat pain tolerance at posttreatment (NT vs. OPR-, OPR+, and 
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DP: t(146) = 0.35, p = .724; OPR- vs. OPR+ and DP: t(146) = 1.15, p = .254; OPR+ vs. DP: 
t(146) = 0.37, p = .711). 
Subjective heat pain ratings. Planned contrasts indicated that the NT group and the 
other three groups did not differ in heat pain intensity ratings at posttreatment (c1: t(146) = -
0.44, p = .658). However, the two groups with a rationale (OPR+ and DP group) showed 
significantly lower ratings at posttreatment when compared to the OPR- group (c2: t(146) = -
2.15, p = .033, d = 0.43). Further, the OPR+ and DP group did not differ from each other (c3: 
t(146) = −1.10, p = .272). Results for heat pain unpleasantness ratings at posttreatment were 
similar. No difference was found between the NT group and the three other groups (c1: t(146) 
= −1.38, p = .169). Participants in the two groups with a rationale (OPR+ group and DP) reported 
lower ratings at posttreatment compared to participants from the OPR- group (c2: t(146) = 
−2.43, p = .016, d = 0.49), and the OPR+ and DP group did not differ from each other (c3: t(146) 
= −0.05, p = .961).  
5. General Discussion  
One aim of this thesis was to assess differences between antidepressant and placebo 
interventions in pediatric (Study I) and geriatric (Study II) patients in order to evaluate the 
potential of placebos in age categories where the efficacy and safety of antidepressants are of 
special concern. Given that patients of different ages demonstrate robust placebo responses in 
antidepressant trials, it is worth considering whether this can be harnessed in clinical practice. 
Despite promising results of an ethically feasible placebo administration with full disclosure, 
open-label placebos have not been directly compared to deceptive placebo administration yet. 
Therefore, a further goal of this thesis (Study III) was to compare the effects of open-label 
placebos with a deceptive placebo administration in a standardized heat pain experiment.  
 Results of study I and II showed that second-generation antidepressants are more 
effective than placebo at treating depression in children and adolescents (Hedges’ g = 0.20, 
Study I), as well as in elderly people (Hedges’ g = 0.37, Study II). However, in both cases, the 
effect is only small and did not reach the proposed cut-off of a standardized effect size of 0.5 
for clinical significance according to the NICE criterion. The small effect size between 
antidepressants and placebo in pediatric and geriatric MDD might be due to lack of a clear 
depression phenotype. This was apparent in DSM-5 Field Trials, which found a low and 
questionable test-retest reliability (kappa: 0.28) for MDD (Regier et al., 2013). Especially for 
children, it may be more challenging to diagnose depression, as the symptoms are assumed to 
be more nonspecific than in adult depression (Parellada et al., 2012). Similarly, there is 
substantial heterogeneity in late-life depression and sub-threshold or minor depressive disorders 
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among elderly people are common (Taylor & Doraiswamy, 2004). Also, geriatric patients 
showed a smaller within-antidepressant group effect size (Hedges’ g = 1.35, Study II) when 
compared to pediatric patients with depression (Hedges’ g = 1.85, Study I). These preliminary 
findings are consistent with the assumption that geriatric patients have a limited response to 
antidepressants or require more time to respond to medication treatment (Alexopoulos et al., 
2007; Walsh & Sysko, 2005).  
Also, findings of our meta-analyses revealed that the within-placebo group effect size 
in depressed youth (Hedges’ g = 1.57, Study I), as well as in depressed elderly (Hedges’ g = 
0.96, Study II), is substantial. On the one hand, it is possible that placebo effects might be even 
more substantial than reported. Thus, placebo effects are larger in experimental studies which 
explicitly investigate mechanisms of placebos than in RCTs where placebos are only used as a 
control condition (Vase et al., 2002). Further, the test of the blind in double-blind designs 
usually reveals that group allocation is penetrated and thus susceptible to the researcher’s 
assumption that the active drug will be more effective than the placebo (Fisher & Greenberg, 
1993). On the other hand, the observed placebo response can be attributed to a variety of factors 
such as natural history factors (e.g., improvement, worsening), and measurement factors (e.g., 
regression to the mean, rater bias and response bias [Rutherford & Roose, 2013]), as well as 
confounding variables such as unreported co-interventions (Benedetti, 2008). Moreover, the 
additivity assumption, that the difference between antidepressant response and placebo 
response is attributable to the pharmacological effect of the antidepressant, has rarely been 
tested in scientific research (Wager & Roy, 2010) and may be incorrect (Kirsch, 2000), thus 
leading to underestimated antidepressant effects in RCTs (Lund, Vase, Petersen, Jensen, & 
Finnerup, 2014). Generally, it is noteworthy that the placebo efficacy in late-life depression is 
about the same when compared to mixed-aged studies (e.g., Sugarman et al., 2014), while, 
however, children and adolescents show a substantially higher placebo response. These 
comparisons—which should be directly compared in a future meta-analytical or experimental 
investigation in order to give conclusive answers—underline the finding that children and 
adolescents tend to improve more with placebos when compared to adults (Janiaud et al., 2017; 
Rutherford & Roose, 2013).  
 Study I and II did not confirm the severity hypothesis proposed in mixed-aged studies, 
in which an increasing advantage of antidepressants over placebo was reported with increasing 
baseline severity (Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008). Our failure to 
find an association between initial severity and antidepressant over placebo efficacy is similar 
to previous pediatric and geriatric studies (Bridge et al., 2009; Gibbons et al., 2012; Nelson et 
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al., 2013). Here, it should be questioned whether the placebo moderators that have been 
explored so far are uniquely important for adults as opposed to children and elderly people.  
Overall, the significant response to placebo in pediatric and geriatric MDD indicates 
that children and elderly people with depression might benefit from innovative treatment 
modalities that attempt to harness the power of the placebo effect in an ethical fashion. Here, 
findings of study III revealed that open-label placebos do not differ in their effects from 
deceptive placebos in subjective outcomes. Therefore, the ubiquitously assumed necessity of 
concealment in placebo administration is questioned.  
5.1 Efficacy and Safety of SSRIs, SNRIs, and Placebo in Common Psychiatric Disorders: 
A Comprehensive Meta-Analysis in Children and Adolescents (Study I) 
The robust response to placebo in pediatric MDD is associated with the finding that 
especially depressed youths have a maximum benefit from contact with research staff who 
invests in the therapeutic alliance and promotes confidence and self-esteem (D. Cohen et al., 
2008; Rutherford et al., 2011). Interestingly, patient expectancy in clinical trials seems to play 
a minor role in the treatment of depressed children and adolescents when compared to adults 
since for pediatric depression, antidepressant response in comparator and placebo-controlled 
trials do not differ significantly (Rutherford et al., 2011). Here, it has been proposed that 
children are less cognitively primed to understand the rationale of the study in which they are 
participating, and that they receive less information at the study enrollment since the parents 
provide informed consent (Rutherford & Roose, 2013). However, especially in depressed 
pediatric patients, family members have an emotional response to the benefit of the treatment 
and hope that the intervention will work (Grelotti & Kaptchuk, 2011; Simmons et al., 2014) 
and parental expectancies, in turn, have a great impact on the treatment outcome of the child 
(Whalley & Hyland, 2013).  
While it appears that the response to placebo is robust in pediatric MDD, children and 
adolescents with anxiety disorders, who respond to antidepressants to the same degree as those 
with MDD, do not appear to exhibit such a robust placebo response. While in line with older 
reviews in children (D. Cohen et al., 2008) this is in contrast to adult studies that found no 
significant differences in placebo effect size between depression and anxiety (Sugarman et al., 
2014). One explanation might be that children and adolescents with MDD may be more 
demoralized than patients with anxiety disorders and are therefore more sensitive to changes in 
hope and favorable meanings (D. Cohen et al., 2008). Further, patients with OCD exhibited a 
significantly smaller response to both antidepressant and placebo treatment compared to AD 
and DD. Here, another feasible explanation is possible: Treatment expectations could vary 
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between disorders since antidepressants have been widely promoted for depression (Lacasse & 
Leo, 2005), yet considerably received less focus in the general population for the treatment of 
anxiety disorders and OCD. However, as no pediatric trial included a no-treatment group that 
could serve as a control for the natural course of the disorders, the difference in placebo 
response may also reflect differences in the probability of spontaneous improvement between 
the pediatric disorders rather than differences in the placebo effect. 
 With regard to side effects, our meta-analysis found that pediatric patients taking 
antidepressants do not report more treatment emergent adverse events than those assigned to 
placebo. Here, it has been shown that negative expectations from investigators and patients can 
influence adverse effect reporting (Rief et al., 2011) and that depressed patients may attribute 
pre-existing symptoms, which are common in the general population (e.g., headache, 
abdominal discomfort) to the intake of antidepressants (Rief et al., 2009). However, these 
explanatory approaches may not apply to serious adverse events. In our study, the serious side 
effects profiles for antidepressants significantly exceeded that of the placebo group. Here, our 
results regarding serious side effect profiles support concerns about the safety of antidepressants 
in children and adolescents (Bridge et al., 2007; Sharma et al., 2016).  
5.2. Moderation of Antidepressant and Placebo Outcomes by Baseline Severity in Late-
Life Depression: A Systematic Review and Meta-Analysis (Study II) 
The finding of a meaningful placebo response in late-life depression is in line with 
present knowledge. Hence, augmented clinical visits and supportive care generate greater 
placebo, yet not antidepressant response in elderly depressed patients (Rutherford et al., 2014). 
Also, in clinical trials with depressed elderly patients, perceived social support is associated 
with subsequent decrease in depressive symptoms (Oxman & Hull, 2001) and increases 
probability of recovery (Bosworth, Hays, George, & Steffens, 2002). It has been argued that 
the impact of social support on treatment outcome is especially relevant for elderly patients, as 
they often live alone and may have little social contact (Bingel et al., 2011). Likewise, it has 
been reported that self-rated reclusiveness predicts response in a supportive patient-practitioner 
relationship (Conboy et al., 2010). Also, as in mixed-aged studies, antidepressant response rates 
are significantly higher (60%) in comparator trials than those in placebo-controlled trials (46%) 
in late-life depression, indirectly underlining the impact of expectancy on treatment outcome 
(Sneed et al., 2008).  
 The finding of a non-association of baseline severity and antidepressant-placebo 
differences may be influenced by the initial severity grades of the trials under investigation. We 
included only one study of very severely depressed patients reporting a HDRS baseline severity 
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of 26.9 (Heun et al., 2013). The fact that only a few investigations have focused on severely 
depressed elderly patients (Kok et al., 2012) may be closely related to restrictive inclusion 
criteria in clinical trials for late-life depression (Konrat et al., 2012; Zimmerman et al., 2016).  
5.3. Is the Rationale More Important than Deception? A Randomized Controlled Trial of 
Open-Label Placebo Analgesia (Study III) 
We found that healthy participants given open-label placebos with a persuasive rationale 
showed a decrease in subjective heat pain intensity and unpleasantness ratings of pain tolerance 
which, surprisingly, did not differ significantly from deceptive placebo administration. Hence, 
the necessity of deception in placebo application—at least in healthy participants—needs to be 
reconsidered. This indicates that the ethically troubling component of placebos—a counterfeit 
rationale (Blease, Colloca, & Kaptchuk, 2016)—may under certain circumstances be 
comparable to a transparent and scientific rationale.  
In line with our hypothesis, the provision of a convincing rationale, either open or 
deceptive (OPR+ and DP), did outperform the placebo cream application without any rationale 
(OPR- group) with regard to subjective ratings for heat pain tolerance. This confirms the finding 
of an older study, showing that for a verum (i.e., naproxen) as well as for a placebo, the 
analgesic effect is significantly better in the informed-consent group when compared to the 
uninformed group (Bergmann et al., 1994). The impact of the comprehensible theoretical 
embedding, which was offered to the participants in both groups, underlines the importance of 
plausibility and conviction of treatment rationales (Borkovec & Nau, 1972). Our finding is also 
interesting when focusing on the one pilot study with only 20 participants investigating open-
label placebo administration in patients suffering from depression (Kelley et al., 2012) which 
reported ambiguous findings: There were no significant improvements in comparison to a 
waitlist control group, though a medium effect size for open-label placebos was found (d = 
0.54), which is larger than typical antidepressant-placebo differences in clinical trials and above 
the criterion for clinically significant improvement defined by NICE. It should be noted, 
however, that the rationale of the open-label placebo administration was in accordance with the 
Kaptchuk et al. (2010) study, which was originally developed for patients suffering from pain 
conditions (see Section 1.5 for details). Here, it is most likely that additional openly 
communicated and disorder-specific explanatory mechanisms besides classical conditioning, 
such as the impact of the patient-physician relationship and psychological variables (e.g., the 
transformation from hopelessness into hope, called remoralization), would make the rationale 
more plausible—an aspect which is utmost important for any treatment to be effective (Frank, 
1986; Wampold & Imel, 2015). 
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5.4. Limitations 
Our non-significant findings regarding the severity hypothesis in study I and II must be 
considered with caution. First, for both studies, heterogeneity was small to moderate between 
trials, making it very unlikely to find moderators. Also, multivariate analyses in study I may 
have lacked the power to reveal statistically significant interaction effects (Gerger, Hlavica, 
Gaab, Munder, & Barth, 2015). A randomized trial in which participants are stratified by the 
predictor under investigation (Cuijpers, Van Straten, Warmerdam, & Smits, 2008) or a patient-
level meta-analysis (Fournier et al., 2010) might be better suited to investigate the association 
between baseline severity and effect sizes. Regarding our meta-analyses with depressed 
children and adolescents (Study I), none of the included trials directly compared the 
effectiveness across disorders and, therefore, only indirect conclusion with regard to disorder 
specificity can be made. Also, it is well known that if studies are genuinely diverse, the pooled 
effect-size may be invalid (the so-called apple and oranges problem) (Gerger & Gaab, 2016; 
Sharpe, 1997). However, we mainly focused on effect sizes stratified by disorder, rather than 
the combined effect sizes across all disorders. The meta-analysis with geriatric patients (Study 
II) was limited to published data, which may have resulted in a considerable bias towards 
studies reporting a benefit of antidepressants over placebo (Turner et al., 2008). 
Regarding study III, subjective intensity and unpleasantness ratings are not independent 
of the corresponding objective heat pain tolerance. Thus, differences in subjective heat pain 
ratings could be suppressed since assessing heat pain tolerance allows participants to stop the 
pain stimulus at different points in time. However, in our study, objective heat pain tolerance 
and the corresponding subjective ratings were not correlated. Further, we did not find the 
hypothesized group differences between the no treatment group and the combined effect of the 
three other groups. This may be due to the conceptual heterogeneity between the three groups 
receiving the placebo cream. Also, we only found significant group differences in subjective 
heat pain ratings and not in objective heat pain tolerance. Nevertheless, our findings are in line 
with the view that placebos primarily affect subjective self-report (Kaptchuk & Miller, 2015) 
5.5. Conclusions and Implications for Future Research 
Despite these limitations, the result of this thesis—that there is a substantial placebo 
response in depressed children and elderly people—shows that those patients seem to respond 
well to clinician contact that promotes the therapeutic alliance and other common factors such 
as the patients’ expectations and hopes of improvement. This is especially relevant since both 
the safety and efficacy of antidepressants is controversial in these sensitive populations. Here, 
a stepwise approach is proposed, i.e., to initially offer depressed children and elderly people 
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psychosocial interventions—a safer alternative—and only consider antidepressants if patients 
do not response. Further, the results of this thesis point to the need for additional research into 
the factors that moderate the efficacy of antidepressants and placebos in children and elderly 
people; similarly, additional research in understanding the developmental ontogeny of the 
placebo response is highly warranted. 
Besides the use of psychosocial interventions, another way to harness the powerful effect of 
placebos in clinical practice without the violation of patients’ autonomy are open-label 
placebos. Here, survey findings suggest that adult patients accept the idea of using placebos 
within the clinic, but their attitudes depend on several factors, such as transparency (Fässler, 
Gnädinger, Rosemann, & Biller-Andorno, 2011). Similarly, a recent review of parental 
attitudes about placebo use in children revealed that parents would acknowledge the use of 
open-label placebos (Faria et al., 2017). Authors of earlier studies already argued that open-
label placebos could be prescribed with a “wait and watch” strategy before the administration 
of drugs (Kaptchuk et al., 2010) or to be administered after repeated intake of active drugs to 
achieve drug-like effects (Colloca, Enck, & DeGrazia, 2016). Moreover, open-label placebos 
may have the potential to work in treatment resistant patients, assumedly due to a form of 
empowerment (Carvalho et al., 2016). The question arises whether open-label placebos could 
be used as vehicles to boost placebo effects in depression. Experimental open-label placebo 
studies investigating the role of a plausible rationale in the field of depression are surely 
warranted (see Section 5.3. for details). Moreover, one should bear in mind that antidepressants 
are viewed as a long-term treatment including an acute, continuation and maintenance phase 
(Cartwright, Gibson, Read, Cowan, & Dehar, 2016). Withdrawal reactions when 
antidepressants are discontinued include a wide range of physical and psychological symptoms 
and occur with any type of antidepressants (Fava, Gatti, Belaise, Guidi, & Offidani, 2015). 
When patients taper down their dosage, withdrawal symptoms are usually attributed to 
pathophysiological mechanisms. However, it is well known that an open (i.e., expected) 
interruption of drugs is accompanied by fear and negative expectations of symptom relapse, 
mechanism which are characteristic for the nocebo effect (Benedetti, Lanotte, Lopiano, & 
Colloca, 2007). Here, open-label placebos could bear the potential to be deployed as a 
replacement therapy. With regard to clinical care, findings of study III, indicate that an open 
application of a placebo with a convincing rationale is more effective than an open application 
of a placebo without a rationale or theoretical embedding and call attention to whether 
physicians may best benefit from placebo effects by enhancing patients’ expectation through 
communication and a convincing story behind any intervention.   
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Abstract 
Importance: Depressive disorders (DD), anxiety disorders (AD), obsessive-compulsive disorder 
(OCD), and posttraumatic stress disorder (PTSD) are among the most common mental disorders 
in children and adolescents. 
 
Objective: To examine the relative efficacy and safety of SSRIs, SNRIs and placebo for the 
treatment of DD, AD, OCD, and PTSD in children and adolescents. 
 
Data Sources: PubMed, Embase, PsycINFO, Web of Science, and Cochrane through August 
2016.  
 
Study Selection: Published and unpublished randomized, double-blind, placebo controlled 
studies of SSRIs or SNRIs in youth diagnosed with DD, AD, OCD, or PTSD were included. 
Trials that used other antidepressants (e.g. tricyclic antidepressants, MAOIs) were excluded.  
 
Data Extraction and Synthesis: Effect sizes (ES) were summarized as standardized mean 
differences (Hedges’g) in a random-effects model.  
 
Main Outcome(s) and Measure(s): Primary outcomes as defined by authors on pre- and post-
intervention data or mean change data and side effect data were extracted independently by 
multiple observers following PRISMA guidelines. 
  
Results: We deemed 36 studies eligible, including 6778 participants; 17 studies for DD, 10 for 
AD, 8 for OCD and one study for PTSD. Overall, SSRIs and SNRIs were significantly more 
effective compared to placebo, yielding a small effect size (g=0.323, p<0.001). AD (g=0.557, 
p<0.001) showed significantly larger between group ES than DD (g=0.201, p<0.001). This 
difference was driven primarily by the placebo response: patients with DD exhibited 
significantly larger placebo responses (g=1·569, p<0·001) compared to those with AD (g=1.023, 
p<0.001). Compared to placebo, patients taking either SSRIs or SNRIs reported significantly 
more serious adverse events (SSRI: 6.80% and SNRI: 7.59% vs. placebo: 3.32%; ps≤0.05), but 
showed no significant difference in treatment emergent adverse events (p=0.73). No moderator 
was significant in the multivariate meta-regression. 
 
Conclusion and Relevance: SSRIs and SNRIs are more effective than placebo, however, the 
effect is small and disorder-specific, yielding a larger effect for AD than for other conditions. 
Response to placebo is large, especially in DD. Adverse event profiles appear to be disorder-
dependent, and serious adverse events are significantly more common in SSRIs and SNRIs 
compared to placebo.  
  
Introduction 
Depressive disorders (DD), anxiety disorders (AD), obsessive-compulsive disorder (OCD), and 
posttraumatic stress disorder (PTSD) are among the most common mental disorders in children 
and adolescents 1. All these disorders are major public health concerns and predict long-term risk 
for various adverse outcomes 2. Thus, early diagnosis and proper treatment is of critical 
importance. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine 
reuptake inhibitors (SNRIs) are first line pharmaceutical treatments for these disorders 3. This 
meta-analysis aims to contribute to the current literature by comparing the efficacy of these drugs 
across the disorders for which they are primarily prescribed in a pediatric population, focusing 
on differences in the response to placebo as well as differences in side effects.  
 Since the release of fluoxetine in the mid 1980’s, the number of SSRIs and SNRIs has 
grown dramatically. However, their use in children and adolescents is still debated. This relates 
to the need for more research into their safety and efficacy as well as questions about 
comparative efficacy for the newer SNRIs versus SSRIs 5. Current data suggests that fluoxetine 
has the most favorable risk-benefit ratio in pediatric DD 6, but recent meta-analyses generate 
many questions about the overall benefits versus costs of using SSRIs to treat major depression 
in children and adolescents 7. The small amount of research on SNRIs for pediatric DD has had 
mixed results 8. One meta-analysis on pediatric depression found that while SSRIs differed 
significantly from placebo, SNRIs and tricyclic antidepressants did not 9.  
 Although most prior reviews and meta-analyses of the effects of SSRIs and SNRIs 
focused on pediatric DD, considerable data also exist on pediatric AD and OCD. The latter 
studies suggest that most SSRIs (fluoxetine, fluvoxamine, sertraline and paroxetine) have a 
favorable risk-benefit ratio, while there are insufficient data for the remaining SSRIs (citalopram, 
escitalopram) 8. There have been relatively few studies on SNRIs for pediatric AD, despite the 
fact that the only FDA-approved agent for pediatric AD, duloxetine, is an SNRI. No double-
blind RCTs of SNRIs for pediatric OCD have been conducted as of 2016, and only very limited 
data have been reported for either SSRIs or SNRIs in pediatric PTSD 10.  
 In addition to disorder-specific and drug-specific analyses, another segment of the 
literature on SSRIs/SNRIs among pediatric cases has focused on safety and tolerability. Research 
indicates a high risk of developing treatment emergent adverse effects (TEAEs), most 
prominently headache and nausea, during treatment with an antidepressant, including SSRIs and 
SNRIs, in pediatric DD 9. More severe side effects such as an increased risk of suicidal thoughts 
and behavior in adults and youth taking antidepressants have also been reported 11, leading to the 
implementation of a “black box” warning on the labels of all antidepressants for pediatric use by 
the FDA in 2004. However, this remains controversial due to conflicting results of re-analyses of 
the data 12. Additionally, no recent meta-analyses have focused on how pediatric side effect 
profiles of SSRIs, SNRIs, and placebo might differ across disorders.  
Finally, there is a growing body of literature that aims to consider the role of placebo 
effects in studies of SSRIs and SNRIs, based on large placebo response rates in studies of 
antidepressants in both adult and pediatric samples 13. Factors such as the contact with research 
staff may lead to high placebo response rates in pediatric depression 14 and may in fact explain 
much of the variability in pediatric antidepressant trials 15. For adult patients with DD, a genuine 
placebo effect is discussed, as the combination of placebo and supportive care has been shown to 
be more effective than supportive care alone 16. Conversely, patients in the placebo group also 
demonstrate treatment emergent adverse events 9. However, how response to placebo differs 
across disorders or other study design features in pediatrics is relatively understudied.   
To our knowledge, only one other review or meta-analysis has examined the use of 
SSRIs and SNRIs across DD, AD, OCD, and PTSD 17. However, that earlier study is now nearly 
a decade old and predates eleven primary studies (n=2068) that fulfill our inclusion criteria. The 
earlier review also did not include any studies on duloxetine, which is currently the only 
medication approved for pediatric AD. We therefore conducted an updated and extended review 
to assess the efficacy and safety of these drugs for DD, AD, OCD, and PTSD along with 
between-disorder variation in these drug and placebo responses. Psychological therapies will not 
be part of this meta-analysis, however, a recent review has compared psychological therapies 
alone and in combination with antidepressant medication for depression in children and 
adolescents 4. 
 
Methods 
Search Strategy and Study Selection: 
For this meta-analysis, we searched PubMed, Embase, PsycInfo, Cochrane, Web of Science, 
Clinicaltrials.gov and fda.gov and checked references of originally identified papers and reviews. 
For additional information on search terms, see Supplemental Material (S1). In total, this 
returned 4899 articles, which were reviewed by three authors (CL, HK, and SZ) (sFigure 1). We 
included randomized, double blind, placebo-controlled trials of SSRIs and SNRIs in children and 
adolescents < 18 years of age published through August 2016, including studies that examined 
drug vs. placebo in the context of a psychosocial intervention (i.e., drug+CBT vs. 
placebo+CBT), in which case the combination group was extracted only if no comparison of 
drug and placebo alone was given. Subjects were required to have a diagnosis of a depressive 
disorder, an anxiety disorder, obsessive-compulsive disorder, or posttraumatic stress disorder 
based on DSM-III, DSM-III-R, or DSM-IV-TR criteria. Comorbidity was allowed and any 
information about comorbid disorders was extracted. 
Case reports, comments, letters, gray literature, and reviews were excluded. Further, non-
second-generation antidepressants (e.g., monoamine oxidase inhibitors, tricyclic antidepressants) 
were excluded since they are not recommended as first-line medication for children and 
adolescents 18.  
 
Methodological Quality Assessment 
Two authors (CL and SZ) independently rated the quality of included papers according to the 
Cochrane Risk of Bias Assessment Tool 19, with final quality ratings based on consensus. Risk of 
Bias was assessed in individual studies (Table 1) and across studies (sFigure 2).  
 
Outcome Measures and Data Extraction:  
The primary outcome as defined by authors was chosen as the sole outcome measure for 
each individual study. Pre- and post-intervention data or mean change data had to be available. 
Outcomes had to be reported on a well-validated disorder specific scale (e.g., CDRS-R, MASC, 
CY-BOCS) or on a general severity scale (i.e., CGI-S). We included only continuous outcome 
data, since dichotomizing continuous scores into categorical outcome data leads to a loss of 
information, reduces power, and creates an artificial boundary 20,21. We did not extract data from 
improvement scales such as the CGI-I. If unavailable, data were requested directly from the 
authors. Some studies did not include SDs or SEs and they had to be imputed 22,23.  
Data were extracted independently by three authors (CL, HK, and SZ). Any discrepancies 
were resolved by consensus. To fit with our a priori hypotheses, data extraction concentrated on 
demographic information, dropout rates, adverse events, safety information, and baseline and 
endpoint assessment points. Data from open label extensions or follow up after the pre-
designated endpoint was not extracted. 
 
Data Analysis: 
Comprehensive Meta-Analysis V3 (Biostat, Englewood, NJ) and R 3.2.1 (R Foundation; Vienna, 
Austria) were used for calculations and analyses. Effect sizes were calculated as Hedges’ g 24. 
We chose to use random-effects models rather than fixed-effects models as the studies we 
included were heterogeneous and the number of studies for the sub-analyses was relatively small 
25. Three effect sizes were calculated for each included study. First, differences in mean change 
scores between groups were evaluated. We also calculated within-group pre-post effect sizes for 
both drug and placebo. Heterogeneity was assessed by calculating the Q statistic 26, the τ2, and 
the I2, a transformation of Q that indicates the proportion of observed variance that can be 
attributed to heterogeneity rather than sampling error 27. The τ2 offers an estimate of the variance 
among true effect sizes 28. Effect size differences between subgroups were analyzed using a 
mixed-effects model 29. 
Moderator analyses were conducted for six continuous moderators (treatment duration, 
publication year, illness duration, age of onset, number of sites, and baseline severity) and four 
categorical moderators (placebo lead-in, comorbidity, region, and primary funding source) for 
both the combined disorders group and individual disorders groups. We examined whether 
specific characteristics of the studies were related to the effect sizes (i.e., drug-placebo 
differences) in univariate analyses and multivariate regression analyses. Details of the applied 
statistical approaches are provided in the Supplemental Material (S5). 
 Publication bias was assessed visually by means of funnel plots 30 and formally by means 
of the fail-safe N 31 and the Begg adjusted-rank correlation test 32. We estimated the sensitivity of 
publication bias using the trim-and-fill method 33.  
This study is registered with PROSPERO, number CRD42016048552. 
 
Role of the funding source: 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing the report.  
  
Results 
Our search identified thirty-six randomized, double blind trials 10,22,23,34-661 including 6778 
participants that compared an SSRI or an SNRI against placebo in patients <18 years with a 
diagnosis of AD, DD2, OCD, or PTSD (sFigure 1). Characteristics of the thirty-six included trials 
are shown in Table 1. Details regarding heterogeneity and publication bias can be found in the 
Supplemental Material (S3).  
We conducted three main pre-post analyses: a between group analysis stratified by 
disorder and by drug, a within antidepressant group analysis stratified by disorder and by drug, 
and a within placebo group analysis stratified by disorder. The combined analysis between group 
across all disorders yielded a small effect size (g=0.32, CI=0.25-0.40, p<.001). In the between 
group analysis stratified by disorder, AD (g=0.56, CI=0.40-0.72, p<.001) and OCD (g=0.39; 
CI=0.25-0.54, p<.001) did not differ from each other (p=.14) but both were significantly higher 
(AD vs. DD: p<.001 and OCD vs. DD: p=.02) than the DD group (g=0.20, CI=0.13-0.27, 
p<.001) (Figure 1). Between drug analysis yielded the smallest effect sizes for citalopram 
(g=0.18, CI=-0.18-0·54, p=.33) and escitalopram (g=0.18, CI=0.01-0.34, p=.03) and the largest 
effect size for fluvoxamine (g=0.68, CI=-0.05-1.41, p=.07). However, due to the large 95% CI, 
fluvoxamine did not yield significance.  
In the between group analysis stratified by drug category, SSRIs and SNRIs did not differ 
significantly for the DD group (p=.51), but SSRIs were significantly better (p=.04) compared to 
SNRIs in the AD group. No studies investigated the use of SNRIs in OCD. 
The within antidepressant group analysis stratified by disorder yielded no significant 
difference (p=0.06) between studies of AD (g=1.58, CI=1.35-1.81, p<.001) and DD (g=1.85, 
CI=1.7-2.0, p<.001), yet both yielded significantly larger effect sizes (ps<.001) than studies of 
OCD (g=1.01, CI=0.88-1.14, p<.001). When stratified by drug, duloxetine yielded the largest 
effect size (g=1.95, CI=1.73-2.18, p<.001) and fluvoxamine the smallest (g=1.22, CI= 0.41-2.02, 
p=.003), however, the difference between those two was not significant (p=.08). The combined 
analysis across all disorders for the within group analysis yielded an antidepressant effect size of 
                                                
1	One study reported two trials that were treated independently for analyses 53	
2 We use the abbreviation DD rather than MDD, as one study included MDD, Dysthymia, and Depressive Disorder 
Not Otherwise Specified 45. 
g=1.62 (CI=1.48-1.76, p<.001). SSRIs and SNRIs did not differ significantly in both the DD 
group (p=.13) and in the AD group (p=.40)  
The within placebo group analysis stratified by disorder yielded a large placebo response 
for studies of DD (g=1.57, CI=1.36-1.78, p<.001), which was significantly larger (p<.001) than 
the effect size for studies of AD (g=1.02, CI=0.85-1.20, p<.001). The moderate placebo response 
in the OCD group (g=0.63, CI=0.47-0.79, p<.001) was significantly lower than both the DD 
(p<.001) and AD (p=.001) groups (Figure 2). The combined analysis across all disorders for the 
within group analysis yielded a placebo effect size of g=1.22 (CI=1.06-1·38, p<.001).  
 
Side Effect Analysis:  
Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) were examined 
and tabulated across diagnosis categories to determine if emergent events were dependent on 
diagnosis or intervention type (Table 2).   
Data on individual TEAEs and SAEs were available for a total of 2,542 patients taking an 
SSRI/SNRI and 2,294 patients taking placebo (sTable 2).   
TEAE and SAE data revealed a diagnosis-dependent main effect. In patients treated with 
SSRIs or SNRIs, those with DD were significantly less likely to report TEAEs than those with 
AD (DD: 60.5% vs. AD: 80.85%; p=.001). The SAE data revealed the opposite pattern: 
Depressed patients treated with either SSRI or SNRI were significantly more likely to experience 
SAEs than AD (DD: 6.77% vs. AD: 2.30%; p=.007). The TEAEs (82.61%) and SAEs (2.42%) 
rates in the OCD group were almost identical to those in the AD group (Table 2). However, 
OCD side effect data differed significantly from DD with regard to TEAEs (p=.009), but not 
with regard to SAEs (p=.44). 
 Compared to placebo, patients taking both SSRIs and SNRIs reported significantly more 
SAEs (SSRI: 6.80%, SNRI: 7.59%) compared to placebo (3.32%; p=.01), but reported no 
significant difference in TEAEs. No difference in rates of SAEs and TEAEs was found between 
SSRIs and SNRIs. 
 
Moderator Analysis: 
The results of the univariate moderator analyses are presented in the Supplemental Material (S5, 
sTables 3-4). Notably, none of the categorical or continuous moderators was found to be 
significant in a multivariate meta-regression with weighted effect sizes to adjust for multiple 
comparisons (S5, sTable 5). 
            
Discussion  
Our meta-analysis addresses the effectiveness and the safety profile of SNRIs and SSRIs in 
pediatric depression, anxiety disorders, OCD, and PTSD. We undertook both between group and 
within group analyses to determine effect sizes of SSRIs, SNRIs, and placebo treatments. The 
results indicate that SSRIs and SNRIs are more effective than placebo at treating several 
commonly diagnosed conditions in children and adolescents. However, it should be noted that 
this effect is only small. The magnitude of the drug versus placebo difference varies significantly 
by disorder, with a larger effect in AD than DD in between group analyses. This is surprising, 
given that only one SNRI, duloxetine, is currently FDA-approved for pediatric AD. However, it 
should be noted that DD and AD yield similar effect sizes in the within antidepressant group 
analysis. Further, patients with OCD exhibit a significantly smaller response to both drug 
treatment and placebo treatment compared to AD and DD.  
The small effect size between SSRIs/SNRIs and placebo in pediatric DD might be due to 
lack of a clear depression phenotype. This was apparent in DSM-5 Field Trials on MDD, which 
found a low test-retest reliability (kappa: 0·28) for children, adolescents and adults 67. This is 
further complicated by the high comorbidity between the disorders. A recent review on the use of 
SSRIs and SNRIs in pediatric populations reported that around 25% of patients with MDD had a 
comorbid AD 68. In the studies included in our meta-analysis, while not all studies report 
comorbidity rates, those doing so report rates ranging between 6-56% of depressive patients 
having a comorbid anxiety disorder. Yet, attempts by the DSM-5 work group to create a “mixed 
anxiety and depression disorder” resulted in an unacceptable rate of test-retest reliability (kappa: 
-0·04) when tested in the DSM-5 Field Trials 67.  
While it appears that the response to placebo is robust in pediatric DD, children and 
adolescents with anxiety disorders, who respond to pharmacological treatment to the same 
degree as those with DD, do not appear to exhibit such a robust placebo response. While in line 
with older reviews in children 69, this is in contrast to adult studies that found no significant 
differences in placebo effect size between depression and anxiety 70. This contrast is not unique: 
placebo responses between children and adults differ significantly for binary outcomes across a 
wide variety of diseases 71. One explanation might be that children and adolescents with MDD 
may be more demoralized than patients with anxiety disorders and are therefore more sensitive 
to changes in hope and favorable meanings 69. However, as no pediatric trial included a no-
treatment arm, that could serve as a control for the natural course of the disorders, the difference 
in placebo response may also reflect differences in the probability of spontaneous improvement 
between the two pediatric disorders rather than differences in the placebo effect. Due to the small 
amount of studies in children, we could not estimate the drug and placebo response for the 
individual anxiety disorders, yet a recent adult study found drug-placebo effects size to be 
roughly equivalent across anxiety disorders 72 . In pediatric patients, however, those with panic 
disorder seem to experience a greater placebo response compared to patients with GAD or social 
phobia73.   
The substantial placebo response in MDD indicates that children and adolescents with 
depression might benefit from innovative treatment modalities that attempt to harness the power 
of the placebo effect in an ethical fashion, as these children and adolescents seem to respond well 
to clinician contact and social support that promote the therapeutic alliance 74 and other common 
factors such as the patients’ expectations of improvement, their desire for relief, and the exposure 
to treatment rituals. It also offers several implications for research designs in antidepressant 
trials. Alternative designs such as a discontinuation design 75 or n of 1 trials 76,77 might be 
recommended when establishing efficacy 78, yet also have their individual shortcomings. The 
former is comprised of an acute treatment phase (i.e. patients receive their medication in an open 
fashion), followed by a continuation treatment phase (i.e. patients who had an adequate response 
are randomly assigned to medication or placebo), though this design might be prone to breaking 
blind 79. Differences between the two medication groups could provide information about the 
magnitude of expectancy effects 80. In this regard, response and remission rates to antidepressants 
have been shown to be significantly higher in comparator trials compared to placebo-controlled 
trials 81. Future instructive studies could incorporate designs in which people who respond to 
placebo are kept on placebo. 
With regard to side effects, our meta-analysis found that a similar percentage of patients’ 
experience at least one side effect (TEAE), irrespective of being assigned to SSRIs (71.46%), 
SNRIs (65.92%), or to placebo (68.59%). Patients taking SSRIs and SNRIs did not report more 
TEAEs compared to placebo. This is in line with previous research showing that antidepressant 
and placebo groups present with a similar risk to develop adverse events in both depressive 
children and adolescents 9. With regard to TEAEs, it has been shown that negative expectations 
from investigators and patients can influence adverse effect reporting 82. Further, some depressed 
patients may attribute pre-existing symptoms, which are highly common in the general 
population (e.g., headache, abdominal discomfort) to the antidepressant under investigation 83. 
However, these mechanisms might not apply to serious adverse events. Accordingly, the serious 
side effects profiles for both SSRIs and SNRIs significantly exceeded that of the placebo arm in 
our meta-analysis. This is in line with other meta-analyses reporting increased suicidality (Odds 
Ratio=2.39, CI=1.31- 4.33) 84, suicidal ideation, and suicide attempts (risk difference: 
antidepressant vs. placebo: 0.7%, CI=0.1%-1.3%) 17 in children and adolescents receiving SSRIs 
and SNRIs compared to placebo. In conclusion, our results regarding serious side effects profiles 
support concerns about the safety of antidepressants in children and adolescents. 
 Perhaps the most remarkable finding regarding moderators in our meta-analysis is that we 
did not find a single predictor that was significantly related to the effect size in the multivariate 
analyses. However, this must be considered with caution. First, the absolute amount of statistical 
heterogeneity was small to moderate between studies, therefore making it very unlikely to detect 
moderators. Second, the multivariate analyses may have lacked the power to reveal statistically 
significant interaction effects 85. A randomized trial in which participants are stratified by the 
predictor under investigation 86 or a patient-level meta-analysis 87 might be better suited to 
investigate the association between predictors and effect sizes than the methodology applied in 
this meta-analysis. 
 
Limitations:  
First, none of the RCTs included directly compared effectiveness across disorders. Accordingly, 
we could only make indirect conclusions with regard to disorder specificity. We only looked at 
observational comparisons, as no randomization across studies was possible. Second, although 
our meta-analysis included unpublished trials, reporting bias could lead to an overly positive 
representation of findings in the literature 88. Third, restrictive inclusion criteria of clinical trials 
such as non-inclusion of comorbidity and a higher symptom severity threshold make it difficult 
to generalize results to real-world populations 89. Fourth, there was significant heterogeneity in 
how side effects were reported and few studies explain how TEAE data are elicited from the 
patients (i.e., open questions versus structured questionnaire). Fifth, for PTSD, only one study fit 
our inclusion criteria10. Therefore, we were unable to include a categorical analysis of 
SSRIs/SNRIs for the treatment of pediatric PTSD.  
 
Future directions:  
The main findings of this analysis present multiple avenues for further analyses. First, the nearly 
identical response rate for pediatric DD and AD deserves further investigation and perhaps the 
revision of federal prescribing guidelines for these two conditions. While several SSRIs and 
SNRIs have been approved for the treatment of pediatric DD and OCD, only one – duloxetine – 
has recently received FDA approval for pediatric ADs 90. Second, the substantial differential 
response to both drug treatment and placebo treatment between OCD compared to AD and DD 
highlights underlying differences in the etiologies and pathogeneses of the disorders that may 
require additional interventions for pediatric patients with OCD (see for example 91). It is our 
hope that an RDoC approach 92 will help elucidate the above-mentioned points and could lead to 
better treatment outcomes in the future. Third, our results point to the need for additional 
research into the factors that moderate the efficacy of SSRIs and SNRIs in children and highlight 
the need for more comprehensive reporting of population and illness details (such as age of onset 
and duration of illness) in clinical and pragmatic trials. Similarly, additional research in 
understanding the developmental ontogeny of the placebo response is warranted. Finally, our 
results highlight the need for a standardized method of reporting TEAEs and SAEs. Given the 
potential for life threatening events in young children and adolescents, understanding the extent 
to which these medications pose a genuine risk to youth is of extreme urgency. This would allow 
future research to deviate from the current line of research estimating the magnitude and 
differences between drug and placebo effects and focus more on precision medicine driven 
questions, such as which treatment (or combination thereof) may be most advantageous for 
certain patient subgroups in certain clinical settings.  
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Table 1. Demographics and Study Characteristics  
Source Diagnosis 
Tx 
Length 
wk 
No. of 
Patientsc 
Primary 
Outcome Intervention 
FDA 
Approval 
Mean 
Age, 
y 
Female 
% 
Length 
of 
Illness, 
m 
Age of 
Onset, 
y Quality Funding Location 
Depressive Disorder 
Simeon et   
al,34 1990 
 
MDDa 7 40 HAM-D Fluoxetine (20 - 60 mg/d) ≥ 8 years 16 55 - - 0.33 Industry 
North 
America 
Emslie et 
al,35 1997 
 
MDDa, b 8 96 CDRS-R Fluoxetine (20 mg/d) ≥ 8 years 
12.35 
(2.65) 46 18.40 
10.80 
(2.65) 0.78 Public 
North 
America 
Keller et 
al,36 2001d 
 
MDD 8 180 HAM-D Paroxetine (20 - 40 mg/d) N/A 
14.95 
(1.60) 64 13.52 
13.29 
(2.56) 0.89 Industry 
North 
America 
Emslie et 
al,37 2002 
 
MDDb 9 219 CDRS-R Fluoxetine (20 mg/d) ≥ 8 years 
12.70 
(2.57) 49 14 
10.33 
(3.02) 0.89 Industry 
North 
America 
Wagner et 
al,38 2003 
 
MDD 10 376 CDRS-R 
Sertraline 
(50 - 200 
mg/d) 
N/A 6-17e 51 23.07 10.04 0.78 Industry Inter-national 
March et 
al,39 2004d, 
h 
 
MDD 12 328 CDRS-R Fluoxetine (10 - 40 mg/d) 
≥ 8 years 
 
14.60 
(1.5)f 55
f 40a - 1.00 Publici North America 
Wagner et 
al,22 2004a 
 
MDD 8 178 CDRS-R Citalopram (20 - 40 mg/d) N/A 
12.10 
(2.95) 63 27 
9.80 
(3.15) 0.78 Industry 
North 
America 
Berard et 
al,40 2006 
 
MDD 12 286 MADRS Paroxetine (20 - 40 mg/d) N/A 
15.60 
(1.60) 67 - - 0.89 Industry 
Inter-
national 
Emslie et 
al,41 2006 
 
MDDa 8 206 CDRS-R Paroxetine (10 - 50 mg/d) N/A 
12.00 
(2.97) 47 25.90 
9.80 
(3.30) 0.78 Industry 
North 
America 
von 
Knorring 
et al,42 
2006 
MDD 12 244 K-SADS-P Citalopram (10 - 40 mg/d) N/A 
16 
(1.00) - - - 0.44 Industry Europe 
              
 Table 1. Demographics and Study Characteristics (cont.) 
Source Diagnosis 
Tx 
Length 
wk 
No. of 
Patientsc 
Primary 
Outcome Intervention 
FDA 
Approval 
Mean 
Age, 
y 
Female 
% 
Length 
of 
Illness, 
m 
Age of 
Onset, 
y Quality Funding Location 
Wagner et 
al,23 2006 
 
MDD 8 268 CDRS-R Escitalopram (10 - 20 mg/d) ≥ 12 years 
12.30 
(3.00) 52 25.80 
10.15 
(3.25) 0.67 Industry 
North 
America 
Emslie et 
al,43 2007 
 
MDD 8 367 CDRS-R 
Venlafaxine 
ER 
(37.50 - 225 
mg/d) 
N/A 12.25 (2.60) 46 21.13 - 0.78 Industry 
North 
America 
Emslie et 
al,44 2009 
 
MDD 8 316 CDRS-R Escitalopram (10 - 20 mg/d) ≥ 12 years 
14.60 
(1.55) 59 16.10 
12.35 
(2.55) 0.67 Industry 
North 
America 
Findling et 
al,45 2009 
MDD, 
Dys-
thymia, 
DDNOS, 
SUD 
8 34 CDRS-R Fluoxetine (10 - 20 mg/d) ≥ 8 years 
16.46 
(1.08) 15 49.04 
11.41 
(2.50) 0.89 Industry 
North 
America 
PIR-
112487,46 
2011 
 
MDDb 8 56 CDRS-R Paroxetine (10 - 40 mg/d) N/A 
14.59 
(2.33) 61 - - 0.56 Industry Asia 
Atkinson 
et al,47 
2014 
MDDa, b 10 337 CDRS-R 
Duloxetine 
(60 - 120 
mg/d) 
N/A 13.20 
(3.14) 52 - 11.60 0.89 Industry 
Inter-
national Fluoxetine 
(20 - 40 mg/d) ≥ 8 years 
Emslie et 
al,48 2014 MDD
a, b 10 463 CDRS-R 
Duloxetine 
(60 mg/d) N/A 
12.98 
(2.98) 51 - - 0.78 Industry 
Inter-
national 
Duloxetine 
(30 mg/d) N/A 
Fluoxetine 
(20 mg/d) ≥ 8 years 
Table 1. Demographics and Study Characteristics (cont.) 
Source Diagnosis 
Tx 
Length 
wk 
No. of 
Patientsc 
Primary 
Outcome Intervention 
FDA 
Approval 
Mean 
Age, 
y 
Female 
% 
Length 
of 
Illness, 
m 
Age of 
Onset, 
y Quality Funding Location 
Anxiety Disorder 
RUPP,49 
2001 
 
SP, SAD, 
GAD 8 128 PARS 
Fluvoxamine 
(50 - 300 
mg/d) 
N/A 10.30 (2.95) 49 - - 0.67 
Public / 
Industry 
North 
America 
Rynn et 
al,50 2001 
 
GAD 9 22 HAM-A Sertraline (25 - 50 mg/d) N/A 
11.70 
(3.90) 23 >12 - 0.67 Public 
North 
America 
Birmaher 
et al,51 
2003 
SAD, SP, 
GAD, SM, 
PH, PD 
12 74 PARSf Fluoxetine (10 - 20 mg/d) N/A 
11.80 
(2.80) 54 62.70 - 0.78 Public
i North America 
Wagner et 
al,52 2004b 
 
SP 16 322 LSAS-CAf Paroxetine (10 - 50 mg/d) N/A 
13.10 
(2.77) 49 - - 0.89 Industry 
Inter-
national 
March et 
al,53 2007 
 
SP 16 293 SAS-CA 
Venlafaxine 
ER 
(37.50 - 225 
mg/d) 
N/A 13.60 (2.55) 57 58 - 1.00 Industry 
North 
America 
Rynn et 
al,54 2007g 
 
GAD 8 323 K-SADS-GA 
Venlafaxine 
(37.50 - 225 
mg/d) 
N/A 11.30 (2.86) 41 39.12 - 0.78 Industry 
North 
America 
Walkup et 
al,55 2008d, 
h 
SAD, 
GAD, SP 
 
12 
 
349 
 PARS 
Sertraline 
(25 - 200 
mg/d) 
N/A 
 
10.70 
(2.80) 
 
50 
 - - 1.00 
Publici 
 
North 
America 
 
da Costa 
et al,56 
2013d 
 
GAD, 
SAD, SP 12 21 MASC
f Fluoxetine (10 - 60 mg/d) N/A 11.50 48 - - 0.56 Public 
South 
America 
Strawn et 
al,57 2015 
 
GAD 10 272 PARS 
Duloxetine 
(30 - 120 
mg/d) 
N/A 12.40 (2.95) 53 52.20  1.00 
Public / 
Industry 
Inter-
national 
Melvin et 
al,58 2016 
SP, PH, 
GAD, 
SAD, PD 
10 42 RCMASf 
Fluoxetine + 
CBT 
(10 - 60 mg/d) 
≥ 8 years 13.60 (1) 45 - - 0.89 Public
i Australia 
              
Table 1. Demographics and Study Characteristics (cont.) 
Source Diagnosis 
Tx 
Length 
wk 
No. of 
Patientsc 
Primary 
Outcome Intervention 
FDA 
Approval 
Mean 
Age, 
y 
Female 
% 
Length 
of 
Illness, 
m 
Age of 
Onset, 
y Quality Funding Location 
Obsessive-Compulsive Disorder 
Riddle et 
al,59 1992 
 
OCD 8 14 CY-BOCSf Fluoxetine (20 mg/d) ≥ 7 years 
11.80
(2.30) 57 - - 0.44 Public
i North America 
March et 
al,60 1998 
 
OCD 12 189 CY-BOCSf 
Sertraline 
(25 - 200 
mg/d) 
≥ 6 years 
12.60 
(6-
17)e 
- 45.60 - 0.78 Industry North America 
Geller et 
al,61 2001 
 
OCD 13 103 CY-BOCS Fluoxetine (20 - 60 mg/d) ≥ 7 years 
11.40 
(2.90) 37 >6 - 0.89 Industry 
North 
America 
Riddle et 
al,62 2001d 
 
OCD 10 120 CY-BOCS 
Fluvoxamine 
(50 - 200 
mg/d) 
≥ 8 years 13.03 47 43.20 - 0.67 Industry North America 
Liebowitz 
et al,63 
2002d 
 
OCD 8 43 CY-BOCS Fluoxetine (20 - 80 mg/d) ≥ 7 years 
12.65 
(2.19) 42 ≥12 - 1.00 
Public / 
Industry 
North 
America 
POTS,64 
2004h 
 
OCD 12 84 CY-BOCS Sertraline (25-200 mg/d) ≥ 6 years 
12 
(2.70) 45 - - 1.00 Public
i North America 
Geller et 
al,65 2004 
 
OCD 10 207 CY-BOCS Paroxetine (10 - 50 mg/d) N/A 
11.30 
(3.00) 42 50.40 
7.50 
(3.09) 1.00 Industry 
North 
America 
Storch et 
al,66 2013 OCD 18 47 CY-BOCS 
Sertraline 
(Reg) + CBT 
(25 - 200 
mg/d) 
≥ 6 years 
11.90 
(3.47) 38 - - 0.67 Public
i 
North 
America 
Sertraline 
(Slow) + CBT 
(25 - 200 
mg/d) 
≥ 6 years 
 
Table 1. Demographics and Study Characteristics (cont.) 
Source Diagnosis 
Tx 
Length 
wk 
No. of 
Patientsc 
Primary 
Outcome Intervention 
FDA 
Approval 
Mean 
Age, 
y 
Female 
% 
Length 
of 
Illness, 
m 
Age of 
Onset, 
y Quality Funding Location 
Posttraumatic Stress Disorder 
Robb et 
al,10 2010 
 
PTSD 10 131 UCLA-PTSD 
Sertraline 
(50 - 200 
mg/d) 
N/A 10.98 (1.75) 60 29.40 - 0.78 Industry 
North 
America 
Abbreviations: OCD, Obsessive Compulsive Disorder; MDD, Major Depressive Disorder; DDNOS, Depressive Disorder Not Otherwise Specified; SUD, Substance Use 
Disorder; SAD, Separation Anxiety Disorder; SP, Social Phobia; GAD, Generalized Anxiety Disorder; SM, Selective Mutism; PH, Specific Phobia; PD, Panic Disorder.  
aWithout psychotic features.  
bSingle episode or recurrent.  
cN included in our analysis. Some studies included additional arms (i.e., tricyclic antidepressant, CBT alone, etc.) that were not extracted.  
dOnly SSRI or SNRI treatment arms from acute treatment phase / pre-crossover phase extracted as per protocol.   
eRange. Mean (SD) not available.  
fPrimary outcome not specified or data not usable; most common measure for which data was available was chosen.  
gTwo trials. Analyses broken down by study.  
hAdditional arm (antidepressant + CBT) was not extracted.  
iStudy medication and matching placebo provided by the drug manufacturer.  
jBased on specification of a main outcomes, selective reporting, observer-rated outcomes, blinding of outcome assessors, selective attrition, generation of allocation 
sequence, concealment, randomization, and ITT-analyses. Scores denote means over all items ranging from 0 to 1, with higher scores implicating greater methodological 
quality. 
 
 Table 2. Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) 
 
 TEAE  SAE  
     
Disorder & Intervention Total No. Patients with ≥1 TEAE, %  Total No. 
Patients with ≥1 
SAE, %  
In Drug and Placebo Groups by Disorder 
DD    
SSRI 1099 65.70  1120 8.66  
SNRI 510 51.76  169 13.61  
Placebo 999 60.16  1280 4.22  
DD Overall 2608 60.85  2569 6.77  
AD    
SSRI 163 88.34  436 1.38  
SNRI 429 82.75  292 4.11  
Placebo 604 77.48  532 2.07  
AD Overall 1196 80.85a  1260 2.30a  
OCD    
SSRI 254 85.04  136 3.68  
SNRI - -  - -  
Placebo 229 79.91  112 0.89  
OCD Overall 483 82.61a  248 2.42  
In SSRI, SNRI and Placebo Groups 
SSRI      
Citalopram 121 75.21  121 14.88  
Escitalopram 286 73.78  286 2.10  
Fluoxetine 479 62.21  223 17.49  
Fluvoxamine 58 81.03  - -  
Paroxetine 573 75.74  666 6.76  
Sertraline 67 76.12  556 3.24  
SSRI Overall 1584 71.46  1852 6.80b  
SNRI       
Duloxetine 476 67.65  135 7.41  
Venlafaxine 463 64.15  326 7.67  
SNRI Overall 939 65.92  461 7.59b  
Placebo       
Placebo Overall 1894 68.59  1986 3.32  
aStatistically different from corresponding DD values with p-value <.01.  
bStatistically different from corresponding Placebo values with p-value <.05.  
 
 
 
  
   
Figure 1. Forest Plot of Between Group Analyses (Stratified by Disorder) 
 
Medication Source Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error limit limit
SSRI Atkinson et al,47 2014 0.05 0.17 -0.27 0.38
Emslie et al,48 2014 0.07 0.19 -0.29 0.44
PIR112487,46 2011 0.34 0.27 -0.18 0.87
Emslie et al,44 2009 0.21 0.11 -0.01 0.43
Findling et al,45 2009 0.35 0.39 -0.42 1.11
von Knorring et al,42 2006 0.00 0.13 -0.25 0.26
Wagner et al,23 2006 0.14 0.12 -0.10 0.38
Berard et al,40 2006 0.08 0.13 -0.18 0.33
Emslie et al,41 2006 0.05 0.14 -0.22 0.33
Wagner et al,22 2004a 0.37 0.15 0.07 0.67
March et al,39 2004 0.40 0.17 0.07 0.72
Wagner et al,38 2003 0.19 0.11 -0.02 0.39
Emslie et al,37 2002 0.52 0.14 0.25 0.80
Keller et al,36 2001 0.21 0.15 -0.08 0.51
Emslie et al,35 1997 0.60 0.21 0.19 1.00
Simeon et al,34 1990 0.21 0.36 -0.49 0.91
0.21 0.04 0.13 0.29
SNRI Atkinson et al,47 2014 0.00 0.17 -0.33 0.33
Emslie et al,48 2014 0.17 0.19 -0.20 0.54
Emslie et al,48 2014 0.22 0.19 -0.15 0.58
Emslie et al,43 2007 0.20 0.11 -0.02 0.42
0.16 0.08 0.01 0.31
-2.00 -1.00 0.00 1.00 2.00
Birmaher et al,51 2003 0.53 0.23 0.08 0.99
da Costa et al,56 2013 1.11 0.45 0.23 2.00
Melvin et al,58 2016 0.47 0.31 -0.14 1.07
RUPP,49 2001 1.06 0.19 0.69 1.43
Wagner et al,52 2004b 0.72 0.18 0.49 0.95
Rynn et al,50 2001 1.48 0.47 0.56 2.39
Walkup et al,55 2008 0.32 0.18 -0.04 0.68
0.71 0.13 0.45 0.97
Strawn et al,57 2015 0.48 0.12 0.24 0.73
March et al,53 2007 0.38 0.12 0.15 0.62
Rynn et al,54 2007a 0.49 0.16 0.17 0.81
Rynn et al,54 2007a 0.26 0.16 -0.05 0.57
0.41 0.07 0.27 0.54
-2.00 -1.00 0.00 1.00 2.00
Storch et al,66 2013 0.00 0.45 -0.89 0.89
Storch et al,66 2013 0.14 0.51 -0.85 1.13
Geller et al,65 2004 0.44 0.14 0.15 0.72
POTS,64 2004 0.40 0.32 -0.24 1.04
Liebowitz et al,63 2002 0.24 0.30 -0.35 0.83
Geller et al,61 2001 0.49 0.21 0.07 0.91
Riddle et al,62 2001 0.31 0.18 -0.04 0.67
March et al,60 1998 0.42 0.15 0.13 0.70
Riddle et al,59 1992 0.78 0.54 -0.28 1.84
0.39 0.08 0.25 0.54
-2.00 -1.00 0.00 1.00 2.00
Robb et al,10 2010 0.16 0.20 -0.23 0.56
0.16 0.20 -0.23 0.56
-2.00 -1.00 0.00 1.00 2.00
Favours Placebo Favours Drug
Subtotal
Subtotal
SSRI
SNRI
Subtotal
Subtotal
SSRI
Subtotal
SSRI
Subtotal
DD
AD
OCD
PTSD
Disorder
Due to the low number of studies (N=1), PTSD is not included in the overall analysis. For the combined 
analysis across all disorders, see Result Section.  
Abbreviations: DD, Depressive Disorders; AD, Anxiety Disorders; OCD, Obsessive Compulsive 
Disorder; PTSD, Posttraumatic Stress Disorder.  
aOne study reported two trials that were treated independently for analyses. 
 Figure 2. Drug and Placebo Effect Size by Disorder Category 
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 S1: Search Terms 
S1.1. PubMed 
"Depressive Disorder"[mesh] OR depression*[tiab] OR depressive[tiab] OR dysthymic[tiab] OR 
dysthymia*[tiab] OR "Anxiety Disorders"[Mesh] OR "Anxiety"[Mesh:noexp] OR anxiety[tiab] OR obsessive-
compulsive[tiab] OR ocd[tiab] OR anankastic[tiab] OR phobic[tiab] OR phobia*[tiab] OR panic[tiab] OR stress 
disorder*[tiab] OR post traumatic stress[tiab] OR posttraumatic stress[tiab] OR post traumatic symptom*[tiab] 
OR posttraumatic symptom*[tiab] OR ptsd[tiab] 
 
"Serotonin Uptake Inhibitors"[Mesh] OR "Serotonin Uptake Inhibitors"[pa] OR serotonin reuptake 
inhibitor*[tiab] OR serotonin uptake inhibitor*[tiab] OR SSRI*[tiab] OR SRI*[tiab] OR serotonin 
norepinephrine reuptake inhibitor*[tiab] OR serotonin norepinephrine uptake inhibitor*[tiab] OR SNRI* OR 
venlafaxin*[tiab] OR desvenlafaxin*[tiab] OR effexor[tiab] OR pristiq[tiab] OR milnacipran[tiab] OR 
levomilnacipran[tiab] OR fetzima[tiab] OR savella[tiab] OR duloxetin*[tiab] OR cymbalta[tiab] OR 
sibutramine[tiab] OR citalopram[tiab] OR celexa[tiab] OR escitalopram[tiab] OR lexapro[tiab] OR 
fluoxetin*[tiab] OR prozac[tiab] OR sarafem[tiab] OR symbyax[tiab] OR fluvoxamin*[tiab] OR luvox[tiab] OR 
paroxetin*[tiab] OR paxil[tiab] OR brisdelle[tiab] OR sertralin*[tiab] OR zoloft[tiab] 
 
Child[MeSH Terms] OR Pediatrics[MeSH] OR child*[tiab] OR adolescen*[tiab] OR toddler*[tiab] OR 
teen*[tiab] OR boy[tiab] OR boys[tiab] OR girl*[tiab] OR pediatric[tiab] OR paediatric[tiab] OR puber*[tiab] 
OR pubescen*[tiab] OR prepubescen*[tiab] OR prepuberty*[tiab] OR schoolchild*[tiab] OR school age*[tiab] 
OR preschool*[tiab] OR kindergar*[tiab] OR primary school*[tiab] OR secondary school*[tiab] OR elementary 
school*[tiab] OR high school*[tiab] OR highschool*[tiab] OR youth*[tiab] 
 
random*[tw] OR blind*[tiab] OR placebo*[tiab] OR trial[tiab] OR untreated[tiab] OR "not treated"[tiab] OR 
sham[tiab] 
 
S1.2. Embase 
'depression'/exp OR depression*:ab,ti OR depressive:ab,ti OR dysthymic:ab,ti OR dysthymia*:ab,ti OR 'anxiety 
disorder'/exp OR 'anxiety'/de OR anxiety:ab,ti OR obsessive-compulsive:ab,ti OR ocd:ab,ti OR anankastic:ab,ti 
OR phobic:ab,ti OR phobia*:ab,ti OR panic:ab,ti OR (stress NEXT/1 disorder*):ab,ti OR (('post traumatic' OR 
posttraumatic) NEXT/1 (stress OR symptom*)):ab,ti OR ptsd:ab,ti 
 
'serotonin uptake inhibitor'/exp OR  'serotonin noradrenalin reuptake inhibitor'/exp OR (('serotonin reuptake' OR 
'serotonin uptake' OR 'serotonin norepinephrine reuptake' OR 'serotonin norepinephrine uptake') NEXT/1 
inhibitor*):ab,ti OR ssri*:ab,ti OR snri*:ab,ti OR venlafaxin*:ab,ti OR desvenlafaxin*:ab,ti OR effexor:ab,ti OR 
pristiq:ab,ti OR milnacipran:ab,ti OR levomilnacipran:ab,ti OR fetzima:ab,ti OR savella:ab,ti OR 
duloxetin*:ab,ti OR cymbalta:ab,ti OR sibutramine:ab,ti OR citalopram:ab,ti OR celexa:ab,ti OR 
escitalopram:ab,ti OR lexapro:ab,ti OR fluoxetin*:ab,ti OR prozac:ab,ti OR sarafem:ab,ti OR symbyax:ab,ti OR 
fluvoxamin*:ab,ti OR luvox:ab,ti OR paroxetin*:ab,ti OR paxil:ab,ti OR brisdelle:ab,ti OR sertralin*:ab,ti OR 
zoloft:ab,ti 
 
'child'/exp AND 'pediatrics'/exp OR child*:ab,ti OR adolescen*:ab,ti OR toddler*:ab,ti OR teen*:ab,ti OR 
boy:ab,ti OR boys:ab,ti OR girl*:ab,ti OR pediatric:ab,ti OR paediatric:ab,ti OR puber*:ab,ti OR pubescen*:ab,ti 
OR prepubescen*:ab,ti OR prepuberty*:ab,ti OR schoolchild*:ab,ti OR (school NEXT/1 age*):ab,ti OR 
preschool*:ab,ti OR kindergar*:ab,ti OR ((primary OR secondary OR elementary OR high) NEXT/1 
school*):ab,ti OR highschool*:ab,ti OR youth*:ab,ti 
 
random*:ab,de,ti OR blind*:ab,ti OR placebo*:ab,ti OR trial:ab,ti OR untreated:ab,ti OR 'not treated':ab,ti OR 
sham:ab,ti 
 
 
  
 S1.3. PsycInfo 
DE ("Major Depression" OR "Dysthymic Disorder" OR "Endogenous Depression" OR "Reactive Depression" 
OR "Recurrent Depression" OR "Treatment Resistant Depression" OR "Anxiety" OR "Acute Stress Disorder" 
OR "Generalized Anxiety Disorder" OR "Obsessive Compulsive Disorder" OR "Panic Disorder" OR "Phobias" 
OR "Posttraumatic Stress Disorder" OR "Panic Disorder" OR "Panic" OR "Panic Attack") OR TI (depression* 
OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd OR anankastic 
OR phobic OR phobia* OR panic OR "stress disorder*" OR "post traumatic stress" OR "posttraumatic stress" 
OR "post traumatic symptom*" OR "posttraumatic symptom*" OR ptsd) OR AB (depression* OR depressive 
OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd OR anankastic OR phobic OR 
phobia* OR panic OR "stress disorder*" OR "post traumatic stress" OR "posttraumatic stress" OR "post 
traumatic symptom*" OR "posttraumatic symptom*" OR ptsd)  
 
DE ("Serotonin Reuptake Inhibitors" OR "Chlorimipramine" OR "Citalopram" OR "Fluoxetine" OR 
"Fluvoxamine" OR "Paroxetine" OR "Zimeldine" OR "Serotonin Norepinephrine Reuptake Inhibitors" OR 
"Venlafaxine") OR TI ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* 
OR "serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR SNRI* 
OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran OR fetzima OR 
savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR escitalopram OR lexapro OR 
fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox OR paroxetin* OR paxil OR 
brisdelle OR sertralin* OR zoloft) OR AB ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR 
SSRI* OR SRI* OR "serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake 
inhibitor*" OR SNRI* OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR 
levomilnacipran OR fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa 
OR escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox 
OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) 
 
AG ("Childhood (birth-12 yrs)") OR TI (child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR 
girl* OR pediatric OR paediatric OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* 
OR "school age*" OR preschool* OR kindergar* OR "primary school*" OR "secondary school*" OR 
"elementary school*" OR "high school*" OR highschool* OR youth*) OR AB (child* OR adolescen* OR 
toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR paediatric OR puber* OR pubescen* OR 
prepubescen* OR prepuberty* OR schoolchild* OR "school age*" OR preschool* OR kindergar* OR "primary 
school*" OR "secondary school*" OR "elementary school*" OR "high school*" OR highschool* OR youth*) 
 
DE (random*) OR TI (random* OR placebo* OR trial OR untreated OR sham) OR AB (random* OR placebo* 
OR trial OR untreated OR sham) 
Note: "not treated" is handled as a stop word so all records with treated are retrieved. 
 
S1.4. Cochrane Central 
TI ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR "serotonin 
norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR SNRI* OR 
venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran OR fetzima OR 
savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR escitalopram OR lexapro OR 
fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox OR paroxetin* OR paxil OR 
brisdelle OR sertralin* OR zoloft) OR AB ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR 
SSRI* OR SRI* OR "serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake 
inhibitor*" OR SNRI* OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR 
levomilnacipran OR fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa 
OR escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox 
OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) 
 
TI (depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd 
OR anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post traumatic stress" OR 
"posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic symptom*" OR ptsd) OR AB 
(depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd OR 
anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post traumatic stress" OR 
"posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic symptom*" OR ptsd)  
 TI (child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR paediatric OR 
puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR "school age*" OR preschool* 
OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary school*" OR "high school*" OR 
highschool* OR youth*) OR AB (child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR 
pediatric OR paediatric OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR 
"school age*" OR preschool* OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary 
school*" OR "high school*" OR highschool* OR youth*) 
 
S1.5. Web of Science 
TS=("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR "serotonin 
norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR SNRI* OR 
venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran OR fetzima OR 
savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR escitalopram OR lexapro OR 
fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox OR paroxetin* OR paxil OR 
brisdelle OR sertralin* OR zoloft) 
 
TS=(depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd 
OR anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post traumatic stress" OR 
"posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic symptom*" OR ptsd) 
 
TS=(child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR paediatric OR 
puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR "school age*" OR preschool* 
OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary school*" OR "high school*" OR 
highschool* OR youth*) 
 
TS=(random* OR placebo* OR trial OR untreated OR sham) 
 
 
 
 
 
  
S2: Study Selection 
sFigure 1. Flow Chart 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4899 potentially relevant citations screened for retrieval 
1481 identified by Embase Search 
1436 identified by Web of Science Search 
  812 identified by PubMed Search 
  765 identified by PsycInfo Search 
  404 identified by Cochrane Central Search 
      1 identified in clinical.trials.gov 
 
1984 duplicates removed 
2915 records screened  2850 records excluded by abstract and title  
65 full-text articles assessed 
for eligibility 
29 records excluded after full-text review: 
 14 had incomplete or insufficient data 
   9 were re-analysis of included data 
   4 were no double-blind RCT 
   1 had no DSM criteria 
   1 for other reason 
36 studies included in the 
meta-analysis 
 
 S3: Details on Heterogeneity and Publication Bias 
sTable 1. Heterogeneity 
Drug 
Treatment 
Arms Hedges g 95% CI SE p-Value Q-value p-Value I2 Tau2 
Stratified Between Drug 
Citalopram 2 0.18 -0.18 - 0.54 0.18 .33 N/Aa N/Aa N/Aa N/Aa 
Escitalopram 2 0.18 0.01 - 0.34 0.08 .03 N/Aa N/Aa N/Aa N/Aa 
Fluoxetine 13 0.38 0.26 - 0.51 0.06 <0.001 13.17 .36 8.90 0.01 
Fluvoxamine 2 0.68 -0.05 - 1.41 0.37 .07 N/Aa N/Aa N/Aa N/Aa 
Paroxetine 6 0.31 0.07 - 0.54 0.12 .01 19.83 .001 74.78 0.06 
Sertraline 8 0.31 0.15 - 0.47 0.08 <.001 9.38 .23 25.37 0.01 
Venlafaxine 4 0.31 0.18 - 0.44 0.07 <.001 2.66 .45 0.00 0.00 
Duloxetine 4 0.24 0.06 - 0.46 0.16 .04 5.91 .12 49.20 0.03 
Stratified Within Drug 
Citalopram 2 1.78 1.56 - 2.04 0.12 <.001 N/A
a N/Aa N/Aa N/Aa 
Escitalopram 2 1.68 1.48 - 1.87 0.10 <.001 N/Aa N/Aa N/Aa N/Aa 
Fluoxetine 13 1.73 1.32 - 2.13 0.21 <.001 100.36 <.001 88.05 0.45 
Fluvoxamine 2 1.22 0.41 - 2.02 0.41 .003 N/Aa N/Aa N/Aa N/Aa 
Paroxetine 6 1.46 1.31 - 1.61 0.08 <.001 7.19 .21 30.45 0.01 
Sertraline 8 1.38 1.02-1.73 0.18 <.001 37.54 <.001 81.35 0.18 
  
 
 
 
S3.1. Stratified by Disorder 
OCD: The eight studies exhibited no heterogeneity (Q=2.28, p=.07, I2=0.00 2=0.00). There was no evidence of publication bias in a funnel plot. 
Neither the Begg’s test nor the Egger’s test yielded a significant result. The fail-safe N indicated that 43 unpublished null studies would be needed 
to remove the significance from the findings. The trim-and-fill method lead to a very slight adjustment of Hedges’s g (g=0.41, CI=0.26-0.55).  
 
DD: The seventeen studies exhibited moderate heterogeneity (Q=20.28, p=.38, I2=6.31, 2=0.00). There was no evidence of publication bias in a 
funnel plot. Neither the Begg’s test nor the Egger’s test yielded a significant result. The fail-safe N indicated that 165 unpublished null studies 
would be needed to remove the significance from the findings. The trim-and-fill method did not lead to an adjustment of Hedges’s g.  
 
AD: The ten studies exhibited moderate heterogeneity (Q=22.93, p=.01, I2=56.40, 2=0.04). There was some evidence of publication bias in a 
funnel plot. Both the Begg’s test and the Egger’s test yielded a non-significant result (2-tailed p > .05). The fail-safe N indicated that 308 
unpublished null studies would be needed to remove the significance from the findings. The trim-and-fill method lead to a slight adjustment of the 
standard mean difference (g=0.53, CI=0.36-0.70). 
 
Across all studies: The combined analysis yielded low to moderate heterogeneity (Q=76.62, p<.001, I2=47.79, 2=0.03). 
 
 
 
sTable 1. Heterogeneity (cont.) 
Drug 
Treatment 
Arms Hedges g 95% CI SE 
p-
Value Q-value p-Value I2 Tau2 
Venlafaxine 4 1.77 1.59-1.95 0.09 <.001 3.71 .29 19.15 0.01 
Duloxetine 4 1.95 1.73-2.18 0.11 <.001 5.17 .16 41.97 0.02 
aHeterogeneity was not assessed due to the low number of studies. 
 S3.2. Risk of Bias Assessment 
sFigure 2 
 
Note: The large amount of high risk in the “other risk of bias” category was mainly due to per protocol 
analysis rather than intent-to-treat analysis. 
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 S4. Side Effects 
 
 
  
sTable 2. Individual Side Effects by Drug and Placebo 
 
Side Effect  
Drugs (No.=2542) Placebo (No.=2294)  
         
No. Reported 
 
Percent  No. Reported Percent p-Value 
Headache 321 12.63 266 11.60 .58 
Nausea 205 8.06 136 5.93 .16 
Insomnia 203 7.99 193 4.05 .04a 
Abdominal Pain 187 7.36 139 6.06 .38 
Agitation 119 4.68 20 0.87 .11 
Diarrhea 111 4.37 49 2.14 .03a 
Pharyngitis 103 4.05 96 4.18 .55 
Vomiting 99 3.89 33 1.44 .18 
Asthenia 87 3.42 47 2.05 .21 
Respiratory Illness  84 3.30 71 3.10 .42 
Hyperkinesia 79 3.11 25 1.09 .03a 
Rhinitis 73 2.87 52 2.27 .21 
Decreased Appetite 63 2.48 19 0.83 .002a 
Anorexia 62 2.44 13 0.57 .08 
Fatigue 57 2.24 24 1.05 .05a 
Somnolence 56 2.20 25 1.09 .19 
Individual side effects are reported across all drugs (SSRI and SNRI) due to insufficient data in the studies of 
SNRIs. Percent indicates total percent of all reported side effects that were the specific side effect in question.  
aSignificant. 
 
 S5. Moderator Analysis 
S5.1. Methods and Results for the Univariate Analyses – Continuous Variables 
Methods: Continuous variables were analyzed with a meta-regression analysis using method-
of-moments analyses in a random-effects model. The Z-statistic was used to test the 
significance of the slope. As various scales were used to assess baseline severity, we 
standardized the baseline and outcome values by dividing the mean values by the SD. 
Results: The relationship between effect size and publication year was significant in the 
combined analyses (Z=-2.36, p=.02), as well as in the DD subgroup analyses (Z=-2.26, 
p=.02), with recently published studies yielding smaller antidepressant-placebo differences. 
Further, the relationship between effect size and illness duration was significant in the 
combined analyses (Z=2.89, p=.004), indicating that children with a longer duration of illness 
exhibit greater response to antidepressants compared to placebo. Finally, number of sites was 
found to be significantly correlated to effect size in the combined analyses (Z=-2.98, p=.003), 
as well as in the DD subgroup analyses (Z=-2.16, p<.03), and the OCD subgroup analyses 
(Z=-2.16, p=.03), with number of study sites negatively associated with magnitude of 
differences between antidepressants and placebo. 
 
S5.2. Methods and Results for the Univariate Analyses – Categorical Variables 
Methods: Categorical variables were analyzed using a mixed-effects model. 
Results: The relationship between effect size and primary funding source was significant in 
the combined analyses (p = .02), as well as in the DD subgroup analyses (p = .02). In both 
cases, studies that were funded by industry yielded significantly smaller effect sizes than 
those that reported public sources of funding only (e.g., NIMH). 
 
S5.3. Methods for the moderator analysis: Multivariate metaregression analysis 
Given the relatively large number of moderator analyses, we decided to conduct a 
multivariate meta-regression in order to adjust for multiple comparisons. Effect sizes (i.e., 
dependent variable) were weighted by the sample size divided by s2 (i.e., n/var; (1)). 
Multivariate regression analyses were conducted in SPSS (Version 21.0.0.2). 
 
This approach is in line with the methods adopted by Cuijpers (2-5). Besides adjusting for 
multiple comparisons, the model indicates the significance of each potential moderator while 
controlling for the others. To avoid collinearity among the predictors of the regression model, 
we first tested whether high correlations (i.e., correlations higher than 0.60) were found 
among the moderators that could be entered into the model. Three variables were found to 
have correlations higher than 0.60: the funding source correlated high with the number of 
sites (r = .698), treatment duration correlated high with illness duration (r = 0.62), and 
comorbidity correlated high with the number of sites (r = -0.75). We decided to use the 
number of sites (not funding source or comorbidity) and treatment duration (not illness 
duration) as predictors in the model. All remaining variables (i.e., treatment duration, 
publication year, baseline severity number of sites, age of onset, placebo lead-in, and study 
location) were included as predictors in the model.	  
 sTable 3. Continuous Moderator Analyses: treatment duration, publication year, baseline severity, number of 
sites, illness duration, and age of onset.  
 
Moderator 
Point 
Estimate Standard Error 95 % CI Z-Value p-Value 
Overall 
Treatment Duration 0.01 0.02 -0.02 – 0.04 0.57 .57 
Publication Year -0.02 0.01 -0.03 – -0.00 -2.36 .02 
Baseline Severity 0.00 0.02 -0.03 – 0.03 0.20 .84 
Number of Sites -0.01 0.00 -0.01 – -0.00 -2.10 .003 
Illness Duration 0.01 0.00 0.00 – 0.01 2.89 .004 
Age of Onset -0.04 0.03 -0.10 – 0.03 -1.11 .27 
Depressive Disorder 
Treatment Duration -0.03 0.02 -0.07 – 0.02 -1.12 .26 
Publication Year -0.02 0.01 -0.03 – -0.00 -2.26 .02 
Baseline Severity 0.02 0.02 -0.01 – 0.05 1.21 .23 
Number of Sites -0.00 0.00 -0.01 – -0.00 -2.16 .03 
Illness Duration 0.00 0.01 -0.01 – 0.01 -0.00 1.00 
Age of Onset -0.01 0.04 -0.10 – 0.07 -0.31 .76 
Obsessive-Compulsive Disorder 
Treatment Duration -0.02 0.04 -0.09 – 0.05 -0.47 .64 
Publication Year -0.01 0.02 -0.06 – 0.02 -0.88 .38 
Baseline Severity -0.05 0.15 -0.35 – 0.25 -0.33 .74 
Number of Sites -0.00 0.00 -0.01 – -0.00 -2.16 .03 
Illness Duration 0.01 0.03 -0.05 – 0.07 0.45 .65 
Age of Onset N/Aa     
Anxiety Disorder 
Treatment Duration -0.02 0.04 -0.09 – 0.05 -0.55 .58 
Publication Year -0.04 0.02 -0.08 – -0.00 -1.90 .06 
Baseline Severity -0.03 0.03 -0.08 – 0.02 -1.18 .24 
Number of Sites -0.01 0.00 -0.02 – 0.00 -1.84 .07 
Illness Duration 0.01 0.01 -0.00 – 0.02 1.62 .11 
Age of Onset N/Ab     
  aOnly 1 Study 
  bNo Studies 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
sTable 4. Categorical Moderator Analyses: placebo lead-in, comorbidity, study location, primary funding source 
Moderator 
Number of 
included 
studies Hedges g 95% CI Q-value I2 p-Value 
Overall 
Placebo lead-in    0.23  .63 
 No 28 0.36 0.24 - 0.48  64.30  
 Yes 13 0.29 0.21 - 0.38  8.66  
Comorbidity    2.47  .12 
 No  6 0.24 0.04 - 0.43  29.90  
 Yes 28 0.41 0.31 - 0.51  60.61  
Study location    1.94  .16 
 US only 27 0.38 0.28 - 0.48  50.10  
 Not US only 14 0.26 0.13 - 0.39  62.97  
Primary funding source    5.42  .02a 
 Industry only 27 0.26 0.19 - 0.33  37.91  
 Public only 11 0.48 0.31 - 0.64  2.97  
Depressive Disorder 
Placebo lead-in    2.71  .10 
 No 11 0.15 0.06 - 0.24  0.00  
 Yes 9 0.26 0.16 - 0.35  23.51  
Comorbidity    1.98  .16 
 No  3 0.12 -0.04 - 0.28  0.00  
 Yes 11 0.25 0.16 - 0.35  27.54  
Study location    2.61  .11 
 US only 10 0.25 0.16 - 0.35  15.15  
 Not US only 10 0.15 0.05 - 0.24  0.00  
Primary funding source    5.64  .02a 
 Industry only 18 0.18 0.11 - 0.25  0.00  
 Public only 2 0.46 0.24 - 0.68  0.00  
Obsessive-Compulsive Disorder 
Placebo lead-in    0.05  .83 
 No 7 0.41 0.22 - 0.60  0.00  
 Yes 2 0.38 0.15 - 0.60  0.00  
Comorbidity N/Ab      
Study location N/Ab      
Primary funding source    0.07  .79 
 Industry only 4 0.41 0.25 - 0.58  0.00  
 Public only 4 0.36 -0.03 - 0.74  0.00  
Anxiety Disorder 
Placebo lead-in    1.69  .19 
 No 9 0.69 0.47 - 0.91  71.87  
 Yes 2 0.37 -0.06 - 0.80  4.13  
Comorbidity    3.32  0.07 
 No  3 0.37 0.06 - 0.69  0.00  
 Yes 8 0.74 0.51 - 0.97  71.38  
Study location    0.00  0.96 
 US only 7 0.62 0.37 - 0.88  78.68  
 Not US only 4 0.63 0.28 - 0.99  9.85  
Primary funding source    0.31  0.58 
 Industry only 4 0.47 0.24 - 0.70  55.44  
 Public only 5 0.57 0.28 - 0.87  48.85  
aSignificant. 
bNot enough variance.       
 sTable 5. Multivariate Metaregression Analyses 
 B 95% CI p 
Placebo lead-in 0.09 -6377.27 – 7630.54 .83 
Study location 0.11 -6719.62 – 8175.84 .89 
Treatment Duration 0.41 -818.31 – 1766.67 .40 
Publication Year -0.38 -830.60 – 437.03 .48 
Age of Onset 0.01 -2421.64 – 2444.84 .99 
Number of Sites 0.39 -113.43 – 223.59 .45 
Baseline Severity -0.00 -1179.76 – 1177.66 1.00 
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Background: Baseline severity is a crucial moderator of trial outcomes in adult depression, with the
advantage of antidepressants over placebo increasing as severity increases. However, this relationship
has not been examined in late-life depression.
Methods: PubMed, Embase, Web of Science, PsycINFO, and Cochrane were searched for studies published
through September 2014. Randomized, acute phase, and double-blind studies comparing an antide-
pressant group with a placebo group in depressed elderly patients were included.
Results: Nineteen studies met all inclusion criteria. Within-group effect sizes revealed signiﬁcant
improvement in antidepressant groups (g¼1.35, po .000), as well as in placebo groups (g¼ .96,
po .000). Change in depressive symptoms assessed by Hamilton Depression Rating Scale (HDRS) was
moderated by baseline severity in antidepressant groups (Z¼2.67, p¼ .008) and placebo groups (Z¼4.46,
po .000). However, this would be expected as a result of regression toward the mean, and mean
differences between groups did not increase (r¼ .19, p¼ .469) as a function of baseline severity.
Limitations: Limited to published data and information was only analyzed at the level of treatment
groups.
Conclusion: Baseline severity was not associated with an antidepressant–placebo difference and placebo
responses are large in the treatment of depressed elderly people. We propose a stepwise approach, i.e., to
initially offer elderly depressed patients psychosocial interventions and only consider antidepressants if
patients do not respond.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Although the placebo effect and its moderators have been
examined extensively in adult populations with major depressive
disorder (MDD) (Brunoni et al., 2009; Kirsch et al., 2008), comparable
studies for late-life depression are scarce. There is no agreement
upon deﬁnition of late-life depression; the term may be used to refer
to patients with symptoms that fall on a continuum from sub-
threshold to clinically signiﬁcant, and a minimum age criterion in the
range 55–65 years (Rodda et al., 2011). MDD is the most common
psychiatric disorder in elderly people, showing a point prevalence of
4.6–9.3% (Meeks et al., 2011). In addition, subclinical symptoms such
as minor depression and dysthymia are more common in old age,
with a point prevalence of 10% (Pinquart et al., 2006). All of these
forms of depression have been found to have a negative inﬂuence on
the quality of life (Nelson et al., 2013). Late-life depressive disorders
also increase disability (Nelson et al., 2013), are associated with
poorer outcomes in clinically signiﬁcant illnesses (Jiang et al., 2001),
and a higher suicide rate (Conwell et al., 2002).
With regard to effective treatment of depression in elderly
patients, practice guidelines identiﬁes both antidepressants and
psychotherapeutic interventions as a ﬁrst line treatment for MDD,
especially for mild to moderate depression, and a combination
thereof or antidepressants alone for severe depression (American
Psychiatric Association, 2010). Given that psychotherapy and
pharmacotherapy did not show strong differences in effect sizes
in elderly patients in a direct comparison (Pinquart et al., 2006),
the authors recommend that treatment choice should be based on
other criteria, such as contraindications, treatment access, or
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patient preferences. For neuropharmacological practice, selective
serotonin reuptake inhibitors (SSRIs) and other second-generation
antidepressants medications should be considered over mono-
amine oxidase inhibitors or tricyclic antidepressants (American
Psychiatric Association, 2010; Rodda et al., 2011). Moreover, anti-
depressant use in elderly people with depression increased over
the last years, mainly due to a growing SSRI-use (Sonnenberg
et al., 2008). SSRIs have been shown to be superior to a placebo pill
in controlled clinical trials and meta-analyses investigating late-
life depression (Kok et al., 2012; Mittmann et al., 1997; Nelson et
al., 2008). However, overall drug effects in elderly patients with
symptoms of depression are only modest, with an odds ratio
(OR)¼1.40 (95% CI: 1.24–1.57) for response (i.e., Z50% improve-
ment from baseline on mood scales), and OR¼1.27 (95% CI: 1.12–
1.44) for remission (i.e., no longer meeting diagnostic criteria)
versus placebo in a meta-analysis of 10 trials (Nelson et al., 2008).
With regard to possible moderators of pharmacological and
placebo outcomes in depression, mixed-age studies have repeat-
edly shown that the mean differences between groups treated
with antidepressant medication and placebo become larger as
baseline severity increases (Fournier et al., 2010; Khan et al., 2002;
Kirsch et al., 2008). It is unclear whether the increasing beneﬁts, as
severity increases, of drug treatment over placebo treatment are
due to a decrease in the response to placebo treatment or an
increase in the response to pharmacological intervention. The data
reported by Kirsch et al. (2008) indicated that the increased
beneﬁt of drug treatment for severely depressed patients is related
to a decrease in responsiveness to placebos, with no change in
responsiveness to the drug. However, two meta-analyses have
shown that initial severity predicted symptom improvement in
adult patients who took antidepressant medication (Fournier et al.,
2010; Khan et al., 2002). In the Khan et al. (2002) analysis,
improvement as a function of baseline severity increased in drug
groups but decreased in placebo groups. In Fournier et al. (2010),
improvement as a function of severity increased signiﬁcantly in
both drug and placebo groups (as would be predicted by regres-
sion toward the mean), but the increase was signiﬁcantly larger in
the drug group. It should be noted that a re-analysis of the Kirsch
et al. (2008) data set, which controlled for the effect of structural
coupling (this occurs when baseline values and change score are
coupled algebraically, thus possibly leading to an inﬂated associa-
tion between the variables; Tu et al., 2004) concluded that base-
line severity did not inﬂuence treatment outcome (Fountoulakis
et al., 2013).
Studies looking at predictors of treatment outcome in elderly
patients with depression are limited and most studies in this ﬁeld
do not focus on baseline depression severity. To date, symptom
severity at baseline has not been shown to be a moderator of
outcome in depressed elderly people. A meta-analysis by Gibbons
et al. (2012) found that in a geriatric subgroup, baseline severity
was not related to a positive treatment outcome for ﬂuoxetine
compared with placebo. Another meta-analysis found an associa-
tion between initial severity and drug over placebo efﬁcacy in
elderly patients who had suffered from depression for at least 10
years, but not in the majority of patients, who had a shorter
disease history (Nelson et al., 2013). However, there are several
limitations to the reported meta-analyses. First, they rely on a
limited number of studies, thus Gibbons et al. (2012) included
4 geriatric studies, whereas Nelson et al. (2013) included 10 trials
of second-generation antidepressants in patients with late-life
depression. Second, the authors included only a restricted range
of baseline severity scores as they focused on MDD. However, only
a minority of signiﬁcantly depressed elderly patients fulﬁll the
diagnostic criteria for depression, yet the rate of sub-threshold
late-life depression rises with age and is responsible for compar-
able disability and distress (Pinquart et al., 2006).
Consequently, to assess treatment effects in late-life depression, a
meta-analysis including a broader range of studies and taking minor
depression and dysthymia into account is of a high relevance. With
this background, we undertook a systematic review and meta-
analysis to test the assumption that mean differences between
antidepressant and placebo interventions become larger as baseline
severity increases in a geriatric population.
2. Method
2.1. Search strategy and eligibility criteria
We performed searches in Cochrane, Embase, PsycINFO,
PubMed, and Web of Science on studies published through
September 30, 2014. Search terms were adapted to the electronic
bibliographic databases and consisted of keyword combinations
based on the inclusion criteria (for details see Appendix). In
addition to the systematic search, the references of all included
articles were reviewed.
We included peer-reviewed randomized, double-blind, placebo-
controlled clinical trials reported in English or German comparing
depressed elderly individuals in a placebo group with depressed
elderly individuals in an intervention group receiving second-
generation antidepressants (i.e., SSRI's and other novel atypical anti-
depressants). We classiﬁed antidepressants according to the Anatomi-
cal Therapeutic Chemical (ATC)2 classiﬁcation system of the World
Health Organization as an internationally accepted standard of deﬁn-
ing whether a drug counts as an antidepressant or not. Moreover, we
grouped antidepressants as SSRI's or other novel atypical antidepres-
sants in accordance with other meta-analyses (Anderson, 2000; Kok
et al., 2012). The minimum age criterion was set at a mean or median
age of 55 years, or described as elderly, geriatric or older adults.
Outcomes had to be reported as mean change in depressive
symptoms on a continuous mood scale, such as the Hamilton
Depression Rating Scale (HDRS; Hamilton, 1967) or Montgomery-
Asberg Depression Rating Scale (MADRS; Montgomery and Asberg,
1979). We included only continuous outcome data, since dichot-
omizing continuous scores into categorical outcome data leads to a
loss of information, reduces power and creates an artiﬁcial
boundary (Altman and Royston, 2006; Moncrieff and Kirsch,
2005). Pre- and post-intervention data had to be available. We
included studies investigating patients with MDD or subclinical
depressive symptoms (i.e., minor depressive disorder or dysthy-
mia) according to explicit, reliable, and reproducible diagnostic
criteria, which were based on DSM-III, DSM-III-R, DSM-IV or DSM-
IV-TR. However, we included one study where diagnostic criteria
were not explicitly stated (Gerner et al., 1980). Medical comorbid-
ities such as diabetes (Paile-Hyvärinen, Wahlbeck, & Eriksson,
2007), diagnosis of heart failure (Fraguas et al., 2010), or age-
related macular degeneration (Brody et al., 2011) were not grounds
for exclusion, as they are not neurological disorders.
Studies in which patients had depression following cerebrovas-
cular disease (i.e., vascular depression and post-stroke depression), a
cognitive impairment (i.e., moderate to severe dementia), or Parkin-
son's disease were excluded. We excluded studies investigating
these neurological disorders because executive dysfunction and
associated learning impairments in older patients with depression
have been associated with a lower probability of antidepressant and
placebo response (Alexopoulos et al., 2005; Benedetti et al., 2006a,
2006b). However, we included patients with mild cognitive impair-
ment according to the Mini Mental-State Examination (MMSE419;
Folstein et al., 1975) and two papers, which had not explicitly
2 Available at: www.whocc.no. Accessed January 27, 2015.
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excluded patients with dementia (Fraguas et al., 2010; Gerner et al.,
1980; Paile-Hyvärinen et al., 2007). Case reports, comments, letters
and reviews were excluded as well. Using these criteria, 19 studies
were identiﬁed and included in our analysis.
2.2. Data extraction and study outcomes
Two independent investigators (C.L. and J.K.) screened citations
from the former databases and reviews. Identiﬁed abstracts were
reviewed twice for eligibility by two independent investigators (C.L.
and J.K.). Inconsistencies were resolved in consensus between the
authors and conﬁrmed with a third reviewer (P.K.) when necessary.
The reported variables were depression diagnosis (i.e., MDD, minor
depressive disorder, dysthymia), diagnostic criteria (i.e., DSM-III,
DSM-IV), minimum age at entry, illness severity score at entry,
MMSE score at entry, trial duration, type of antidepressant treatment
(i.e., SSRIs or novel atypical antidepressants), dropout rate, and
sociodemographic characteristics (see Table 1).
The primary outcome was mean change in depressive symptoms,
reported either on a continuous self-rated mood scale (i.e., Beck
Depression Inventory (BDI; Beck et al., 1961), Geriatric Depression
Scale (GDS; Yesavage et al., 1983), Hospital Anxiety and Depression
Scale (HADS; Zigmond and Snaith, 1983), 20-item Hopkins Symptom
Checklist Depression Scale (HSCL-D-20; Derogatis et al., 1974), or on a
clinical rating of depression (i.e., HDRS, MADRS). With respect to
baseline depression severity, we ﬁrst converted the different mood
scales (i.e., BDI, GDS, HADS, HSCL-D-20, HDRS, MADRS) to a standar-
dized scale (range 0–100), using the largest point of each mood scale
as 100%. Where a study used more than one mood scale, all mood
scales were converted and used independently in analyses. We
conducted separate subgroup analyses for each mood scale. We
pro-rated mean HDRS scores onto a 17-item scale (HDRS17) where
studies had used other versions of the HDRS. For example, a 24-item
HDRS score would be pro-rated as: HDRS17¼17"HDRS24/24 (Heo
et al., 2007).
Studies differed in the effort made to minimize placebo
responses. In two studies, subjects considered placebo responders
in the single-blind, placebo lead-in phase (improvement of at least
20% on the outcome scale) were excluded from protocol (Fraguas
et al., 2010; Tollefson et al., 1995).
2.3. Data analysis
Comprehensive Meta-Analysis V2 (CMA)3 was used for calcula-
tions and analyses. Two main analyses were performed. First,
effect sizes were calculated for the continuous outcome (i.e., mean
change in depressive symptoms). Differences in mean change
scores between groups were evaluated with differences in means
(Hedges's g). Moreover, we calculated within-group pre-post effect
sizes (Hedges's g). They inform about whether a small difference
between groups is explained by a small change in either group or a
meaningful change in both groups over treatment time. Second,
moderator analyses were conducted to investigate the relationship
between baseline depression severity and subsequent continuous
outcomes of the trial.
For the analyses we chose to use random-effects models rather
than ﬁxed-effects models. A ﬁxed-effects model assumes that
there is one true effect size for all studies and any variations are
due to sampling error, whereas a random-effects model assumes
that variations in effect sizes for the samples are a combination
of sampling error and true variance in effect size (Borenstein
et al., 2011). Random effect sizes were preferable for this
meta-analysis as the studies we included were heterogeneous
and we had relatively small numbers of studies for the sub-
analyses.
To assess the moderating effect of baseline depression severity
on outcome measure (i.e., mean change in depressive symptoms),
we conducted within-group and between-group comparisons. To
test the moderating effect of baseline depression severity on
outcome measures within each group, we performed meta-
regression using method-of-moments analyses (random-effects
model). The Z statistic was used to test the signiﬁcance of the
slope. In the case that data conform to the null hypothesis, Z has a
normal distribution. A signiﬁcant Zwould indicate that the slope is
probably not zero, and hence that baseline depression severity
moderates the outcomes within the group (Borenstein et al., 2011).
Further, we analyzed the mean difference scores to test the
hypothesis that between-groups mean differences increase as a
function of baseline depression severity. We calculated the overall
baseline severity for each study (i.e., mean of antidepressant and
placebo baseline severity, weighted by number of participants)
and the antidepressant-placebo difference in improvement. Pear-
son's correlation between those two variables was calculated.
To assess heterogeneity between studies, we calculated the Q
statistic. A statistically signiﬁcant Q indicates a heterogeneous
distribution, meaning that systematic differences between studies
are present and it rejects the null-hypothesis that all the variation
in effects is due to random error. Similarly, the higher the Q value,
the more variation in the studies can be explained by a true
variance of effects between studies (Cochran, 1954). In addition,
the I2 statistic was used to quantify inconsistency. It measures the
proportion of observed variance across studies, that is a result of
real heterogeneity rather than chance. An I2 value of 0% indicates
no heterogeneity, a value of 25% is classiﬁed as low, 50% as
moderate and 75% as high (Higgins et al.,2003).
We conducted additional sensitivity analyses to explore the
effects of possible sources of bias and artifacts on the results: First,
the presence of publication bias was illustrated by the funnel plot
(Egger et al., 1997), and formally calculated by the fail-safe N
method (Rosenthal, 1984) and the Begg adjusted-rank correlation
test (Begg and Mazumdar, 1994). We estimated the sensitivity of
publication bias by the trim-and-ﬁll method (Duval and Tweedie,
2000). Second, we conducted subgroup analyses to test for
signiﬁcant differences between outcome data in different cate-
gories of studies. We focused on type of antidepressant and mood
scale (i.e., categorical variables). Differences between Hedges's g
were calculated using a one-way ANOVA, whereas the effect sizes
were weighted by the sample size divided by s2 (i.e., n/var; Lipsey
and Wilson, 2001). Four studies included two treatment groups
and one placebo group (Katona et al., 2012; Rapaport et al., 2003,
2009; Schatzberg and Roose, 2006). To deal with the resulting
dependency in these cases, we included both comparisons using
the same mean for each placebo sub-group but used half the
sample size for nwhen weighting (n/var) the means of the placebo
group in each comparison.
Moderator analyses, heterogeneity, and publication bias were
only assessed for mood scales used in more than three trials. In
cases where both intention-to-treat and on-treatment data were
available, we used the intention-to-treat data for calculations. We
used the Cochrane Collaboration's tool for assessing the risk of bias
(Higgins and Green, 2011).
3. Results
3.1. Study selection and study characteristics
The study selection procedure is shown in Fig. 1. In total, 19
studies met inclusion criteria and provided relevant data for the3 Available at: www.meta-analysis.com. Accessed June 27, 2014.
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meta-analysis. The trials included a total of 5737 elderly depressed
patients, of whom 3226 received active drug and 2511 received
placebo. Sample sizes of included studies were between N¼16 and
N¼747. Publication year ranged from 1980 to 2014. Most trials
were based on a parallel design, except one study, which used a
crossover design (Brody et al., 2011). We therefore only analyzed
the ﬁrst 8-week period prior to the crossover. Studies investigated
different types of second-generation antidepressants. SSRIs (i.e.,
ﬂuoxetine, escitalopram, paroxetine, sertraline, and citalopram)
were examined in 14 trials, novel atypical antidepressants (i.e.,
duloxetine, trazodone, agomelatine, bupropion, vortioxetine, and
venlafxine) in another 6 trials. Trial duration varied from 4 to 24
weeks (see Table 1). Based on HDRS17, classiﬁcation of baseline
depression severity ranged from mild to very severe (see Table 2).
Table 3 shows an assessment of the risk of bias for each study
using a tool developed by the Cochrane Collaboration (Higgins and
Green, 2011). The risk of bias across the included studies was
generally low or unclear and is summarized in Fig. 2.
Table 1
Selected characteristics of studies investigating the association between baseline depression severity and treatment outcomes.
Study Depression
Diagnosis
Diagnostic
Criteria
Minimum
Age (Years)
Illness Severity
Score at Entry
MMSE
score
Trial Duration
(Weeks)
Group characteristics
Group N Age (years) Sex (%
female)
Dropout
N, %
Bose et al. (2008) MDD DSM-IV 60 MADRSZ22 Z 24 12 Escitalopram 129 68.1 (6.7) 58.9% 36, 27.9%
Placebo 134 68.5 (7.1) 67.5% 26, 19.4%
Brody et al.
(2011)
MDD or
MiDD
DSM-IV – HDRS17Z10 d.e. 2"8 Escitalopram 7 78.7 (6.6) 42.9% 2, 12.5%
(total)Placebo 9 79.8 (2.3) 88.9%
Chen et al. (2011) MDD DSM-IV 65 GDSZ20 d.e. 8 Escitalopram 29 68.9 (6.1)
(total)
61.8%
(total)
2, 6.9%
Placebo 26 2, 7.7%
Devanand et al.
(2005)
DD DSM-IV 60 HDRS24Z8
andr25
4 24 12 Fluoxetine 44 69.0 (6.0) 32.6% 12, 27.3%
Placebo 46 70.8 (6.3) 40.9% 7, 15.2%
Fraguas et al.
(2010)
MDD DSM-IV 65 HDRS31Z18 - 8 Citalopram 19 74.4 (6.0) 47.4% 3, 15.7%
Placebo 18 72.6 (4.6) 55.6% 7, 38.9%
Gerner et al.
(1980)
unipolar
depression
- 60 HDRSZ18 - 4 Trazodone 19 68.4 (60-
90) (total)
38.3%
(total)
7, 36.8%
Placebo 2 7, 35.0%
Heun et al. (2013) MDD DSM-IV-TR 65 HDRS17Z22 Z 22 8 Agomelatine 151 71.9 (5.1) 69.5% 26, 17.2%
Placebo 71 71.7 (4.8) 64.8% 21, 29.6%
Hewett et al.
(2010)
MDD DSM-IV 65 HDRS17Z18 4 24 10 Bupropion 211 70.9 (5.6) 74.4% 49,
23.0%
Placebo 207 71.3 (5.9) 69.6% 46,
22.0%
Katona et al.
(2012)
MDD DSM-IV-TR 65 MADRSZ26 Z 24 8 Vortioxetine 156 70.5 (4.8) 68.6% 20, 12.8%
Duloxetine 151 70.9 (5.5) 66.2% 23, 15.2%
Placebo 145 70.3 (4.4) 62.1% 17, 11.7%
Paile-Hyvärinen
et al. (2007)
mild MDD DSM-IV 50 - - 24 Paroxetine 23 59.2 (5.4) 26.1% 0, 0%
Placebo 20 59.5 (6.0) 20.0% 6, 30.0%
Rapaport et al.
(2009)
MDD DSM-IV 60 HDRS17Z18 4 24 10 Paroxetine12.5mg 164 67.0 (6.1) 60.0% 39,
23.8%
Paroxetine 25mg 173 67.0 (6.6) 60.0% 39,
22.5%
Placebo 179 68.0 (6.7) 63.0% 53,
29.6%
Rapaport, et al.
(2003)
MDD DSM-IV 60 HDRS17Z18 4 24 12 ParoxetineCR 104 70.4 (5.9) 48.1% 23, 22.1%
ParoxetineIR 106 70.1 (6.6) 56.6% 30,
28.3%
Placebo 109 69.4 (5.4) 63.3% 25,
22.9%
Robinson et al.
(2014)
MDD DSM-IV-TR 65 MADRSZ20 Z 20 12 Duloxetine 249 73.0 (6.3) 78.4% 70, 28.1%
Placebo 121 73.1 (5.6) 73.7% 43,
35.5%
Roose et al.
(2004)
MDD DSM-IV 75 HDRS24Z20 4 19 8 Citalopram 84 79.8 (4.0) 53.6% 18, 21.4%
Placebo 90 79.3 (4.7) 62.2% 11, 12.2%
Schatzberg and
Roose (2006)
MDD DSM-IV 65 HDRS21Z20 4 19 8 Venlafaxine 104 71.0 56.0% 36,
34.6%
Fluoxetine 100 71.0 45.0% 30,
30.0%
Placebo 96 71.0 46.0% 24,
25.0%
Schneider et al.
(2003)
MDD DSM-IV 60 HDRS17Z18 Z 24 8 Sertraline 371 70.0 (6.8) 53.6% 87, 23.5%
Placebo 376 69.6 (6.5) 58.4% 65, 17.3%
Sheikh et al.
(2004)
MDD DSM-IV 60 HDRS17Z18 Z 24 8 Sertraline 360 70.0 53.9% 46, 12.8%
Placebo 368 69.6 57.9% 42, 11.4%
Tollefson et al.
(1995)
MDD DSM-III-R 60 HDRS17Z16 Z 24 6 Fluoxetine 335 67.4 (5.4) 53.7% 72, 21.5%
Placebo 336 68.1 (5.9) 55.6% 65, 19.3%
Williams et al.
(2000)
MiDD or DD DSM-III-R 60 HDRS17Z10 4 24 11 Paroxetine 137 71.0 (6.8) 38.7% 43, 31.4%
Placebo 140 71.0 (7.2) 45.0% 31, 22.1%
Note. DD¼Dysthymic Disorder; d.e.¼dementia excluded; MDD¼Major Depressive Disorder; MiDD¼Minor Depressive Disorder.
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3.2. Effect sizes for antidepressant and placebo treatments
Combined over all mood scales, patients in the treatment
groups showed a signiﬁcantly higher mean change in depressive
symptoms than patients in the placebo groups (g¼ .37, 95% CI: .27
– .46, po .001; see Fig. 3). One study differed considerably from
the others (Chen et al., 2011). Excluding the study led to a slightly
lower, yet still signiﬁcant difference between antidepressant and
placebo treatments (g¼ .32, 95% CI: .25–.40, po .001). With
respect to HDRS scores, studies exhibited moderate, yet signiﬁcant
between-studies heterogeneity. There was an evident publication
bias in a funnel plot. The trim-and-ﬁll test led to an adjustment of
the Hedges's g, yet still reached statistical signiﬁcance (see
Table 4). Regarding GDS scores, studies showed high and signiﬁ-
cant between-studies heterogeneity. There was evidence of some
possible publication bias in a funnel plot. The trim-and-ﬁll method
led to a corrected Hedges's g, which then did not reach statistical
signiﬁcance (see Table 4).
To analyze the mean change in depressive symptoms within each
group (see Table 3), we calculated pre-post effect sizes. Findings
revealed that there is a signiﬁcant treatment improvement in
antidepressant groups (g¼1.35, 95% CI: 1.14–1.57, po .000), as well
as in placebo groups (g¼ .96, 95% CI: .79–1.13, po .000).
3.3. Association between baseline severity and mean change in
depressive symptoms
The slope representing the overall relationship between base-
line severity and change in symptoms was not signiﬁcant in either
antidepressant groups (Z¼1.47, p¼ .142) or placebo groups
(Z¼1.38, p¼ .168), nor was baseline severity signiﬁcantly corre-
lated with drug-placebo differences (r ¼ .17, p¼ .392).
Subgroup analyses of various mood scales were only assessed
for mood scales used in more than three trials (i.e., GDS and
HDRS). Separate analysis of self-rated scales produced comparable
results: change in mean total GDS score was not related to baseline
severity in elderly patients taking antidepressants (Z¼1.15, p
¼ .251), or elderly patients taking placebos (Z¼# .04, p¼ .971),
nor was baseline severity signiﬁcantly correlated with drug–
placebo differences (r ¼ .69, p ¼ .199). In contrast, studies using
the clinician-rated HDRS mood scale indicated that mean change
in depressive symptoms increased signiﬁcantly in antidepressant
trials (Z¼2.67, p¼ .008, R2¼ .40) and placebo trials (Z¼4.46, p
o .000, R2¼ .50) as a function of HDRS baseline severity, which
would be expected as a result of regression toward the mean. As
displayed in Fig. 4, the slope of the regression lines increased
within each group. Nevertheless, the overall baseline and the
Full-text papers retrieved (N=646)
Studies identified through an initial review 
process in PsycINFO (N=393), PubMed 
(N=2,273), Embase (N=2,014), Web of 
Science (N=471), Cochrane (N=85)
Keywords: see Appendix
Studies excluded after full-text review (N=627)
Non-geriatric population (N=272)
Non-relevant study design (N=156)
Postroke or vascular depression or dementia (N=73)
Secondary analysis (N=43)
Placebo as add-on (N=25)
Non-relevant outcomes (N=29)
Placebo only as wash-out (N=14)
Non-complete outcomes (N=5)
Article not in English or German (N=4)
Other reasons (N=6)
Studies included in the meta-analysis (N=19)
Studies excluded by abstract and title (N=4,590)
Fig. 1. Study selection procedure.
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Table 2
Outcome characteristics of studies investigating the association between baseline depression severity and treatment outcomes.
Study Mood
scale
Baseline depression
severity drug (mean)
Baseline depression
severity placebo (mean)
Mean change in depressive
symptoms (Drug)
Mean change in depressive
symptoms (Placebo)
Classiﬁcation
(based on HDRS17)
Bose et al. (2008) HDRS17 20.3 19.6 7.5 7.1 Severe
Brody et al.
(2011)
HDRS17 17.1 15.2 6.1 2.9 Mild/moderate
Chen et al. (2011) GDS 23.4 24.0 12.7 2.9
Devanand et al.
(2005)
HDRS17
(modiﬁed)
10.6 10.0 4.1 1.3 Mild/moderate
BDI 12.7 13.1 1.1 .0
Fraguas et al.
(2010)
HDRS17, 15.4 17.3 9.7 9.6 Mild/moderate
MADRS 21.9 20.1 15.1 9.4
Gerner et al.
(1980)
HDRS17
(modiﬁed)
22.1 20.2 14.8 4.1 Severe
BDI 15.1 13.4 5.4 .4
Heun et al.
(2013)
HDRS17 26.9 26.8 13.5 10.7 Very severe
Hewett et al.
(2010)
MADRS 29.5 29.8 16.6 13.6
Katona et al.
(2012)
HDRS17 Vortioxetine: 22.7 22.7 14.7 10.8 Severe
Duloxetine: 22.3 17.0
Paile-Hyvärinen
et al. (2007)
HADS 7.3 8.4 1.8 2.2
Rapaport et al.
(2009)
HDRS17 Paroxetine12.5mg: 22.6 22.7 10.7 8.9 Severe
GDS-
short
Paroxetine 25mg: 23.1 12.1
Paroxetine12.5mg: 8.9 8.7 3.2 2.2
Paroxetine 25mg: 9.1 3.5
Rapaport et al.
(2003)
HDRS17 ParoxetineCR: 22.1 22.1 14.4 10.5 Severe
ParoxetineIR: 22.3 13.9
Robinson et al.
(2014)
HDRS17, 19.4 19.3 6.0 3.9 Severe
GDS 18.5 17.6 4.3 4.5
Roose et al.
(2004)
HDRS17
(modiﬁed)
17.3 17.1 9.6 8.2 Mild/moderate
MADRS 24.4 25.0 9.7 8.5
Schatzberg and
Roose (2006)
HDRS17
(modiﬁed)
Venlafaxine: 19.4 18.6 8.4 7.5 Severe
Fluoxetine: 19.4 6.7
Schneider et al.
(2003)
HDRS17 21.4 21.4 7.4 6.6 Severe
Sheikh et al.
(2004)
HDRS17 21.4 21.4 7.9 6.4 Severe
Tollefson et al.
(1995)
HDRS17 22.2 22.1 8.2 6.4 Severe
GDS 19.1 18.7 3.3 2.1
Williams et al.
(2000)
HSCL-D-
20
1.4 1.4 .6 .4 Mild/moderate
Table 3
Assessment of risk of bias.
Study Random sequence
generation
Allocation
concealment
Adequate
blinding
Incomplete outcome
data
Selective
reporting
Other risks of
bias
Bose et al. (2008) Low risk Unclear Unclear Unclear Low risk Low risk
Brody et al. (2011) Unclear Low risk Unclear Unclear Low risk Unclear
Chen et al. (2011) Low risk Unclear Unclear Low risk Low risk Low risk
Devanand et al. (2005) Low risk Unclear Low risk Low risk Low risk Low risk
Fraguas et al. (2010) Unclear Unclear Unclear High risk Low risk High risk
Gerner et al. (1980) Unclear Unclear Unclear High risk Low risk Unclear
Heun et al. (2013) Low risk Unclear Low risk Unclear Low risk Low risk
Hewett et al. (2010) Low risk Unclear Unclear Low risk Low risk Low risk
Katona et al. (2012) Low risk Low risk Low risk Unclear Low risk Low risk
Paile-Hyvärinen et al.
(2007)
Low risk Low risk Unclear High risk Low risk Low risk
Rapaport et al. (2009) Low risk Unclear Unclear Low risk Unclear Low risk
Rapaport et al. (2003) Unclear Unclear Unclear Low risk Low risk Low risk
Robinson et al. (2014) Low risk Low risk Unclear Unclear Unclear Unclear
Roose et al. (2004) Low risk Low risk Unclear Low risk Low risk High risk
Schatzberg and Roose
(2006)
Low risk Unclear Unclear Low risk High risk Low risk
Schneider et al. (2003) Low risk Unclear Low risk Low risk Low risk Low risk
Sheikh et al. (2004) Unclear Unclear Unclear Low risk Low risk Unclear
Tollefson et al. (1995) Unclear Unclear Unclear Unclear Low risk Low risk
Williams et al. (2000) Low risk Low risk Low risk High risk Low risk Low risk
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antidepressant–placebo difference in improvement were not sig-
niﬁcantly correlated (r¼ .19, p¼ .469).
To clarify further the clinical signiﬁcance of the differences
between the two treatments, we refer to the National Institute for
Clinical Excellence guidelines (NICE, 2004). These suggest that a
standardized mean difference (d) of .5 or a three-point difference
in HDRS17 scores should be used as the threshold for clinical
signiﬁcance. For elderly patients with mild to moderate depression
(HDRS17 score ofr18), Cohen's d was .24 (95% CI: .02–.47, p
¼ .031), for patients with an HDRS17 score in the severe range (19–
22), Cohen's d was .39 (95% CI: .25–.52, p o .001), and for patients
with HDRS17 score in the very severe range (Z 23), we found an
effect size of d¼ .37 (95% CI: .09–.66, p ¼ .011). In summary, none
of the values reached the proposed cutoff of d¼ .5 for clinical
signiﬁcance. However, the criterion of a difference of Z3 points on
the HDRS was met for baseline HDRS17 scores of Z21, indicated
by a red line in Fig. 4.
3.4. Categorical moderator variables
Moderator analyses examined whether several categories of
studies were related to improvement. Different types of antidepres-
sant (i.e., agomelatine, bupropion, citalopram, duloxetine, escitalo-
pram, ﬂuoxetine, paroxetine, sertraline, trazodone, vortioxetine, and
venlafaxine) were unrelated to effect sizes (F(10,20)¼1.92, p¼ .104).
Similarly, there was no signiﬁcant association between different
mood scales (i.e., BDI, GDS, HADS, HDRS, HSCL-D-20, MADRS) and
improvement (F(5,25)¼ .77, p¼581).
4. Discussion
The purpose of the present meta-analysis was to investigate the
moderating effects of baseline severity on mean outcome mea-
sures in depressed elderly patients treated with antidepressants or
placebos.
Concerning HDRS scores, we did ﬁnd an increase in mean change
in depressive symptoms with increasing baseline severity within
antidepressant and placebo interventions. However, one must be
careful in interpreting relations between baseline severity and within-
group changes, as they can be strongly inﬂuenced by regression
toward the mean (Calati et al., 2013). Consequently, we analyzed
between-group data, looking at the antidepressant-placebo difference
as a function of baseline. The overall baseline and the antidepressant–
placebo difference in improvement were not signiﬁcantly correlated.
Therefore, studies in late-life depression do not conﬁrm the severity
hypotheses found in mixed-aged studies, in which an increasing
advantage of antidepressants over placebos was reported with
increasing baseline severity (Fournier et al., 2010; Khan et al., 2002;
Kirsch et al., 2008). Our failure to ﬁnd an association between initial
severity and drug over placebo efﬁcacy is similar to previous geriatric
studies (Gibbons et al., 2012; Nelson et al., 2013). Nevertheless, our
study differed from these reviews as we included a broader range of
studies, including studies looking at minor depression and dysthymia.
Our results indicate that placebo responses are important in
the treatment of depressed elderly people. First, within-group pre-
post effect sizes revealed that there is a treatment improvement
for depressed elderly participants taking placebos. Second, clini-
cally meaningful differences between antidepressant and placebo
interventions were only observable in patients with severe depres-
sive symptoms (i.e., HDRS17Z21) at baseline. On the one hand, it
is possible that placebo effects might even be larger and more
important than reported. Analgesia trials indicate that the way in
which instructions are given inﬂuences the magnitude of placebo
analgesia; placebo effects were larger in experimental studies that
explicitly investigated mechanisms of placebo analgesia than in
RCTs where placebo was only used as a control condition (Vase
et al., 2002). Studies also indicate that the tests of the blind in
double-blind designs usually show that it is penetrated and thus
susceptible to the researcher's assumption that the active drug will
prove to be more effective than the placebo (Fisher and Greenberg,
1993). Moreover, a recent study demonstrated that a belief in the
effectiveness of the antidepressant and a supportive therapeutic
alliance were crucial elements in determining the treatment
response (Leuchter et al., 2014). On the other hand, the observed
placebo response can be attributed to a number of factors,
including spontaneous remission, measurement factors (i.e.,
regression to the mean, rater bias and response bias), unreported
co-interventions, and clinical characteristics of participating
patients (Benedetti, 2008; Rutherford and Roose, 2013). Moreover,
the additivity assumption, that the difference between antidepres-
sant response and placebo response is attributable to the pharma-
cological effect of the antidepressant, may be incorrect (Kirsch,
2000). It is therefore possible that antidepressant effects are
underestimated in RCTs (Lund et al., 2014). Nevertheless, the
Fig. 2. Risk of bias assessment.
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ﬁnding of a meaningful placebo effect needs to be considered with
respect to its therapeutic implications.
Over time, the conceptualization of the placebo has shifted from
an inert sugar pill (i.e., a deceptive technique to increase outcome
expectations) to the emphasis of contextual factors (Wampold et al.,
2005), including implicit or explicit psychosocial stimulation of a
therapeutic procedure (Finniss et al., 2010), and a therapeutic alliance
(Kaptchuk et al., 2008). In the elderly, psychosocial support is
described as a highly relevant part of placebo treatment
(Alexopoulos et al., 2007). All therapeutic treatment is administered
in the context of a complex sociocultural system, resulting in the
perception of a meaningful therapeutic encounter (Di Blasi et al.,
2001). Contextual cues may induce positive expectations, hope, trust,
security, and hence a placebo response in elderly patients (Bingel
et al., 2011). In clinical trials with depressed elderly participants,
perceived social support is associated with subsequent decreases in
depression (Oxman and Hull, 2001) and increased probability of
recovery (Bosworth et al., 2002). Similarly, control treatments can
have positive outcomes when they involve social contact. Hence, a
study comparing placebo, paroxetine, and problem-solving
treatments in subclinically depressed elderly participants concluded
that the minimal between-groups differences were due to the impact
of clinical management, which included social contact and was
additionally given to all patients (Oxman and Hull, 2001). Similarly,
depressed nursing home residents under a treatment condition
involving exercise training and a control condition involving social
conversation both showed improvement (Williams and Tappen,
2008). It is assumed that the impact of social support on treatment
outcome is especially relevant for elderly patients, as they often live
alone and may have little social contact (Bingel et al., 2011).
Correspondingly, a recent study reported that self-rated reclusiveness
predicted response in a supportive patient–practitioner relationship
(Conboy et al., 2011).
Our failure to ﬁnd that baseline severity is associated with an
antidepressant–placebo difference in study outcome may be
inﬂuenced by the initial severity grades of the examined trials.
We included only one study of very severely depressed patients,
showing a HDRS initial severity of 26.9 (Heun et al., 2013).
Similarly, Kok et al. (2012) concluded that only a few studies have
focused on severely depressed older people. In contrast, other
Fig. 3. Mean change in depressive symptoms of antidepressant treatment for depression compared to placebo treatment (random effects).
The red diamonds indicate the combined effect sizes for studies sorted by mood scale, as well as the overall effect size of the meta-analysis (top to bottom). An asterisk
indicates that the study included two separate antidepressant samples.
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meta-analyses of mixed-age patients examined more strongly
affected patients with HDRS baseline scores of over 30.0 in several
trials (Fournier et al., 2010; Khan et al., 2002; Kirsch et al., 2008).
One reason for our lack of studies investigating the most severe
cases is due to our exclusion of elderly patients with executive
dysfunctions, as severe depression has been shown to be asso-
ciated with Alzheimer Disease (Gracia-García et al., 2013), all-
cause dementia (Chen et al., 2008), and other memory deﬁcits
(Boeker et al., 2012).
Our meta-analysis has several limitations. First, the investi-
gated studies had substantial differences regarding outcome
measures, resulting in heterogeneity across studies. Second, our
meta-analysis was limited to published data, which may have
resulted in a considerable bias towards studies reporting a positive
outcome (Turner et al., 2008). There was evidence of such a bias in
mean difference outcome data in our study, which we attempted
to rectify using statistical adjustment procedures, namely the
trim-and-ﬁll method. Third, our study analyzed information only
at the level of treatment groups, yet contained no data for a
patient-level analysis (Fournier et al., 2010). This may have
resulted in ecologically fallacious ﬁndings, where the cumulative
association fails to reproduce associations at the individual level
(Spoerri et al., 2010). Finally, stable physical illness and comorbid
disorders were common in our sample. Nevertheless, elderly
patients with a number of age-related disorders in addition to
depression are representative of the population of elderly patients
with depression (Nelson et al., 2013).
Despite these limitations, we found clear indications that
placebo responses are large and meaningful in the treatment of
depressed elderly people, irrespective of baseline depression
severity. Further studies should investigate antidepressant and
placebo reactions in severely depressed old patients without
executive dysfunctions – assessed by more comprehensive and
valid tests than the MMSE – in order to make ﬁnal conclusions
about the possible moderating effect of initial depression severity.
In addition, further research into the determinants of the effect of
psychological interventions in the treatment of late-life depression
is needed.
Nevertheless, our placebo responses ﬁndings should remind
healthcare practitioners that the therapeutic environment and
social support are of particular importance in elderly patients. In
accordance with Bingel et al. (2011), we propose that it is essential
to make use of supportive psychosocial and environmental
mechanisms to optimize treatment with antidepressants. More-
over, social support and increased attention to patients has been
shown to improve compliance with medication regimes (Packer,
1990). Finally, we note that this knowledge may be particularly
important in elderly patients, as they are more likely to have
serious medical conditions and thus receiving polypharmacother-
apy, which often leads to adverse drug reactions and interactions
between medications (Taylor and Doraiswamy, 2004). We propose
a stepwise approach, i.e., to initially offer elderly depressed
patients psychosocial interventions and only consider antidepres-
sants if patients do not respond. Given the propensity to multiple
adverse drug reactions noticed in elderly patients, psychosocial
interventions may represent a safer alternative (Andreescu and
Reynolds, 2011).
Table 4
Results of publication bias and heterogeneity.
Variable
Mean difference df or 95% CI
Measured with GDS
Publication bias
Funnel plot distribution Asymmetrical
Begg’s adjusted-rank correlation (p value) .043
Classic fail-safe N 57
Trim-and-ﬁll test (Hedges’s g or RR) .20 # .21–.62
Heterogeneity
I2 statistica 90.79nnn 4
tau2 statisticb .17
Measured with HDRS
Publication bias
Funnel plot distribution Asymmetrical
Begg’s adjusted-rank correlation (p value) .010
Classic fail-safe N 520
Trim-and-ﬁll test (Hedges’s g or RR) .25 .13–.37
Heterogeneity
I2 statistica 64.24*** 18
tau2 statisticb .03
a The data represent the variance between studies as a proportion of the total
variance; heterogeneity was tested using the I2 statistic (low heterogeneity¼25%;
moderate heterogeneity¼50%; high heterogeneity¼75%). The P values refer to
signiﬁcance of the Q statistic (the I2 statistic does not include a test of signiﬁcance).
b Heterogeneity was tested using the tau2 statistic, which estimates the
between-study variance.
nnn p r .001.
Fig. 4. Relationship between baseline severity and mean change in HDRS17 score among the antidepressant and placebo groups. The NICE threshold for clinical signiﬁcance
(HDRS mean differenceZ3) was met for initial HDRS17 scores of 21 or greater, visualized by the red line. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article).
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 Abstract 
Research on open-label placebos questions whether deception is a necessary characteristic of 
placebo effects. Yet, comparisons between open-label and deceptive placebos are lacking. We 
therefore assessed effects of open-label and deceptive placebos in comparison to no treatment 
with a standardized experimental heat pain paradigm in a RCT in healthy participants. 
Participants (N = 160) were randomly assigned to no treatment (NT), open-label placebo 
without rationale (OPR-), open-label placebo with rationale (OPR+) and deceptive placebo 
(DP). We conducted baseline and posttreatment measurements of heat pain threshold and 
tolerance. Apart from the NT, all groups received an application of a placebo cream. Primary 
outcomes were planned comparisons of heat pain tolerance and the corresponding intensity 
and unpleasantness ratings. Objective posttreatment pain tolerance did not differ among 
groups. However, for subjective heat pain ratings at the posttreatment tolerance level, groups 
with a rationale (OPR+ and DP) reported diminished heat pain intensity (t(146) = -2.15, p = 
.033, d = 0.43) and unpleasantness ratings (t(146) = -2.43, p = .016, d = 0.49) compared to the 
OPR- group. Interestingly, the OPR+ and the DP groups did not differ in heat pain intensity 
(t(146) = -1.10, p = .272) or unpleasantness ratings (t(146) = -0.05, p = .961) at posttreatment 
tolerance level. Our findings reveal that placebos with a plausible rational are more effective 
than placebos without a rationale. Even more, open-label placebos do not differ in their 
effects from deceptive placebos. Therefore, we question the ubiquitously assumed necessity 
of concealment in placebo administration. 
 
 Keywords 
Pain; open-label placebos; TSA II; rationale; deception; heat pain paradigm  
 Introduction 
A vast body of research corroborates the substantial benefit of placebos on healthy 
participants [24,56,63] as well as on certain clinical conditions [25,32,35,39], and for some 
disorders placebo effects are even as effective as active medication [68]. Yet, the 
implementation of deceptive placebos in clinical practice is ethically unfeasible and 
incompatible with key principles of openness and patient autonomy [6]. However, recent 
evidence generally questions whether deception is indeed a necessary characteristic of the 
placebo effect and suggests the possibility of openly prescribed placebos with full 
transparency [1,9,30,31,34,46,49,58].  
Several open-label placebo studies have been conducted with full disclosure and the 
provision of a scientific rationale, i.e. explanations of the effects and mechanisms of placebos 
[30,31,34], and thereby aimed to alter subjective expectation by the means of verbal 
suggestions [50]. Open-label placebo administration led to symptom reduction of irritable 
bowel syndrome [31] and juvenile ADHD [58,59] when compared to no treatment, and two 
further studies underpinned the effectiveness of open-label placebos compared to treatment as 
usual conditions in patients suffering from rhinitis [60] and chronic low back pain [9]. In 
contrast, a pilot open-label study with patients suffering from major depression did not find 
any significant improvements compared to a waiting list control group; yet a medium effect 
size for open-label placebos was found, exceeding standardized drug-placebo differences 
found in antidepressant RCT’s [34].  
Despite these promising results, open-label placebos with full disclosure have not been 
directly compared to deceptive placebo administration and they have yet to be studied in an 
experimental analgesia paradigm although pain is the best examined condition in placebo 
research [3] and a current meta-analysis emphasizes the high susceptibility of pathological 
pain to placebo effects [14]. We therefore set out to examine the effects of open-label 
placebos in a standardized heat pain experiment [22,37,40] with healthy participants. We 
 compared open-label placebo administration with a rationale (OPR+) and without a rationale 
(OPR-) to deceptive placebo (DP) administration and a no treatment (NT). Primary outcomes 
were heat pain tolerance and the corresponding intensity and unpleasantness ratings. The 
following hypotheses were tested. First, we predicted that participants’ heat pain analgesia 
(i.e., an increase in heat pain tolerance and a decrease of corresponding intensity and 
unpleasantness ratings) is enhanced after the application of a placebo cream in groups with a 
convincing rationale (OPR+ and DP) compared to subjects receiving a placebo cream without 
any rationale (OPR-). Second, we hypothesized that deception (DP) promotes placebo 
analgesia more efficiently than an open-label placebo administration with a rationale (OPR+). 
Third, we hypothesized that the three groups with an application of a placebo cream (OPR-, 
OPR+, and DP) would show an enhanced heat pain analgesia when compared to the NT group. 
Methods 
Study Design 
Between January 2016 and July 2016, we conducted a randomized-controlled trial 
(RCT) at the Division of Clinical Psychology and Psychotherapy at the University of Basel, 
Switzerland. Written informed consent was obtained from each participant before 
participation in the study. The Local Ethics Committee of the Canton Basel, Switzerland, 
approved the design and informed consent of the study. The study is registered at 
ClinicalTrials.gov: NCT02578420.  
Study Population 
160 healthy adults from the general population were recruited via advertisements for 
“a novel mind-body management study of individual pain perception” [31]. They had to be 
healthy by self-report, right-handed, aged between 18 and 65 years and have sufficient 
German language skills. Exclusion criteria were any acute or chronic diseases (e.g., chronic 
 pain, hypertension, heart disease, renal disease, liver disease, diabetes) as well as skin 
pathologies, neuropathies or nerve entrapment symptoms, or any other sensory abnormalities 
affecting the tactile or thermal modality. Participants were also excluded if they took 
medications (e.g., psychoactive medication, narcotics, or intake of analgesics), were in 
psychological or psychiatric treatment, reported current or regular drug consumption, or 
consumed more than three alcoholic standard beverages per day. Finally, we did not include 
Psychology or Medicine students, since they potentially have a previous knowledge of 
placebo mechanisms and effects. All participants were paid 50 Swiss francs for their 
participation in the study.  
Study Procedure 
Participants were randomly assigned to no treatment (NT; N = 40), open-label placebo 
without a rationale (OPR-; N = 40), open-label placebo with a rationale (OPR+; N = 40), and 
deceptive placebo (DP; N = 40). Upon arrival, all participants performed an objective baseline 
assessment of heat pain, as well as subjective heat pain ratings (for a description of the heat 
pain assessments, see below). After baseline measurements, the treatment phase was 
conducted.  
Participants in the NT group did not receive any treatment and were told that they are 
in the “no treatment group”. All participants in the three other groups (OPR-, OPR+, and DP) 
received an inert white placebo cream. However, the provided rationale in the three groups 
differed. In the OPR- group, participants were informed that they are receiving an inert 
placebo cream and no additional information regarding placebo mechanisms was provided. In 
the OPR+ group, participants were informed that they are receiving an inert placebo cream. In 
accordance with Kaptchuk et al. [31], the investigator explained that (a) the placebo effect is 
powerful, (b) the body can automatically respond to placebos like Pavlov’s dogs who 
salivated when they heard a bell, and (c) a positive attitude towards placebos can be helpful 
 but is not necessary. We did not mention the importance of compliance (i.e., taking the 
placebo faithfully is critical) as in Kaptchuk et al. [31], since our treatment consisted of a 
single application of the placebo cream. In the DP group, participants were told that they are 
receiving an analgesic cream – named "Antidolor”, containing the active substance Lidocaine 
– while in fact they received an inert placebo cream. 
After the treatment phase, heat pain measurement procedures were performed again 
(posttreatment), regardless of group allocation.  
Randomization and Blinding  
The random allocation sequence was created using the built-in random number 
generator in Microsoft Excel for Mac, version 15 (Microsoft Corp, Redmond, WA). 
Regarding the location of the heat pain stimuli on the left forearm, block randomization was 
used such that an equal number of participants followed the same location sequence in each 
group (see below for detailed description). Participants were enrolled and assigned to 
treatments by the first author (CL). In order to implement the random allocation sequence, 
investigators received the participant number, group allocation and patch position sequence 
before the start of the trial.  
Due to the study design, only participants from the deceptive group were blinded. 
Study investigators knew the allocation code at the start of the trial.  
Objective Heat Pain Threshold and Tolerance and Corresponding Subjective Heat Pain 
Ratings 
Pain sensation was assessed using the suprathreshold method of the Thermo Sensory 
Analyser (TSA-II). The TSA-II is a commonly used and safe device to study analgesic effects. 
To prevent physical injuries, the measurement stops automatically at a maximum temperature 
of 52°C. The thermode of the TSA-II was fixed on two different locations (location A and B; 
determined by using a positioning device) on the left volar forearm [45], applying a randomly 
 counterbalanced order within each group. Half of the participants started with the location A 
for the baseline measurements of heat pain stimuli, followed by the location B for the 
posttreatment measurements (for the other half of the participants, it was the exact opposite). 
The thermode of the TSA-II was moved to different locations in order to prevent effects of 
sensitization or habituation [16].  
Prior to the actual measurements, participants were made familiar with the heat stimuli 
and the handling of the controlling device. Heat pain threshold was measured to determine the 
point when the sensation went from being warm to feeling painful using the method of limits, 
starting at 32 °C. Participants were asked to stop the heat stimulus at the point they feel it 
changes from “hot” to “painful” with a rise of 0.5 °C every second. Heat pain thresholds were 
assessed three times [55]. Heat pain tolerance was also determined using the method of limits: 
participants were asked to stop the increasing heat stimulus at the moment they could not 
stand the heat any longer. Three measurements were taken, each starting at 32 °C, with a rise 
of 0.5 °C every second [26]. Heat pain threshold was assessed before measuring heat pain 
tolerance in order to minimize interference between heat pain threshold and tolerance [38].  
Following each heat pain threshold and tolerance stimulation, participants were asked 
to rate pain intensity and unpleasantness on Visual Analogue Scales (VAS) [53]. The intensity 
VAS with a range from 0 up to 100 was titled at the left by the descriptors “no pain sensation” 
and at the right by “the most intense pain sensation imaginable”. Similarly, the unpleasantness 
VAS (ranged from 0-100) was anchored by the descriptors “not at all unpleasant” and “the 
most unpleasant imaginable”. Subjective pain intensity and unpleasantness are commonly 
assessed pain dimensions in heat pain paradigm studies [48]. Intensity entails the cognitive 
dimensions of pain, whereas unpleasantness comprises the affective dimension of pain [51]. 
Our design allows for the assessment of individual heat pain threshold and tolerance 
temperatures for each of the three baseline and posttreatment stimulations as well as for the 
corresponding subjective heat pain intensity and unpleasantness ratings [40]. 
 Measures and Questionnaires  
At screening, demographic variables (i.e., age, gender, nationality, family status, 
educational level, employment situation, and income) were assessed.  
Furthermore, after the treatment phase and before the second heat pain measurement 
procedures (posttreatment), pain expectancy and desire for relief were assessed. In order to 
measure expectancy of relief, we deployed a VAS to assess the expected pain intensity 
(“What do you expect the pain intensity to be after the application of the cream?”) and pain 
unpleasantness (“What do you expect the pain unpleasantness to be after the application of the 
cream?”). Pain expectancy ratings were made on the same VAS (ranging from 0-100) as those 
for pain intensity and pain unpleasantness [53]. The Desire for Relief Scale (DRS) assessed 
the participants desire for relief on a VAS (ranging from 0-100) with the anchors “no desire 
for relief” on the left and “the most intense desire for relief imaginable” on the right [53]. 
After the posttreatment phase, the credibility of the treatment was measured. 
Participants from the DP group were asked to rate whether they believed they had received an 
analgesic cream (Likert scale from 1 = “I was sure that I received an analgesic cream”, 2 = ”I 
doubted whether I received an analgesic cream” and 3 = “I did not belief that I received an 
analgesic cream”), whereas participants from the OPR- and OPR+ group had to report whether 
they believed they had received a placebo (Likert scale from 1 = “I was sure that I received a 
placebo cream”, 2 = “I doubted whether I received a placebo cream” and 3 = “I did not 
believe that I received a placebo cream”). As in previous studies [55], participants who 
disbelieved that they had received a placebo cream or an analgesic cream, respectively (i.e., 
rating 3 on the Likert scale) were excluded from analyses. Further, all participants had to fill 
out the placebo interventions questionnaire (Likert scale from 1 = “I know the term placebo 
and I can describe it in my own words”, 2 = “I have heard about the term placebo but I do not 
know what it is” and 3 = “I have never heard the term placebo before”) [17]. Participants who 
 were randomized to the OPR- or OPR+ group, but could not define the term placebo at the end 
of treatment (i.e., rating 2 or 3 on the Likert scale) were also excluded from analyses.  
Statistical Analyses 
Primary outcomes were objective heat pain tolerance and the corresponding subjective 
intensity and unpleasantness ratings. Objective heat pain threshold and the corresponding 
subjective intensity and unpleasantness ratings, as well as pain expectancy and desire for 
relief were chosen as secondary outcomes. We decided to use heat pain tolerance and the 
corresponding subjective intensity and unpleasantness ratings as primary outcomes since heat 
pain tolerance has been shown to be more connected with affective and motivational aspects 
than heat pain threshold which has been shown to be more associated with a sensory 
discrimination of nociceptive quality [22,27,42]. Hence, heat pain tolerance entails the 
experience of maximal discomfort, leading to enhanced subjective distress [22] and has 
further been shown to be linked to pathological pain [15].  
For our objective primary outcome, i.e., posttreatment heat pain tolerance, we 
calculated one one-way analysis of covariance (ANCOVA), using the treatment group (NT, 
OPR-, OPR+, and DP) as independent between-subject factor and baseline heat pain tolerance 
as covariate. For our subjective primary outcomes, i.e., intensity and unpleasantness ratings 
for heat pain tolerance at posttreatment, we conducted two separate one-way ANCOVAs with 
treatment group as between-subject factor and the corresponding outcome variable measured 
at baseline as covariate. For all three primary outcome ANCOVAs, we tested three orthogonal 
planned contrasts (two-tailed): (c1) NT group vs groups with a cream application (OPR-, 
OPR+, and DP) which is in line with the recommendation to compare the NT group against all 
treatment groups [18]; (c2) OPR- group vs groups with a rationale (OPR+ and DP) in order to 
test the significance of the rationale; and (c3) OPR+ group vs DP group in order to evaluate 
the significance of deception. Here, we decided to define the contrasts a priori since it has 
 been recommended to use planned contrasts instead of post hoc tests: they reduce the risk of 
type I errors, derive from specific hypotheses and complex comparisons can be 
accommodated [53,57]. 
 Regarding primary outcomes, two sensitivity analyses were calculated: First, 
completer analyses were applied, whereby all participants who were randomized and who 
finished the experiment were included in the analyses (N = 159). Second, we tested whether 
there is a significant correlation between objective posttreatment heat pain tolerance and the 
corresponding subjective intensity and unpleasantness ratings. Then, we calculated additional 
ANCOVAs for subjective heat pain ratings by including the objective heat pain tolerance as a 
further covariate [18]. A detailed description of the statistical procedure used for the 
secondary outcomes (i.e. objective heat pain threshold and the corresponding subjective 
intensity and unpleasantness ratings) can be found in the Supplement (S1).  
Regarding subjective expectancy ratings, we calculated two one-way ANCOVAs, with 
expectancy ratings of intensity and unpleasantness for heat pain tolerance, respectively, as 
outcome, defining the treatment group as an independent between-subject factor. 
Corresponding subjective ratings for heat pain tolerance at baseline were included as 
covariates. Further, desire for relief ratings were subjected to one one-way ANCOVA with 
treatment group as independent between-subject factor. No orthogonal planned contrasts were 
defined for all secondary outcomes. However, as the ANCOVA cannot provide detailed 
information on differences between particular pairs of treatment groups, post hoc tests were 
conducted for analysis with a significant omnibus test for treatment group, applying the 
Benjamini-Hochberg (BH) multiple testing correction [28]. 
Cohen’s d was computed to provide an effect size estimate and were interpreted as 
small (d= 0.2), medium (d = 0.5), and large (d = 0.8) based on benchmarks suggested by 
Cohen [11]. All hypotheses were tested with an alpha-level of p ≤ 0.05. On the basis of an 
omnibus test in a one-way analysis of variance with four groups and 5% error level, we 
 estimated that the total sample size of N = 160 would provide 99% power to detect a large 
effect (f = 0.4, effect size calculation based on Kaptchuk et al. [31]) and 75% power to detect 
a medium effect (f = 0.25, effect size estimation based on Kam-Hansen et al. [30]).  
All statistical analyses were computed using R for Mac, version 3.3.2. (R Foundation; 
Vienna, Austria).  
Results 
Sample Characteristics 
Participants had a mean age of 27.15 (SD 9.51) years and 68% of the participants were 
female (see Table 1 for more descriptive details). In total, we included 151 participants: One 
participant from the OPR- group did not have sufficient German language skills and had to be 
excluded during the trial by the investigator. Two participants in the OPR- and three 
participants in the OPR+ group had to be excluded since they could not define the term 
placebo at the end of treatment. Further, three participants in the DP group who did not 
believe that they received an analgesic cream were not included in the analyses (see 
Supplement SF1).  
Objective Heat Pain Tolerance 
Planned contrasts indicated that the groups did not differ regarding their objective heat 
pain tolerance at posttreatment (NT vs. OPR-, OPR+, and DP: t(146) = 0.35, p = .724; OPR- vs. 
OPR+ and DP: t(146) = 1.15, p = .254; OPR+ vs. DP: t(146) = 0.37, p = .711). The results did 
not change in the additional completer analyses (see Supplement ST1).  
Subjective Intensity and Unpleasantness Ratings for Heat Pain Tolerance 
In contrast to objective heat pain tolerance, the corresponding subjective intensity and 
unpleasantness ratings did differ among groups (see Table 2 for group means). First, planned 
contrasts indicated that the NT group and the other three groups did not differ in heat pain 
 intensity ratings at posttreatment (c1: t(146) = -0.44, p = .658). However, the two groups with 
a rationale (OPR+ and DP) showed significantly lower ratings at posttreatment when 
compared to the OPR- group (c2: t(146) = -2.15, p = .033, d = 0.43). Further, the OPR+ and 
DP group did not differ from each other (c3: t(146) = -1.10, p = .272; see Figure 1).  
Results for heat pain unpleasantness ratings at posttreatment were similar. No 
difference was found between the NT group and the three other groups (c1: t(146) = -1.38, p 
= .169). Participants in the two groups with a rationale (OPR+ and DP) reported lower ratings 
at posttreatment compared to participants from the OPR- group (c2: t(146) = -2.43, p = .016, d 
= 0.49), and the OPR+ and DP group did not differ from each other (c3: t(146) = -0.05, p = 
.961; see Figure 2).  
The results of the primary outcomes did not change significantly in the additional 
sensitivity analyses. First, the completer analyses revealed comparable results (N = 159) (see 
Supplement ST1). Second, the results of the subjective heat pain intensity and unpleasantness 
ratings did not change when objective heat pain tolerance was included as an additional 
covariate (see Supplement ST2). Also, the correlations between objective heat pain tolerance 
and the corresponding subjective intensity (p = .906), as well as unpleasantness (p = .462) 
ratings, were not significant.  
Objective Heat Pain Threshold and Corresponding Subjective Intensity and 
Unpleasantness Ratings  
Secondary analyses of objective heat pain threshold and the corresponding subjective 
intensity and unpleasantness ratings did not reveal distinct significant findings; detailed 
outcomes can be found in the Supplement (S3, S4, ST3).  
Expectancy and Desire for Relief Ratings  
For all groups, expectancy ratings of intensity and unpleasantness for posttreatment 
heat pain tolerance and threshold can be found in Table 2 and ST3, respectively. The 
 ANCOVA revealed that the treatment groups differed in expectancy ratings of intensity for 
posttreatment heat pain tolerance (omnibus test F(3, 146) = 5.41, p = .001). Post hoc 
comparisons revealed that the difference between the NT and the DP groups was significant, 
indicating that participants in the NT group expected a significantly higher heat pain intensity 
than the DP group (p = .038). Findings for expectancy ratings of unpleasantness for 
posttreatment heat pain tolerance were similar, again resulting in a significant omnibus test 
for treatment group (F(3, 146) = 5.00, p = .002), whereby post hoc comparisons revealed that 
the NT and DP group significantly differed from each other (p = .039). The ANCOVA for 
desire of relief, however, did not indicate a significant treatment group effect (omnibus test, 
F(3, 147) = 0.70, p = .555). 
Discussion 
Despite their clinical potential, very little is known about open-label placebos as basic 
research on their analgesic effects as well as comparisons to deceptive placebos is lacking. 
We addressed this dearth and conducted – to the best of our knowledge – the first RCT 
comparing open-label placebos with and without a rationale directly to a deceptive group in 
an experimental standardized heat pain paradigm. We found that healthy participants given 
open-label placebos with a persuasive rationale showed a decline in subjective intensity and 
unpleasantness ratings for heat pain tolerance which, surprisingly, did not differ significantly 
from deceptive placebo administration. This is in line with an older study, showing that for a 
verum (i.e., naproxen) as well as for a placebo, the analgesic effect is significantly better in 
the informed-consent group when compared to the uninformed group [4]. Accordingly, the 
necessity of deception in placebo application – at least in healthy participants – needs to be 
reconsidered.  
In line with our prediction, the provision of a convincing rationale, either open or 
deceptive (OPR+ and DP group), did outperform the mere cream application without any 
 rationale (OPR- group) with regard to subjective ratings for heat pain tolerance. The impact of 
the comprehensible theoretical embedding, which was offered to the participants in both 
groups, emphasizes the importance of plausibility and conviction of treatment rationales [7].  
Further, we did not find group differences between the no treatment group and the 
combined effect of the three other groups which may be due to the conceptual heterogeneity 
between the three groups receiving the placebo cream. This finding, which stands in contrast 
to our hypothesis, may be due to the fact that the OPR- group had numerically higher 
subjective ratings of heat pain tolerance than the NT group and in contrast to the other groups, 
the OPR- group did not report pain analgesia in any of the subjective outcomes but rather 
displayed higher subjective ratings of heat pain tolerance at posttreatment compared to 
baseline scores. This stands in contrast to a study by Kam-Hansen et al. [30], where an open 
application of placebos without additional information lead to a 14.5% pain reduction in 
patients with episodic migraine, which differed significantly from the untreated attacks, where 
patients reported a pain increase of 15.4%. In our case, it is possible that participants in the 
OPR- were disappointed to “only receive a placebo.” In fact, the experience of disappointment 
is an issue in control groups as well as in in experiments with healthy participants [41,62]. 
Further, the application of the cream may have led to an increased focus on the forearm in 
combination with the absence of any cognitive processing of a rationale [65].  
We only found significant group differences in subjective heat pain ratings and not on 
objective heat pain tolerance. Whether placebo effects are merely detected in subjective 
measurements or also on objective parameters seems to depend on the object of investigation 
as well as on further conceptual aspects of studies. Thus, several studies detected placebo 
effects only on a subjective level [29,61,69], whereas placebo responses are indeed 
measurable with neuroimaging [36] and the impact of placebo on immune and endocrine 
processes has been reported [3]. Our results are in line with the view that placebos primarily 
affect subjective self-report and self-appraisal symptoms [33]. It is noteworthy that Kam-
 Hansen et al. [30] also only found an impact of openly prescribed placebos on subjective 
measures and not on pain freedom – which would be the absolute absence of pain and is more 
objective than subjective pain sensation ratings. Interestingly, a former account of a heat pain 
study in children showed reversed effects – placebo treatment responses were detected on an 
objective level only (i.e. heat pain threshold and tolerance), however not on subjective heat 
pain ratings [37].  
Regarding heat pain expectancy ratings, participants’ expectations differed 
substantially according to group allocation, indicating that expectancy manipulations occurred 
due to the differing treatment procedures. In particular, participants in the DP group expected 
reduced heat pain intensity and unpleasantness for posttreatment compared to the NT group. 
These findings are in line with evidence of a link between placebo effects and induced 
expectations [47] and the general association between enhanced analgesia and induced 
positive expectations [5], besides showing that the deception in the DP group was successful.  
To sum up, placebo analgesia in healthy participants may be achieved with an 
adequate and convincing rationale whereby deception may not be necessary as long as 
participants find the explanation at hand meaningful and plausible [44]. 
Strengths and Limitations 
In any case, our study corroborates previous findings of open-label placebo 
effectiveness and shows that verbal constructs and the rationales, in particular play a 
fundamental role in altering expectancies and, hence, induce a placebo response [50]. 
Remarkably, this placebo response is achievable even with full disclosure. It has to be 
considered that we examined open-label placebo analgesia in a healthy population, hence the 
effect may be higher than in a comparable clinical setting [66,67]. However, a recent meta-
analysis suggests that patients with clinical conditions benefit even more from analgesic 
placebo treatments than healthy participants, and that clinical pain conditions and pain 
 induced in experiments may respond equally to placebo application [20]. In this regard, the 
increased desire for pain relief that significantly contributes to placebo analgesia in patients 
[52] has been shown to be lower in healthy volunteers [10]. Also, the value of social support 
regarding positive physical health outcomes [23] turns out to be superfluous in experimental 
pain.  
This RCT has several limitations. Importantly, subjective intensity and unpleasantness 
ratings are not independent of the corresponding objective heat pain tolerance. Differences in 
subjective heat pain ratings could be suppressed since assessing heat pain tolerance allows 
participants to stop the pain stimulus at different points in time. However, in our study, 
objective heat pain tolerance and the corresponding subjective ratings were not correlated. 
Further, additional sensitivity analyses of the subjective primary outcomes in which we 
statistically controlled for participants’ individual heat pain tolerance did not lead to different 
results (see Supplement ST2) 
We found medium effect sizes for subjective heat pain ratings. However, it is well 
known that placebo analgesic effects are smaller in studies that use short-term stimuli (as did 
our study) when compared to long-term pain stimuli (> 20s) [64,66]. Finally, advertisement of 
a “novel mind–body study of individual pain perception” may have selectively attracted 
individuals who are open to new approaches and concepts [9]. Nevertheless, selective 
attraction to the advertised study is present in almost all experimental trials [31].  
Implications and Future Studies 
Given the long-held belief of an inextricable interconnection between deceit and 
placebo usage [19,43], our findings offer an empirical starting point for a conceptual 
rethinking of the necessity of deception in placebo application. The ethically problematic 
aspect of placebos – a spurious rationale [6] – may under certain circumstances be 
comparable to a transparent and scientific rationale – at least in terms of their effects on 
 subjective outcomes. In this sense, our study also affirms that open-label placebos bare the 
potential to be harnessed in clinical practice, especially concerning the alleviation of 
subjective ailments. Authors of earlier studies already argued that open-label placebos could 
be prescribed with a “wait and watch” strategy before the administration of drugs [31] or to be 
prescribed after repeated administration of active drugs to achieve drug-like effects [13]. 
Moreover, open-label placebos may have the potential to work in treatment resistant patients, 
assumedly due to a form of empowerment [9], and therefore offers a unique approach to 
patients with chronic diseases without conventional treatment response. 
Most intriguingly, the non-effect of our placebo group without any theoretical 
embedding indicates the special significance of the rationale itself. Clinicians should be aware 
that a convincing story behind an intervention leads to better outcomes - at least concerning 
openly prescribed placebos. The importance of a certain rationale, i.e. a verbal suggestion, is 
also of relevance regarding the augmentation of nocebo effects [54] and in other domains 
such as in psychotherapy [7,21]. Therefore, our findings emphasise that the power of verbal 
suggestions should not be underestimated and deserves further scrutiny in relation to future 
placebo research. This is also in line with the recommendation that physicians may best 
benefit from placebo effects by enhancing patients’ expectations through communication 
[2,8]. Here, the claim that the proceeding study of placebo effects must go hand in hand with 
ethical debates to avoid misuse [12] must be picked up again.  
Conclusion  
Open-label placebos can lead to relevant changes in subjective experiences in healthy 
participants whereby the rationale itself is the vehicle which transports the meaning: An open 
application of a placebo cream with a convincing rationale had an impact on subjective pain 
relief, whereas an open application of a placebo cream without any rationale or theoretical 
embedding showed no effects. The observation that open-label placebos have the same effects 
 on our subjective primary outcome as deceptive placebos indicates that the rationale in fact 
might bear more weight than the deception in placebo application. 
Acknowledgements 
This study was supported by a grant project (325130_170117) awarded to JG by the 
Swiss National Science Foundation. The authors wish to thank Nafisa Müller, Larissa Tellini, 
and Christoph Werner for providing excellent help with the recruitment. We also want to 
thank Dr. Markus Messerli for his helpful suggestions regarding the design of the placebo 
cream. The authors are also very grateful for the support of Sebastian Hasler.  
Declaration of Interests 
The authors declare no financial interest or potential conflicts of interest. 
 
 References 
[1] Aulas JJ, Rosner I. [Efficacy of a non blind placebo prescription]. Encephale 2003;29:68–
71. 
[2] Barrett B, Muller D, Rakel D, Rabago D, Marchand L, Scheder JC. Placebo, meaning, and 
health. Perspect Biol Med 2006;49:178–98. 
[3] Benedetti F. Placebo effects (2nd ed). Oxford, UK: Oxford University Press, 2014. 
[4] Bergmann JF, Chassany O, Gandiol J, Deblois P, Kanis JA, Segrestaa JM, Caulin C, 
Dahan R. A randomised clinical trial of the effect of informed consent on the analgesic 
activity of placebo and naproxen in cancer pain. Clin Trials Metaanal 1994;29:41–7. 
[5] Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, Tracey I. 
The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of 
the opioid remifentanil. Sci Transl Med 2011;3:70ra14. 
[6] Blease C, Colloca L, Kaptchuk TJ. Are open-label placebos ethical? Informed consent and 
ethical equivocations. Bioethics 2016;30:407–14. 
[7] Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Ther Exp 
Psychiatry 1972;3:257–60. 
[8] Bystad M, Bystad C, Wynn R. How can placebo effects best be applied in clinical 
practice? A narrative review. Psychol Res Behav Manag 2015;8:41–5. 
[9] Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo 
treatment in chronic low back pain: a randomized controlled trial. Pain 
2016;157:2766–72. 
[10] Charron J, Rainville P, Marchand S. Direct comparison of placebo effects on clinical and 
experimental pain. Clin J Pain 2006;22:204–11. 
[11] Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence 
Erlbaum Associates, 1988. 
 [12] Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev 
Neurosci 2005;6:545–52. 
[13] Colloca L, Enck P, DeGrazia D. Relieving pain using dose-extending placebos: a scoping 
review. Pain 2016;157:1590–8. 
[14] Cragg JJ, Warner FM, Finnerup NB, Jensen MP, Mercier C, Richards JS, Wrigley P, 
Soler D, Kramer JL. Meta-analysis of placebo responses in central neuropathic pain: 
impact of subject, study, and pain characteristics. Pain 2016;157:530–40. 
[15] Edwards RR, Doleys DM, Fillingim RB, Lowery D. Ethnic differences in pain tolerance: 
clinical implications in a chronic pain population. Psychosom Med 2001;63:316–23. 
[16] Emerson NM, Zeidan F, Lobanov OV, Hadsel MS, Martucci KT, Quevedo AS, Starr CJ, 
Nahman-Averbuch H, Weissman-Fogel I, Granovsky Y, Yarnitsky D, Coghill RC. 
Pain sensitivity is inversely related to regional grey matter density in the brain. Pain 
2014;155:566–73. 
[17] Fässler M, Gnädinger M, Rosemann T, Biller-Andorno N. Placebo interventions in 
practice: a questionnaire survey on the attitudes of patients and physicians. Br J Gen 
Pract 2011;61:101–7. 
[18] Field A, Jeremy M, Field Z. Discovering statistics using R. London, UK: SAGE 
Publications, 2012. 
[19] Foddy B. A duty to deceive: placebos in clinical practice. Am J Bioeth 2009;9:4–12. 
[20] Forsberg JT, Martinussen M, Flaten MA. The placebo analgesic effect in healthy 
individuals and patients: a meta-analysis. Psychosom Med 2017;79:388–94. 
[21] Gaab J, Blease C, Locher C, Gerger H. Go open: a plea for transparency in 
psychotherapy. Psychol Conscious (Wash D C) 2016;3:175–98. 
[22] Gaab J, Jiménez J, Voneschen L, Oschwald D, Meyer AH, Nater UM, Krummenacher P. 
Psychosocial stress-induced analgesia: an examination of effects on heat pain 
 threshold and tolerance and of neuroendocrine mediation. Neuropsychobiology 
2017;74:87–95. 
[23] Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of 
personality in placebo effects: dispositional optimism, situational expectations, and the 
placebo response. J Psychosom Res 2005;58:121–7. 
[24] Geers AL, Weiland PE, Kosbab K, Landry SJ, Helfer SG. Goal activation, expectations, 
and the placebo effect. J Pers Soc Psychol 2005;89:143–59. 
[25] Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow 
WC, Shoulson I, Tandon PK, Parkinson Study Group, Leurgans S. Placebo response 
in Parkinson's disease: comparisons among 11 trials covering medical and surgical 
interventions. Mov Disord 2008;23:690–9. 
[26] Granot M, Sprecher E, Yarnitsky D. Psychophysics of phasic and tonic heat pain stimuli 
by quantitative sensory testing in healthy subjects. Eur J Pain 2003;7:139–43. 
[27] Harris G, Rollman GB. The validity of experimental pain measures. Pain 1983;17:369–
76. 
[28] Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. 
Stat Med 1990;9:811–8. 
[29] Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials 
comparing placebo with no treatment. N Engl J Med 2001;344:1594–602. 
[30] Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein 
R. Altered placebo and drug labeling changes the outcome of episodic migraine 
attacks. Sci Transl Med 2014;6:218ra5. 
[31] Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, 
Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a 
randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591. 
 [32] Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, 
Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, 
Drossman DA, Goldman P, Lembo AJ. Components of placebo effect: randomised 
controlled trial in patients with irritable bowel syndrome. BMJ 2008;336:999–1003. 
[33] Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med 2015;373:8–9. 
[34] Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major 
depressive disorder: a pilot randomized controlled trial. Psychother Psychosom 
2012;81:312–4. 
[35] Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial 
severity and antidepressant benefits: a meta-analysis of data submitted to the Food and 
Drug Administration. PLoS Med 2008;5:e45. 
[36] Krummenacher P, Candia V, Folkers G, Schedlowski M, Schönbächler G. Prefrontal 
cortex modulates placebo analgesia. Pain 2010;148:368–74. 
[37] Krummenacher P, Kossowsky J, Schwarz C, Brugger P, Kelley JM, Meyer A, Gaab J. 
Expectancy-induced placebo analgesia in children and the role of magical thinking. J 
Pain 2014;15:1282–93. 
[38] Kut E, Schaffner N, Wittwer A, Candia V, Brockmann M, Storck C, Folkers G. Changes 
in self-perceived role identity modulate pain perception. Pain 2007;131:191–201. 
[39] Macedo A, Baños JE, Farré M. Placebo response in the prophylaxis of migraine: a meta-
analysis. Eur J Pain 2008;12:68–75. 
[40] Maeoka H, Hiyamizu M, Matsuo A, Morioka S. The influence of repeated pain 
stimulation on the emotional aspect of pain: a preliminary study in healthy volunteers. 
J Pain Res 2015;8:431–6. 
[41] McCambridge J, Sorhaindo A, Quirk A, Nanchahal K. Patient preferences and 
performance bias in a weight loss trial with a usual care arm. Patient Educ Couns 
2014;95:243–7. 
 [42] Merskey H. Psychological and psychiatric aspects of pain control. In: Smith WL, 
Merskey H, Gross SC, editors. Pain: Meaning and Management. New York, NY: SP 
Medical and Scientific Books, 1980. pp. 105–117. 
[43] Miller FG, Wendler D, Swartzman LC. Deception in research on the placebo effect. 
PLoS Med 2005;2:e262. 
[44] Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning 
response. Ann Intern Med 2002;136:471–6. 
[45] Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. 
Neuropsychologia 1971;9:97–113. 
[46] Park LC, Covi L. Nonblind placebo trial: an exploration of neurotic patients' responses to 
placebo when its inert content is disclosed. Arch Gen Psychiatry 1965;12:36–45. 
[47] Petersen GL, Finnerup NB, Grosen K, Pilegaard HK, Tracey I, Benedetti F, Price DD, 
Jensen TS, Vase L. Expectations and positive emotional feelings accompany 
reductions in ongoing and evoked neuropathic pain following placebo interventions. 
Pain 2014;155:2687–98. 
[48] Petersen GL, Finnerup NB, Nørskov KN, Grosen K, Pilegaard HK, Benedetti F, Price 
DD, Jensen TS, Vase L. Placebo manipulations reduce hyperalgesia in neuropathic 
pain. Pain 2012;153:1292–300. 
[49] Petkovic G, Charlesworth JEG, Kelley J, Miller F, Roberts N, Howick J. Effects of 
placebos without deception compared with no treatment: protocol for a systematic 
review and meta-analysis. BMJ Open 2015;5:e009428. 
[50] Pollo A, Amanzio M, Arslanian A, Casadio C, Maggi G, Benedetti F. Response 
expectancies in placebo analgesia and their clinical relevance. Pain 2001;93:77–84. 
[51] Price DD. Psychological and neural mechanisms of the affective dimension of pain. 
Science 2000;288:1769–72. 
 [52] Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent 
advances and current thought. Annu Rev Psychol 2008;59:565–90. 
[53] Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of 
factors that contribute to the magnitude of placebo analgesia in an experimental 
paradigm. Pain 1999;83:147–56. 
[54] Quinn VF, Livesey EJ, Colagiuri B. Latent inhibition reduces nocebo nausea, even 
without deception. Ann Behav Med 2017 [Epub ahead of print]. 
http://dx.doi.org/10.1007/s12160-016-9867-8 
[55] Rief W, Glombiewski JA. The hidden effects of blinded, placebo-controlled randomized 
trials: an experimental investigation. Pain 2012;153:2473–7. 
[56] Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of 
experimental conditions on the adverse events profile during phase I studies. Clin 
Pharmacol Ther 1993;54:578–83. 
[57] Ruxton GD, Beauchamp G. Time for some a priori thinking about post hoc testing. 
Behav Ecol 2008;19:690-3. 
[58] Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot 
study. Child Care Health Dev 2008;34:104–10. 
[59] Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new 
treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr 
2010;31:369–75. 
[60] Schaefer M, Harke R, Denke C. Open-label placebos improve symptoms in allergic 
rhinitis: a randomized controlled trial. Psychother Psychosom 2016;85:373–4. 
[61] Schwarz KA, Büchel C. Cognition and the placebo effect--dissociating subjective 
perception and actual performance. PLoS One 2015;10:e0130492. 
 [62] Skingley A, Bungay H, Clift S, Warden J. Experiences of being a control group: lessons 
from a UK-based randomized controlled trial of group singing as a health promotion 
initiative for older people. Health Promot Int 2014;29:751–8. 
[63] Turi Z, Mittner M, Paulus W, Antal A. Placebo intervention enhances reward learning in 
healthy individuals. Sci Rep 2017;7:41028. 
[64] Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil 
JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. 
Pain 2015;156:2616–26. 
[65] van Laarhoven AI, Kraaimaat FW, Wilder-Smith OH, Evers AW. Role of attentional 
focus on bodily sensations in sensitivity to itch and pain. Acta Derm Venereol 
2010;90:46–51. 
[66] Vase L, Petersen GL, Riley JL III, Price DD. Factors contributing to large analgesic 
effects in placebo mechanism studies conducted between 2002 and 2007. Pain 
2009;145:36–44. 
[67] Vase L, Riley JL III, Price DD. A comparison of placebo effects in clinical analgesic 
trials versus studies of placebo analgesia. Pain 2002;99:443–52. 
[68] Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: 
estimating placebo effects in medicine and psychotherapy from randomized clinical 
trials. J Clin Psychol 2005;61:835–54. 
[69] Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk 
TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N 
Engl J Med 2011;365:119–26. 
 
  
 Figure Captions 
Figure 1. Posttreatment scores of subjective intensity ratings for heat pain tolerance of 
participants in the no treatment (NT), open-label placebo without rationale (OPR-), open-label 
placebo with rationale (OPR+), and deceptive placebo (DP) group. Positive values indicate 
placebo analgesia. Scores were adjusted for baseline ratings. 
Figure 2. Posttreatment scores of subjective unpleasantness ratings for heat pain tolerance of 
participants in the no treatment (NT), open-label placebo without rationale (OPR-), open-label 
placebo with rationale (OPR+), and deceptive placebo (DP) group. Positive values indicate 
placebo analgesia. Scores were adjusted for baseline ratings. 
 
 
 
 Table 1  
Sociodemographic Characteristics of Study Participants  
Group N 
(included) 
Age (SD) N (%) 
Female 
Family Status N(%) Highest Educational Level 
N(%)  
Employment Level N(%) 
NT 40 27.9 (8.52) 
29 
(73%) 
single: 37 (92.5%) 
married: 0 (0%) 
registered partnership: 1 (2.5%) 
divorced: 2 (5%) 
 
primary school: 0 (0%) 
secondary school: 6 (15%) 
high school: 15 (37.5%) 
university: 19 (47.5%)  
 
full-time: 5 (12.5%) 
part-time: 21 (52.5%) 
none or student: 14 (35%) 
 
 
OPR- 37 28.27 (11.34) 
24 
(65%) 
single: 32 (86.5%) 
married: 5 (13.5%) 
registered partnership: 0 (0%) 
divorced: 0 (0%) 
 
primary school: 0 (0%) 
secondary school: 4 (10.8%) 
high school: 23 (62.2%) 
university: 10 (27%) 
 
full-time: 3 (8.1%) 
part-time: 15 (40.5%) 
none or student: 19 (51.4%) 
 
 
OPR+ 
 
37 
 
25.7 
(7.76) 
 
27 
(73%) 
 
single: 34 (91.9%) 
married: 2 (5.4%) 
registered partnership: 0 (0%) 
divorced: 1 (2.7%) 
 
primary school: 0 (0%) 
secondary school: 3 (8.1%) 
high school: 23 (62.2%) 
university: 11 (29.7%) 
 
full-time: 6 (16.2%) 
part-time: 19 (51.4%) 
none or student: 12 (32.4%) 
 
 
DP 37 26.65 (10.25) 
23 (62 
%) 
single: 35 (94.6%) 
married: 1 (2.7%) 
registered partnership: 0 (0%) 
divorced: 1 (2.7%) 
 
primary school: 1 (2.7%) 
secondary school: 5 (13.5%) 
high school: 19 (51.4%) 
university: 12 (32.4%) 
 
full-time: 7 (18.9%) 
part-time: 14 (37.8%) 
none or student: 16 (43.3%) 
 
 
Note. DP = deceptive placebo; NT = no treatment group; OPR- = open-label placebo without rationale; OPR+ = open-label placebo with rationale.  
 
 
 
  
Table 2  
Objective Heat Pain Tolerance and Corresponding Subjective Intensity and Unpleasantness Ratings  
 
Group Baseline   Posttreatmenta   Expectancy Ratingsb  
 Objective Heat 
Pain Tolerance 
Subjective Heat 
Pain Intensity 
Subjective Heat 
Pain Unpleasantness 
Objective Heat 
Pain Tolerance 
Subjective Heat 
Pain Intensity 
Subjective Heat 
Pain Unpleasantness 
Heat Pain 
Intensity 
Heat Pain 
Unpleasantness 
 
NT (N=40) 
        
Outcomes 
(mean, se) 
48.11 (0.27) 62.24 (3.80) 64.26 (4.10) 48.07 (0.14) 60.35 (1.36) 63.80 (1.48) 60.26 (2.21) 62.42 (2.44) 
 
OPR- (N=37) 
        
Outcomes 
(mean, se) 
48.15 (0.28) 59.02 (3.94) 64.28 (4.26) 47.99 (0.14) 62.13 (1.42) 64.47 (1.54) 53.38 (2.29) 54.52 (2.53) 
 
OPR+ (N=37) 
        
Outcomes 
(mean, se) 
48.80 (0.28) 62.48 (3.94) 64.48 (4.26) 48.15 (0.14) 59.51 (1.42) 59.93 (1.54) 54.99 (2.29) 53.71 (2.53) 
 
DP (N=37) 
        
Outcomes  
(mean, se) 
48.32 (0.28) 59.11 (3.94) 60.77 (4.26) 48.23 (0.14) 57.30 (1.42) 59.83 (1.55) 47.52 (2.29) 49.09 (2.54) 
         
Note: a=posttreatment means are adjusted for the corresponding baseline mean; b=expectancy means are adjusted for the corresponding baseline mean; DP = deceptive placebo; NT = 
no treatment group; OPR- = open-label placebo without rationale; OPR+ = open-label placebo with rationale. 
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S1: Methods: Objective Heat Pain Threshold 
For posttreatment heat pain threshold, we calculated one separate one-way 
ANCOVAs, using the treatment group as independent between-subject factor and baseline 
heat pain threshold as covariate.  
S2: Methods: Subjective Ratings for Heat Pain Threshold 
Regarding intensity and unpleasantness ratings for heat pain threshold at 
posttreatment, we conducted two separate one-way ANCOVAs with treatment group (NT vs 
OPR- vs OPR+ vs DP) as between-subject factor and the corresponding outcome variable 
measured at baseline as covariate. 
S3: Results: Objective Heat Pain Threshold 
The one-way ANCOVA for posttreatment heat pain threshold did not show a 
significant main effect for treatment group (F(3, 146) = 0.17, p = .918).  
 
 S4: Results: Subjective Ratings for Heat Pain Threshold 
In the intensity ratings for heat pain threshold at posttreatment, we found no 
differences among the four groups (omnibus test, F(3, 146) = 1.35, p = 0.259). Similarly, the 
groups did not differ in the unpleasantness ratings for heat pain threshold (omnibus test, F(3, 
146) = 2.19, p = .091).  
 ST1 
Sensitivity Analyses for Primary Outcomes: Completer Analyses (N = 159) 
 Objective Heat Pain 
Tolerance 
Subjective Heat Pain 
Intensity 
Subjective Heat Pain 
Unpleasantness 
Statistical 
Analyses 
   
Contrast 1  
(NT vs. OPR-, 
OPR+, and DP) 
 
t(154) = 0.28, 
p = .776 
t(154) = -0.42, 
p = .676 
t(154) = -1.35, p = 
.178 
Contrast 2 
(OPR- vs. 
OPR+ and DP) 
t(154) = 1.00, 
p = .321 
t(154) = -1.89, 
p = .061 
t(154) = -2.19,  
p = .03 
Contrast 3 
(OPR+ group 
vs DP) 
t(154) = -0.39, 
p = .699 
t(154) = -1.24, 
p = .217 
t(154) = -0.19,  
p = .853 
  
  
ST2 
Sensitivity Analyses for Primary Outcomes: Subjective Intensity and Unpleasantness Ratings Adjusted for Objective Heat Pain Tolerance  
Tolerance Intensity   Unpleasantness   
Statistical 
Analyses 
Adjusted for baseline 
heat pain tolerance 
Adjusted for mean 
heat pain tolerance 
Adjusted for 
posttreatment heat 
pain tolerance 
Adjusted for baseline 
heat pain tolerance 
Adjusted for mean 
heat pain tolerance 
Adjusted for 
posttreatment heat 
pain tolerance 
Contrast 1  
(NT vs. OPR-, 
OPR+, and DP) 
 
t(145) = -0.43, 
p = .665 
t(145) = -0.45, 
p = .65 
t(145) = -0.47,  
p = .637 
t(145) = -1.44, 
p = .152 
t(145) = -1.47, 
p = .143 
t(145) = -1.49,  
p = .138 
Contrast 2 
(OPR- vs. 
OPR+ and DP) 
t(145) = -2.12, 
p = .035 
t(145) = -2.14, 
p = .034 
t(145) = -2.17,  
p = .032 
t(145) = -2.49, 
p = .014 
t(145) = -2.54, 
p = .012 
t(145) = -2.58,  
p = .011 
Contrast 3 
(OPR+ group 
vs DP) 
t(145) = -1.10, 
p = .273 
t(145) = -1.08, 
p = .281 
t(145) = -1.07,  
p = .286 
t(145) = -0.02, 
p = .984 
t(145) = 0.03, 
p = .973 
t(145) = -0.03,  
p = .976 
 
 
 
 
 ST3 
Objective Heat Pain Threshold and Corresponding Subjective Intensity and Unpleasantness Ratings 
 
Group Baseline   Posttreatmenta   Expectancy Ratingsb  
 Objective Heat 
Pain Tolerance 
Subjective Heat 
Pain Intensity 
Subjective Heat 
Pain Unpleasantness 
Objective Heat 
Pain Tolerance 
Subjective Heat 
Pain Intensity 
Subjective Heat 
Pain 
Unpleasantness 
Heat Pain 
Intensity 
Heat Pain 
Unpleasantness 
 
NT (N=40) 
        
Outcomes 
(mean, se) 
44.25 (0.44) 29.89 (3.48) 33.09 (3.63) 43.49 (0.33) 23.57 (2.11) 23.34 (2.19) 41.98 (3.33) 41.62 (3.35) 
 
OPR- (N=37) 
        
Outcomes 
(mean, se) 
44.81 (0.46) 29.11 (3.61) 35.31 (3.77) 43.64 (0.34) 28.74 (2.19) 30.68 (2.28) 37.18 (3.47) 38.76 (3.49) 
 
OPR+ (N=37) 
        
Outcomes 
(mean, se) 
45.04 (0.46) 30.78 (3.61) 32.46 (3.77) 43.69 (0.34) 26.23 (2.19) 28.09 (2.28) 34.10 (3.47) 33.07 (3.48) 
 
DP (N=37) 
        
Outcomes  
(mean, se) 
45.13 (0.46) 31.94 (3.61) 30.79 (3.77) 43.39 (0.34) 23.38 (2.19) 24.62 (2.28) 27.12 (3.47) 28.50 (3.49) 
         
Note: a = posttreatment means are adjusted for the corresponding baseline mean; b = expectancy means are adjusted for the corresponding baseline mean; DP = deceptive placebo; NT 
= no treatment group; OPR- = open-label placebo without rationale; OPR+ = open-label placebo with rationale. 
 
  
SF1: Flow Chart 
 
 
 
Excluded		(n=121)
• Not	meeting	inclusion	criteria	
(n=62)
• Declined	to	participate	(n=50)
• Participated	already	in	another	
pain	study	(n=9)
Assessed	for	eligibility	(n=	281)
Allocated	to	no	treatment	arm
(n=	40)
)
Allocated	to	open-label	
placebo	without	rational	arm	
and	received	allocated	
intervention	(n=	40)
Allocated	to	open-label	
placebo	with	rational	arm	and	
received	allocated	intervention	
(n=	40)
Allocated	to	deceptive	placebo								
arm		and	received	allocated	
intervention	(n=	40)
Analysed		(n=	40)
Analysed		(n=		37)	
•	Excluded	from	analysis:	
(insufficient	language	skills)	
(n=	1)	(not	able	to	define	the	
term	placebo)	(n=	2)
Analysed		(n=	37)
• Excluded	from	analysis	(not	
able	to	define	the	term	
placebo)	(n=	3)
Analysed		(n=		37)
•	Excluded	from	analysis	
(deception	failed)	(n=	3)
Randomized	(n=	160)
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